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Abstract 
 
 
This thesis evaluates 20 years of Tay Sachs disease (TSD) preconception genetic 
screening conducted in Jewish communities of Sydney and Melbourne. 
 
TSD is an inherited neurodegenerative disease, usually lethal in infancy or early 
childhood. More common in individuals with Ashkenazi Jewish (AJ) heritage, TSD 
was the first Mendelian condition to be targeted by community-based preconception 
genetic screening. Internationally AJ TSD screening programs have been operating 
since the 1970’s and have reduced the incidence of TSD in AJ populations in 
Canada, USA and Israel by 90%. The aim of such programs is to identify at-risk 
individuals and couples and to offer access to antenatal genetic counselling and 
reproductive options. In Sydney, following a successful pilot program (1993-1995), a 
TSD screening program was launched in 1995. In Melbourne a TSD screening 
program commenced in 1998. TSD screening programs in Australia are an 
archetypal model for preconception genetic screening of inherited conditions. The 
success of TSD screening programs in targeting individuals at risk (Chapter 4), 
reducing Tay Sachs disease incidence (Chapter 5), and translating screening 
program principles to a primary care setting (Chapter 6) has not been evaluated 
previously.  
  
Jewish community genetic screening for TSD now occurs in the context of a panel of 
26 genetic conditions common in individuals of Jewish descent.  
 XXIII 
The advent of emerging DNA sequencing technologies and their incorporation into 
standard laboratory assays for screening purposes introduces the facility to expand 
the spectrum of screening programs to include a broader range of conditions without 
significantly increasing laboratory costs. 
The repercussions of an expanded AJ screening panel on the identification of 
carriers for 1 or more conditions has not been evaluated previously. The clinical 
impact of expanded screening on genetic counselling service referral and need for 
partner testing was explored in this thesis (Chapter 7). 
 
On the basis of evidence from my original publications and my extensive systematic 
review of the international literature, I developed the first Clinical position paper to 
guide Ashkenazi Jewish genetic screening in the Australasian context. This work 
was ratified and published by the Human Genetics Society of Australasia (Chapter 
8). 
 
Work exploring issues of acceptability and cost effectiveness of broader screening 
panels in a preconception context in Jewish and other Australians, the validity of 
informed consent, and issues related to privacy and storage of genetic information 
obtained via DNA sequencing technologies is ongoing. 
 
 
Key words: Tay Sachs disease, Ashkenazi Jewish, genetic screening, 
Australia, preconception, health promotion  
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Chapter 1: Introduction 
1.1 The structure of this thesis 
This thesis contains 5 publications, consisting of four peer-reviewed papers and 
an original position paper and clinical practice guideline, ratified and published by 
the Human Genetics and Genomics Society of Australasia (Chapter 8). Included 
in Appendix 1 are 4 posters, which have been presented at international 
meetings and published in the proceedings of the relevant society. The posters 
were submitted to further document the course of my research journey. 
 
Collectively these publications describe my doctoral studies, including the 
generation of study hypotheses, the design of research protocols, the 
assessment of outcomes and their clinical translation through the formation of 
clinical practice guidelines. A copy of each paper is inserted into the body of the 
thesis.  
 
The literature review contained in this chapter provides the research background 
to the practice of preconception TSD screening. Chapter 3 is a published 
literature review, detailing the Australian experience in Tay Sachs disease (TSD) 
preconception screening. Chapters 4, 5 and 6 consist of published papers, each 
reporting its aims, methodology and containing a referenced literature review 
specific to the body of work contained in that chapter. Some repetition within the 
literature reviews within published papers was unavoidable and mandatory, 
providing relevant background and contextualising my research within the highly 
 2 
subspecialised area of Ashkenazi Jewish preconception conception screening in 
the Australian primary health promotion clinical environment.    
  
 3 
 
1.2 Research Background and Literature Review 
Tay-Sachs disease (TSD) 
TSD is a fatal neurodegenerative lysosomal sphingolipid storage disorder, caused by 
mutations of HEXA MIM *606869 (gene map locus 15q23-q24). Identified in 1969, 
the HEXA gene product is the α-subunit of ß-hexosaminidase, a dimeric enzyme 
involved in the lysosomal degradation of GM2 gangliosides.1, 2 TSD has autosomal 
recessive inheritance, where genetic carriers are themselves phenotypically normal. 
In a couple where both partners are carriers, 25% of successful pregnancies will 
result in a TSD-affected infant. Most infants with TSD appear healthy at birth. After a 
relatively short period of normal development, TSD-affected babies experience slow 
neurological decline, resulting in death in infancy (infantile TSD) or early childhood 
(intermediate TSD). This occurs secondary to neuronal accumulation of sphingolipid 
GM2 gangliosides. No cure or effective treatment that slows disease progression is 
known.3 A later onset form of TSD also exists. In 1971 an assay for HEXA protein 
was developed, allowing the possibility of TSD antenatal testing and carrier 
screening.4 
 
Tay-Sachs disease in Ashkenazi Jewish populations 
TSD carrier frequency is approximately 1:25 in individuals of Ashkenazi Jewish (AJ) 
(Eastern and Central European) descent.5  TSD incidence in Jewish people is one in 
3,900 births, compared to one in 320,000 births in other populations.6  
 
 
 4 
The HEXA gene 
The HEXA gene was first characterised in 19857 and cloned further to identify intron-
exon organization in 1987.8 In AJ populations several pathological variant HEXA 
alleles have been demonstrated.9 96% of Jewish TSD carriers are found to have one 
of only three common mutations. 10, 11 c.1278insTATC, the most common mutation in 
AJ populations, is a frame-shift mutation due to a 4 base pair insertion in exon 11, 
introducing a premature stop codon and causing HEXA protein truncation,12 
c.1421+1G>C, the second most common mutation in AJ populations, features a 
G→C transversion in the donor splice site of intron 12. 9, 13, 14 The third mutations is 
p.Gly269Ser, a rarer missense mutation.15 TSD also occurs in higher frequencies 
than the general population in some French Canadian, Pennsylvania Dutch, Irish 
and Cajun communities; the relative prevalence of HEXA mutations found in these 
populations is different to those found in AJ populations.16 
  
The most likely explanation for the origin of multiple HEXA mutations in AJ 
populations is that they arose around 1100 AD by founder effect and genetic drift.17-
22 Four independent sphingolipid storage diseases have arisen in AJ populations 
(TSD, Niemann-Pick disease, Gaucher disease and mucolipidosis type IV) leading 
some investigators to hypothesize a possible heterozygote advantage.23, 24 25 
North American demographic studies of AJ TSD carrier frequency have identified 
varying carrier frequencies between AJ communities founded by immigrants from 
different regions of Europe (Toronto 1:14, Baltimore 1:22 and Washington D.C. 
1:28, Average USA 1:30).26 However, these studies were based on results of 
 5 
enzyme-based carrier testing and therefore made no distinction between individual 
AJ HEXA allele frequencies among the sub-populations studied.   
 
History of TSD screening 
The first TSD carrier screening program was introduced in the USA in 1971.11 By the 
year 2000, some 1.4 million individuals had participated in these programs around 
the world, and over 51,000 TSD carriers, including more than 1,400 at-risk couples 
(in which both partners are TSD carriers), had been identified via TSD screening 
programs.10 As technology has evolved, many Jewish TSD screening programs 
have expanded from testing for TSD alone to testing for a panel of recessive genetic 
conditions common to Jewish populations (Canavan disease, Niemann-Pick disease 
type A, Bloom syndrome, Fanconi anaemia, familial dysautonomia, mucolipidosis 
type IV) and cystic fibrosis.27 Cystic fibrosis in Jewish communities has a 1:25 carrier 
frequency, similar to other Caucasian populations, although the prevalence of 
individual mutations may differ.  
 
Testing Methodology 
TSD screening was originally conducted by biochemical testing of HEXA enzyme 
activity and more recently by direct DNA testing of the HEXA gene. Enzyme testing 
in theory affords the possibility of detecting low prevalence HEXA DNA mutations 
and is considered to be the gold-standard testing method in populations of mixed or 
non-AJ ancestry.6 DNA testing has been reported as the best procedure for 
identifying TSD carriers in AJ populations.6, 28 In an orthodox AJ cohort of 38,197 
individuals in Israel, DNA testing had high sensitivity (93.1-99.1%) and equivalent 
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specificity compared to biochemical testing (88.1-98.8%).28 DNA testing of 
mouthwash/cheek brush samples improves participation rates compared with 
venepuncture/blood sampling required for biochemical testing.29 Successful DNA 
testing of hair root specimens offers a sample amenable to extreme ease of 
transport, of potential use for outreach screening programs.30 In the future, 
Massively Parallel DNA Sequencing technologies (MPS) is likely to replace standard 
DNA testing for simultaneous identification of carriers of TSD and other genetic 
errors. This method is explained further in later chapters of this thesis. 
 
The Dor Yeshorim Screening Program 
The Dor Yeshorim screening program was established in 1983 to provide access to 
TSD screening for the ultra-orthodox Jewish community in the USA in a format 
culturally acceptable to this demographic.31 For many ultra-orthodox Jewish couples, 
termination of a TSD-affected pregnancy diagnosed prenatally is not an option they 
would consider acceptable on religious grounds. In ultra-orthodox Jewish 
communities, “arranged marriages” are common, in which young couples are 
introduced with a view to being married. In the Dor Yeshorim model, screening is 
offered to unmarried individuals and occurs prior to the introduction of young 
couples. The outcomes of screening remain anonymous – results are not directly 
disclosed to individuals tested.  
 
In the Dor Yeshorim program, “compatibility” of couples is determined prior to 
introductions being made. Introductions proceed only if couples are found to be 
“compatible”, that is, they are not both carriers of mutations for TSD. Alternatively 
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couples contemplating engagement and found to be “non-compatible” (both carrying 
a TSD mutation, and thus at high-risk of having TSD-affected children) are simply 
not introduced to each other, and instead are introduced to different prospective 
partners. 
  
The Dor Yeshorim screening model has >95% uptake in ultra-orthodox Jewish 
communities. A branch of this program has been operating in Israel since 1986.32 
Since the Dor Yeshorim program was established, the scope of genetic testing 
offered to ultra-orthodox Jewish couples has been expanded to test for other 
significant recessive conditions at higher than background frequencies in Jewish 
populations in addition to TSD.  
 
TSD Screening in Israel 
In addition to the Dor Yeshorim screening program, TSD screening is offered free of 
charge in Israel to at-risk individuals through voluntary community based screening 
programs.33 While it is recommended to undertake screening prior to pregnancy, 
Israeli health care providers are directed to discuss TSD genetic screening with all 
women of fertile age or in early pregnancy.34 With the advent of widespread TSD 
screening in Israel, cases of TSD amongst the Jewish Israeli population are now 
exceedingly rare. 33 The Israeli system is an example of how clinicians in primary 
care settings can effectively facilitate preconception genetic screening strategies, 
which result in the prevention of targeted conditions such as TSD. 
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The Montreal Experience 
The first example of a TSD screening program targeting senior high school students 
was initiated in Montreal, Quebec, in the setting of general access secular high 
schools.35 In this community individuals of either French Canadian origin or AJ origin 
are at high risk of TSD, and a screening program targeting general access secular 
high school students was deemed to be viable. During 30 years of TSD screening, 
TSD incidence in Quebec has been reduced by over 90%.35  
 
Pros and cons of TSD genetic screening in an adolescent 
population 
The ideal setting in which to screen for TSD is an informed adult couple planning a 
future pregnancy.36 Unfortunately this demographic often do not access 
preconception testing for many reasons including low levels of knowledge of TSD 
and carrier risk, low motivation, cost of testing or unplanned pregnancy.37, 38 The 
factor that has been the most successful in increasing uptake of pre-conception 
genetic screening for TSD internationally has been the implementation of screening 
programs that target an adolescent population.39 Screening at senior high school 
level captures a large proportion of the target population in an environment where 
both pre-test education and testing can be carried out with relative ease. Senior high 
school students are mature minors, usually able to understand the implications of 
testing and provide informed consent.40, 41 Students educated immediately prior to 
testing and then screened for TSD in a high school setting have also been found to 
retain more information at the time of testing and recall this information 3-6 years 
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following testing than do adults screened in other settings29, 35, 42, 43 In order to be 
optimally relevant, TSD carrier screening must occur in a window before conception, 
with all reproductive options accessible, allowing couples to make informed choices 
in planning their family.34 Carrier testing in an adolescent population addresses the 
issue of TSD screening prior to pregnancy planning, thus allowing future informed 
access to all possible reproductive options for at-risk carrier couples and extended 
families.44  Targeting adolescents in a multicultural high school environment for 
genetic screening has been criticised for the potential to invoke racial/culturally 
based bullying of carriers,39 however this has not been reported in practice.  
 
International success of TSD screening programs 
In Jewish communities around the world, TSD carrier screening programs have 
reduced the births of infants with TSD by >90%.11, 35, 45 A review of the first 20 years 
of the Montreal TSD carrier screening program evaluated in 199635 showed that it 
had reached 89% of Montreal Jewish high school students with 67% of students 
reached choosing TSD screening. Information regarding the rationale for TSD 
screening was strongly retained and anxiety levels amongst carriers remained low. 
Over this period, new TSD diagnoses in the Jewish population of Quebec fell by 
90%, attributable to both the impact of TSD screening and a decline in population 
birth rate, while TSD frequency in Quebec’s non-Jewish population remained 
static.35 Prior to 1970, 85% of TSD affected infants were born in Quebec had Jewish 
ancestry. In contrast, by 1993 an estimated 60-80% of TSD affected infants born had 
no Jewish ancestry.11  
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Australian Ashkenazi Jewish Communities 
Although a small AJ community has existed in Australia since the time of European 
colonization of Sydney in 1788, the majority of the Australian AJ population was 
founded by immigration subsequent to World War II.  
 
The Australian Jewish community (estimated population over 90,000)46 mainly reside 
in Melbourne and Sydney.47 The majority of Australian Jews have AJ heritage.48 
Over 70% of Jewish adolescents in Melbourne and 50% in Sydney attend Jewish 
High Schools that access TSD screening programs.49  Studies of the allele 
frequencies of several genes in the Australian Jewish population in Sydney including 
HEXA, BRCA1, BRCA2 and APC indicate the Australian AJ population is not 
statistically different in these frequencies from Jewish populations in Israel, USA and 
Canada and therefore is comparable to international AJ populations in regards to 
burden of genetic diseases.50 The impact of wide reaching TSD screening programs 
targeting Jewish communities in Australia would therefore be expected to have 
similar potential for reducing TSD incidence as international programs have 
demonstrated. A detailed review of the Australian experience of TSD genetic 
screening appears in Chapter 2 of this thesis. Chapter 5 of this thesis measures for 
the first time the impact and health outcomes of TSD screening programs in 
Australia.51 
 
Elements of successful TSD screening programs 
Successful TSD screening programs require much more than simply offering 
laboratory testing for TSD.52 In successful International TSD screening programs, 
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educational campaigns have been conducted, focusing on the medical community, 
the lay Jewish community and religious leaders. Community leaders and lay 
representatives should be actively engaged in the planning process to ensure that 
the eventual TSD screening program model is designed and adapted to be 
conducted sustainably in line with community wishes, needs, expectations and 
resources.39, 53 Screening programs should adhere to international ethical standards 
with regards to individual privacy and patient autonomy.54  Genetic screening should 
be fully informed and voluntary. Genetic screening programs that address these 
issues, and which also target senior high school students, have been associated with 
high uptake, both internationally and in Australia.35, 42, 45  
 
Future directions 
 
My work directly resulted in collaboration between the two independent Australian AJ 
preconception screening programs. My research and systematic reporting of 
Australian AJ population data with respect to TSD has provided an evidence base to 
support a planned campaign for future Medicare funding of AJ preconception genetic 
screening strategies. My work will ultimately assist in improving preconception 
genetic screening access to all AJ Australians. 
 
As the routine testing modality for AJ individuals evolves from traditional mutation-
based DNA testing to MPS-based testing, screening for a greatly expanded panel of 
genetic conditions will not only be possible, but also affordable. Broader MPS 
screening panels have the potential to benefit individuals who choose to access 
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preconception genetic screening in their future health care. In this scenario, initial 
results reporting strategies may be limited to targeted pathological variants, with the 
option of in-silico reanalysis at a future time as clinically appropriate. Maintaining 
ethical principles without compromising patients access to longitudinal benefits of 
information derived from genome sequencing is a challenge for our times.55  
 
Measures of the success of a genetic screening program include:  
• the level of uptake within the target population,  
• the percentage of the target population offered access to screening,  
• the level of informed consent among individuals screened,  
• the reduction of target disease incidence over time through the uptake of 
Assisted Reproductive Technologies (ART) and selective pregnancy 
termination, and  
• economic outcomes.56  
 
Studies are underway to audit screened Australian AJ TSD carriers’ access to Pre-
implantation Genetic Diagnosis (PGD) and prenatal diagnostic results from 
amniocentesis and chorionic villus sampling (unpublished data Dr Raelia Lew, 
Professor Martin Delatycki, Ms Anné Proos).  
 
High school screening programs, although extremely successful, cannot hope to be 
the sole mode of delivery for the goal of avoidance of TSD-affected births in 
Australian AJ populations. This is because a minority of Australian Jewish individuals 
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of reproductive age have attended the schools that offer access to these programs.49 
This majority Australian AJ target population relies on primary health care clinician 
referral in order to gain access to preconception and antenatal TSD screening, with a 
small minority also accessing testing via community outreach programs.  
 
Due to expertise I gained via pursuing the research described in earlier chapters of 
this PhD thesis, I was invited to chair a Human Genetics Society of Australasia 
(HGSA) committee, and to be the primary author of Australia’s first clinical practice 
guideline for preconception genetic screening in Ashkenazi Jews. I invited experts 
and lay representatives with leadership experience in the field of Ashkenazi 
preconception genetic screening to form the guideline steering committee. We met 
and collaboratively agreed on a framework for the guideline. I then conducted the 
research review and wrote the guideline, which was then subjected to committee 
review. I then re-wrote the guideline to implement collectively suggested changes. 
The committee then reviewed the guideline for a second time and with unanimous 
agreement submitted the manuscript to the HGSA and RANZCOG joint screening 
committee for external peer review. I received and implemented suggested changes 
from the peer review process, and submitted them to the steering committee for 
consideration. I the prepared and submitted a final version of the guideline to HGSA, 
which was ratified and published in 2015.   With permission of the HGSA, the 
position paper has been included in this thesis (Chapter 8). Development of this 
guideline enables the two Australian Jewish Community genetic screening programs 
(in Sydney and Melbourne) to align their programs’ operations (personal 
communication Professors Leslie Burnett and Martin Delatycki) and will lead to 
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adoption at a national level of a single agreed best-practice framework. This 
guideline is designed to change clinical practice, resulting in the adoption of the 
practice of genetic screening in the primary healthcare setting.  It provides a valuable 
resource to Australasian Health care clinicians and will assist in extending access to 
preconception genetic screening to at-risk AJ individuals outside of the Australian 
high school screening model.   
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Chapter 2:  Research protocols, Aims and Hypotheses 
 
2.1. Introduction 
The body of work contained in this thesis represents the evolution of my research 
conducted in association with Australasian TSD screening programs. In this 
introduction, I will outline the evolution of this project and of the research questions 
hypothesised and addressed by this thesis. My involvement in TSD preconception 
screening research began in 2008. While enrolled as a Master of Medicine 
(Reproductive Health Science and Human Genetics) student at the University of 
Sydney, I began a research treatise investigating the frequencies of common AJ 
HEXA mutations among student participants of existing Australasian TSD screening 
programs, and the correlations between mutation type, grandparent’s country of birth 
and identification of AJ heritage. A questionnaire designed by the Sydney screening 
program, completed by all students undertaking preconception screening over time, 
asked students to document their grandparents’ birthplace. However, this information 
was never synthesised or analysed by other collaborators in the screening program 
and so no conclusions had been drawn from this data. I obtained ethics approval to 
create a secure, de-identified database of screening program participants historical 
family demographic data from completed questionnaires. I was then able to link 
demographic information to allelic status and thus create a mutation profile for 
Ashkenazi and non-Ashkenazi participants by country of grandparents’ origins.  The 
work and conclusions reached proved to be of broad consequence, beyond the 
scope of the proposed treatise and I decided to continue this work as a Master of 
Philosophy. This initial work provided evidence that: 
 24 
a) Australian AJ individuals can correctly self-identify TSD carrier risk to health 
professionals and that  
b) a sustained high TSD carrier frequency exists amongst Australian AJ individuals, 
based on allele frequencies in individuals now aged 20-40 (senior high school 
students at the time of screening). 
 
The methodology and results of this early  work (Lew et al, 2011 Tay-Sachs disease 
preconception screening in Australia: self-knowledge of being an Ashkenazi Jew 
predicts carrier state better than does ancestral origin, although there is an increased 
risk for c.1421+1G>C mutation in individuals with South African heritage, Journal of 
Community Genetics) is included as Chapter 4 of this thesis. 
 
In light of these clinically significant findings, I hypothesised that if TSD 
preconception genetic screening was an effective preventative strategy, then near 
complete prevention of future Jewish TSD cases in Australasia should be 
achievable. More exciting still, if a single rare recessive disease could be prevented 
by preconception screening, why not extend the concept to other recessive diseases 
with similar carrier frequencies such as cystic fibrosis?  However, I identified several 
impediments to this happening. These included: 
1. The lack of awareness of pre-conception genetic screening in the general 
medical community 
2. The lack of public funding for preconception genetic screening 
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3. In the case of Ashkenazi individuals and TSD, the uneven access to 
preconception genetic screening programs, based on whether students 
attended a participating private school.   
 
An obvious barrier to a future application for public health funding of a preconception 
health promotion and preventative medicine based genetic screening strategies was 
the lack of current Australasian supporting evidence based medicine publications 
supporting the relevance and efficacy of this practice. 
 
 At the suggestion of my annual progress report panel and with the support of my 
research supervisors, I decided to extend my research to identify evidence 
supporting or refuting my hypothesis that TSD preconception screening of AJ 
individuals in the Australian context was effective, and that extending TSD screening 
should be supported by an evidence based guideline. I then converted my 
candidature to this PhD. 
 
Prior to my research into this area, the clinical benefit of existing Australasian TSD 
screening programs was hypothesised but unproven. Collaborative research had not 
been previously undertaken by existing Australian AJ genetic screening programs.  
Pooling and analysis of their combined data had never previously been achieved. To 
confirm and quantify the benefit of preconception genetic screening for TSD in at-risk 
AJ populations and from there to argue for extension of TSD preconception 
screening to all Australasian AJ individuals of reproductive age, it was necessary to 
investigate the clinical effectiveness of previously undertaken TSD screening in 
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Australasia. There existed many reasons why this had not been attempted before. 
TSD cases were not mandatorily reported or collected in any existing database and 
occurred across different medical and state jurisdictions. Multiple barriers existed to 
acquiring comprehensive knowledge of cases, amongst them, obtaining the approval 
of 3 parallel ethics committees. 
 
I proposed to conduct a complete and consecutive retrospective audit of all TSD 
cases diagnosed in Sydney and Melbourne during the period in which TSD 
screening programs operated (Chapter 5). A key logistic discovery gave me 
confidence that this undertaking was possible and achievable - only 3 Australian 
testing laboratories had functional diagnostic capability for TSD testing during my 
proposed study period. It was therefore apparent that all TSD cases were referred 
for diagnostic testing to one of  these three laboratories. To discover and synthesise 
a complete record of TSD cases into a single de-identified database involved 
collaboration between the two Australasian TSD screening programs and the three 
national testing laboratories to which diagnostic tests were referred during the time 
period, located in Sydney, Melbourne and Adelaide. With multiple permissions and 
trans-institutional collaborations, I created was able to analyse all cases of TSD 
diagnosed in Sydney and Melbourne during the study period. This not only involved 
a review of laboratory records, but also a physical review of hospital records for 
which I travelled interstate and personally reviewed handwritten medical notes 
relating to cases. From medical and genetic counselling clinical documentation and 
laboratory records I was able to determine and compare observed TSD cases 
(Jewish and non-Jewish) with the number of cases predicted for the same period 
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based on Australian birth registry and Australian Bureau of Statistics national census 
data. From TSD screening program database comparison, I determined that no AJ 
screening program participant found to be a TSD carrier had been the parent of a 
TSD affected child born in Sydney or Melbourne during the study period. I also 
demonstrated a reduction in Jewish TSD cases during the study period. The 
methodology and results of this work (Lew et al, 2012, Tay Sachs disease in 
Australia: reduced disease incidence despite stable carrier frequency in Australian 
Jews, Medical Journal of Australia) is included as Chapter 5 of this thesis. In two 
Jewish cases of TSD diagnosed during the study period, none of four AJ parents had 
TSD preconception screening. Furthermore, no AJ individual who had TSD 
preconception screening had gone on to have a TSD affected child.  
 
It became evident that TSD preconception screening in Australasia, previously 
proved to be cost effective (Warren et al.) was also a highly effective preventative 
strategy. My hypothesis that near-complete prevention of TSD would be possible 
should the entire AJ population of reproductive age at risk of TSD have access to 
preconception genetic screening was now supported by evidence derived from 
Australasian research data.  The challenge for the future, would be reaching the 
residual at-risk Australasian AJ target population who currently have not had access 
to established TSD genetic screening programs and affiliated outreach screening 
strategies. Currently, TSD screening programs target mature adolescents and 
operate in non-government Jewish high schools. Due to these limitations, fewer than 
50% of Australian AJ individuals of reproductive age at risk of TSD have accessed 
these programs. In contrast, Australians may universally access community-based 
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healthcare provision. A feasible strategy to capture the residual AJ target population 
is to offer preconception and antenatal TSD screening via primary healthcare 
providers. Up until now, no Australasian clinical practice guidelines have existed to 
support primary health care clinicians and publicise this practice. 
 
As a precursor to the development of such a guideline, in collaboration with a team 
of experts, I undertook to systematically review the Australian and international 
literature on TSD preconception and antenatal screening practice. This was 
necessary as no similar contemporary Australian or international publication had 
been authored by other researchers. Using the Australian National Health and 
Medical Research Council evidence grading system, we derived the first 
Australasian evidence based best practice recommendations series for TSD 
preconception and antenatal screening in AJ individuals of reproductive age. This 
work, (Lew et al 2014, Ashkenazi Jewish population screening for Tay–Sachs 
disease: The International and Australian experience, Journal of Paediatric and Child 
Health) is included as Chapter 6 of this thesis.  This paper was intended to aid and 
encourage extension of the proven benefits of TSD screening programs to all AJ 
individuals of reproductive age, with the aim to achieve near-complete prevention of 
TSD. While conducting this work, I was thrilled to be invited by the Human Genetic 
Society of Australasia (HGSA)/ Royal Australia and New Zealand College of 
Obstetricians and Gynaecologist Joint Committee for preconception and antenatal 
screening to chair a multidisciplinary expert panel to derive the first Australasian 
clinical practice guideline for population genetic screening in Ashkenazi Jews 
(Chapter 8).  
 29 
 
During the course of my involvement of TSD preconception screening research, 
technological advances have been rapidly occurring. The Sydney TSD program, 
currently based at the PaLMS Pathology North laboratories of NSW Health 
Pathology at Royal North Shore Hospital, St Leonards department of Laboratory and 
Community  Genetics (but shortly to transition to the SEALS Genetics laboratories of 
NSW Health Pathology at Prince of Wales Hospital, Randwick), is in the process of 
assessing the possible implementation of MPS technology as a diagnostic standard 
for AJ preconception screening.  As part of the process of analytical and clinical 
validation, testing for the 2013 and 2014 Sydney AJ screening program for TSD was 
run in parallel using both conventional DNA testing for 5 conditions and a pilot MPS 
expanded panel of 26 conditions (Leslie Burnett, Personal Communication). 
Projected clinical impact of this change and ethical issues raised are explored in 
Chapters 7. 
 
Results from the 26 condition AJ MPS preconception screening pilot study are 
anticipated to be available for analysis in 2017. Together with the Sydney AJ 
Community Genetic screening research group, I plan to submit a further manuscript, 
comparing predicted and observed outcomes for the 26 condition MPS panel pilot 
study. This work will be completed beyond the end of my PhD candidature.  
 
In Chapter 9, I discuss my results, draw conclusions and also outline the directions 
my continued research in the area of preconception health promotion will take in the 
immediate future.      
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Posters presented at international peer review forums and published in their 
respective proceedings have been included alongside this thesis (Appendix 1). 
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2.2 Aims and Hypotheses 
2.2.1. Chapter 4 
Hypothesis: Ashkenazi Jewish individuals at risk of TSD are able to know and 
accurately report their heritage, which correlates strongly to their TSD risk profile.  
 
Study Aim: To assess the ability of Australian Jewish individuals screened for TSD to 
self-report Ashkenazi Jewish heritage. To compare TSD carrier frequency in 
contemporary Australian AJ populations of reproductive age to historical international 
cohort data from the 1970’s and 1980’s in order to quantify current reproductive risk.  
To assess how AJ heritage and grandparental country of origin correlates with TSD 
risk, both overall and in the case of specific common AJ HEXA gene mutations. 
 
Implications: In order to successfully apply preconception screening for TSD in at 
risk individuals as a broadly effective health promotion and disease prevention 
strategy, individuals at risk must be identifiable to clinicians. It has been an 
unconfirmed assumption that high TSD carrier risk exists in contemporary Australian 
AJ populations of reproductive age. Demonstration of individual’s accurate self-
reporting of Ashkenazi Jewish heritage, and strong correlation with TSD risk 
supports the possibility of extending TSD screening to Jewish individuals at risk 
outside of established TSD screening programs through primary care clinician led 
screening. 
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2.2.2 Chapter 5  
Hypothesis: Australian TSD preconception screening programs are a cost-effective 
and effective primary prevention strategy, which result in a reduced incidence of 
TSD. 
Aim: To perform a complete and consecutive audit of all cases of TSD diagnosed in 
Melbourne and Sydney during the period correlating to Jewish TSD screening 
programs operation. To identify the Jewish and non-Jewish heritage of TSD cases. 
To assess for a reduction in observed Vs expected Jewish TSD cases. Predicted 
TSD cases were determined on the basis of Australian Bureau of Statistics census 
population data and known TSD carrier frequencies in Jewish and other populations. 
 
Implications: Demonstrated effectiveness of Australian TSD screening programs in 
primary prevention of TSD cases supports: 
A) The continuation of existing high-school based TSD screening programs offering 
preconception genetic screening to a mature adolescent target population. 
B) The extension of TSD screening to the Australian Jewish population who 1) are at 
increased risk of being a TSD carrier and 2) have not accessed existing TSD 
preconception screening programs.  
C) The development of practice guidelines to facilitate clinician-led, community-based 
TSD screening to complement existing screening programs. 
 
2.2.3 Chapter 6 
Hypothesis: Near total prevention of TSD in Jewish individuals could be achieved by 
extending preconception and antenatal genetic screening to all Jewish individuals at 
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risk. This is cost-effective and achievable via a combination of high-school based 
genetic screening programs and  primary care clinician lead TSD screening. Best 
practice guidelines for TSD preconception screening are called for to provide an 
accessible evidence based resource to aid clinicians to extend the benefits of TSD 
preconception screening to the AJ target population at risk of TSD. 
  
 
Aims: To systematically review the Australian and international literature and develop 
an Australasian best-practice model for primary care clinician lead AJ TSD 
screening. 
 
Implications: Clinicians may access an Australasian evidence based 
recommendations for TSD screening in Jewish individuals at increased risk. By 
facilitating TSD screening in the community setting, equable access to screening 
may be achieved for all AJ individuals at risk of TSD. This will predictably result in a 
net increase in informed reproductive choice and, potentially near total prevention of 
Jewish TSD cases may be achieved. 
 
2.2.4 Chapter 7 
 
Hypothesis:  Next generation DNA sequencing technologies are changing the way 
genetic testing will be conducted in the future. This technology will in the future 
replace conventional DNA testing for preconception genetic screening programs. 
Workplace and ethical implications of this change require evaluation. 
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Aims: To compare current with projected future genetic counselling referral rates 
using a conventional DNA mutation testing panel vs a massively parallel sequencing 
model to conduct Ashkenazi Jewish pre-conception genetic screening.  
To mathematically model rates of primary, secondary and unexpected incidental 
findings (IFs) detected using an MPS screening model for AJ preconception genetic 
screening. 
 
To evaluate the clinical and workforce implications of adopting modernised DNA 
sequencing technologies for TSD carrier screening in the context of an expanded 
Ashkenazi Jewish panel.  Findings of early mathematical modelling of expanded 
screening AJ screening panels projected results are reported in Appendix 1. 
 
Implications: Preconception genetic screening using next generation DNA 
sequencing and an expanded panel will result in much higher number of carriers 
identified requiring genetic counselling. The rate of secondary and unexpected 
incidental findings in this cohort is unknown. Sequencing derived data may be 
longitudinally re-interpreted as scientific knowledge evolves over time, resulting in 
delayed secondary and IFs. The current concepts of informed consent are 
challenged by this practice. Ethical and legal obligations of laboratories and 
clinicians are unspecified. Supportive infrastructure is lacking. These issues require 
discussion and debate. 
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2.2.5 Chapter 8 
Hypothesis:  Providing a high quality, comprehensive, professionally ratified 
universally accessible online resource to primary care clinicians will improve access 
to best practice AJ preconception and antenatal screening and reduce disease 
incidence. 
 
Aims: To synthesise findings from evidence based research conducted in the course 
of this thesis and from the international literature. To design screening protocols and 
clinical pathways that are easy to implement in various relevant reproductive 
scenarios.  To support primary healthcare clinicians by documenting current referral 
pathways and by providing links to patient information and support services.   
 
Implications:  Use of this guideline will aid in improved access to preconception 
genetic screening, improve reproductive options open to couples and reduce disease 
burden in our Australian community. 
 
2.3  Research protocols 
Research methodology of each arm of my thesis is described in detail within 
publications incorporated in Chapters 3, 4, 5, 6,  and 8. 
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2.4  Human Research Ethics Committee (HREC) Approvals 
Ethics approval for the conduct of research described in this thesis was obtained 
prospectively from the following HRECs:  
1. Hawkesbury HREC of the Northern Sydney Central Coast Area Health Service of 
the New South Wales Government Department of Health, (Reference 0810229M) 
2008 
2. Royal Children’s Hospital HREC (Reference 32016A) 2011 
3. Northern Sydney Local Health District HREC (Reference 1201 – 034M) 2012 
 
All HREC approvals relating to all elements of research conducted in the course of 
this PhD assessed work conducted to be of negligible/low risk.  
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Chapter 3: 
 
 
Chapter 3 reviews current Australian practice in screening for TSD. 
 
This paper has been published as: 
 
 
Lew RM, Burnett L, Proos, AL, Delatycki M Tay-Sachs disease : current 
perspectives from Australia,The Application of Clinical Genetics: 2015:8,19-25 
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Abstract: Tay-Sachs disease (TSD) is a fatal, recessively inherited neurodegenerative condition 
of infancy and early childhood. Although rare in most other populations, the carrier frequency is 
one in 25 in Ashkenazi Jews. Australian high-school-based TSD preconception genetic screen-
ing programs aim to screen, educate, and optimize reproductive choice for participants. These 
programs have demonstrated high uptake, low psychological morbidity, and have been shown to 
result in fewer than expected Jewish TSD-affected births over 18 years of operation. The majority 
of Jewish individuals of reproductive age outside of the high school screening program setting 
in Australia have not accessed screening. Recent recommendations advocate supplementing 
the community high school screening programs with general practitioner- and obstetrician-led 
genetic screening of Ashkenazi Jewish individuals for TSD and other severe recessive diseases 
for which this group is at risk. Massively parallel DNA sequencing is expected to become the 
testing modality of choice over the coming years.
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Tay-Sachs disease
Tay-Sachs disease (TSD), a fatal condition, is a neurodegenerative lysosomal sphingo-
lipid storage disorder. TSD is caused by mutations of HEXA (MIM *606869, gene map 
locus 15q23-q24). The HEXA gene product was identified in 1969 as the A-subunit of 
B-hexosaminidase enzyme (HEXA). The normal function of HEXA is to degrade GM2 
gangliosides in central nervous system cell lysosomes.1,2 In TSD, neuronal accumulation 
of sphingolipid GM2 gangliosides results in progressive loss of central nervous system 
function. Most infants with TSD appear healthy at birth. After a period of normal devel-
opment, affected individuals experience slow neurological decline and death in infancy 
(infantile TSD) or early childhood (intermediate TSD). A still milder form of TSD exists 
where individuals survive into adulthood. No cure or effective treatment to slow the 
progression of the disease is known.3 TSD has autosomal recessive inheritance, with 
TSD carriers being unaffected. In the case of carrier couples, 25% of pregnancies will 
be affected by TSD. TSD is a rare disease, with an incidence of one in 320,000 births in 
general populations (carrier frequency one in 250). The specific populations at a higher 
risk of TSD are: Ashkenazi Jewish (AJ), French Canadian, Irish, Pennsylvania Dutch, 
and Cajun communities. All populations exhibit specific HEXA founder mutations at 
high allelic frequencies.4
TSD screening initiatives
TSD incidence in unscreened Jewish populations is one in 3,900 births.5 The first TSD 
carrier screening program was introduced in the USA in 1971, representing a precedent 
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for population genetic screening for inherited diseases.6 By 
the year 2000, over 51,000 TSD carriers, including more than 
1,400 at-risk couples, had been identified via TSD screening 
programs around the world.7 Internationally, screening has 
reduced the incidence of Ashkenazi Jews with TSD-affected 
children by more than 90%.5
TSD and the Australian  
AJ population
The Australian Jewish community mainly reside in 
 Melbourne and Sydney8 and was estimated to number 97,300 
in the 2011 Australian Bureau of Statistics Census of Popula-
tion and Housing.9 The majority of Australian Jews have AJ 
heritage.10 TSD carrier frequency is approximately one in 
2511 in Australian individuals of AJ descent.11
Australian TSD genetic  
screening programs
Over 70% of Jewish adolescents in Melbourne and 50% 
in Sydney attend Jewish high schools that access TSD 
screening programs  (Eckstein, unpublished data, 2006). 
Although the at-risk population was primarily residing 
in Melbourne and Sydney, the testing laboratories were 
located remotely in different states of Australia: at the 
Chemical Pathology Department, Royal Brisbane Hospital 
(now part of Pathology Queensland) and at the Chemical 
Pathology Department, Adelaide Women’s and Children’s 
Hospital (now part of SA Pathology). All cases of TSD 
diagnosed in Australia prior to the commencement of 
TSD carrier screening in the  Australian AJ community 
underwent conf irmatory biochemical and/or genetic 
testing at one or more of these laboratory sites. Prior to 
1993, TSD testing and family cascade carrier screening 
in Australia was available through medical consultation 
only at these two laboratories. In 1993, a 2-year pilot 
study commenced in Sydney12 for what would develop into 
 Australia’s first TSD screening program for Jewish high 
school students.13 With the introduction of community 
screening, diagnostic TSD testing was then carried out 
in two additional  Australian laboratory sites: in Sydney 
(initially in the Clinical  Chemistry Department, Institute 
of Clinical Pathology and Medical Research, Westmead 
Hospital; sub sequently relocating in 1997 to the Laboratory 
and Community Genetics Department, Pacific Laboratory 
Medicine Services [PaLMS, now a part of NSW Health 
Pathology North], Royal North Shore Hospital) and to 
Melbourne (Victorian Clinical  Genetics Service).
Elements of successful international 
TSD screening programs were 
adapted for an Australian 
community
Educational campaigns focusing on the medical community, 
Jewish community, and religious leaders, and training of 
volunteers were undertaken to ensure dialogue occurred and 
the eventual model of TSD screening designed was adapted to 
community needs, expectations, and resources.14,15 Australian 
TSD screening programs adhere to international ethical stan-
dards with regard to individual privacy and patient autonomy.16 
Genetic screening within programs is fully informed and 
voluntary. Genetic screening programs targeting senior high 
school students have been associated with high uptake, both 
internationally and in Australia.13,17,18
TSD screening in Sydney
Following a 2-year pilot study (1993–1994),12 the 
Australasian Community Genetics Program (Laboratory 
and Community Genetics Department, Pacific Labora-
tory Medicine Services [PaLMS, NSW Health Pathology 
North], Royal North Shore Hospital [RNSH], Sydney) 
began as the first Australian TSD screening program 
in 1995, targeting 15–17-year-old students attending 
Jewish high schools.13  Originally based at Westmead 
Hospital, the community and administrative headquar-
ters of the program were relocated to the Wolper Jewish 
Hospital (situated geographically close to the heart of 
Sydney’s Jewish community), and the laboratory service 
subsequently moved to the Laboratory and Community 
Genetics Department, Pacific Laboratory Medicine Ser-
vices (PaLMS, NSW Health Pathology North]. A further 
possible relocation, to be similarly geographically closer 
to the Jewish community, is currently under discussion. 
Testing is free of charge to participating students, with 
costs being funded partially by philanthropic support from 
the Jewish community, and the balance from NSW Health. 
Parental written consent for participation in screening 
is required for students aged less than 16 years. Young 
adult outreach preconception genetic screening for TSD, 
and now also other recessive diseases common in the AJ 
community (cystic fibrosis, mucolipidosis type IV, Fanconi 
anemia, familial dysautonomia, Canavan disease, Bloom 
syndrome), is offered annually.13 As part of the high school 
program, an initial compulsory education session is facili-
tated for all students offered testing several days prior to 
voluntary sample collection, currently led by a qualified 
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genetic counselor. Students’ retention of knowledge 
 following participation in the pre-test education session 
has been found to be high.13 Uptake of voluntary test-
ing is 94%. Students who decline testing are provided 
with written information regarding access to testing in 
the future. Three options (A, B, and D) are offered to 
students regarding access to their test results. Scheme A 
is analogous to the Dor Yeshorim model,19 where carrier 
status is withheld by the testing laboratory. Results may, 
at a nominated later date, be interpreted in the context of 
a partner’s screening result and reported as a risk or pos-
sibility of TSD-affected pregnancy. In scheme B, results of 
the screening are made available to students immediately 
with genetic counseling. In Scheme D, students nominate 
to have a DNA sample taken and analyzed but reporting 
is deferred until a later time of the student’s choosing.20 
The vast majority of students currently choose scheme B 
(direct disclosure). Students who enter in Scheme D can, 
at a later date, nominate to change to Scheme A or B.
The emotional impact of testing has been shown to be 
acceptable to students, generating low levels of concern in 
adolescents found to be carriers.13 Specimen collection was 
initially by venepuncture (1995–2004) and subsequently by 
mouthwash sampling (2004–2014). Testing was initially by 
biochemical methods with DNA testing of confirmed carri-
ers (1995–2004). Today DNA-only initial testing is standard, 
with confirmation of carrier status by a second DNA method 
(1995–2014).21 Genetic counseling is routinely offered to all 
students found to be genetic carriers, and is also available on 
request to all students.
TSD screening in Melbourne
In 1998, a TSD carrier screening program, based on the 
Sydney model and conducted by Genetic Health Services 
Victoria until 2009, and subsequently by Austin Health, 
was established in Jewish high schools in Melbourne.22 
Testing incurred a cost of $40 AUD per student tested in 
1998, but was fully funded thereafter by Melbourne Jewish 
Community philanthropic organizations. The program is 
voluntary and is available to students aged 15–18 years. Ini-
tially, screening was for TSD only but has since expanded 
to include a panel of recessive conditions at increased 
frequency in Jewish populations. Pre-test education is 
provided, currently led by a qualified genetic counselor. 
Uptake increased from 67% (1998–2001) to 96% (2003) 
following the change of sample collection method from 
venepuncture to cheek-brush sampling.23 Informed  consent 
is obtained by a screening program team member in a 
one-to-one interview prior to students providing a DNA 
sample.18 Students found to be carriers are contacted by 
phone by a genetic counselor and offered an outpatient 
genetic counseling appointment. Additionally, carriers 
receive a copy of their result and an explanatory letter by 
mail to facilitate cascade screening of family members. 
A copy of their result and an explanatory letter is mailed 
to non-carrier students.18,23
A recent study was undertaken to assess the long-term 
(5- to 11-year) outcomes of screening within the Melbourne 
program.24 Validated questionnaires were sent to all carriers 
and two non-carriers per carrier screened between 1999 and 
2005. The questionnaire was completed by 34.8% of carriers 
and 21.7% of non-carriers. The percentage of participants 
who retained good knowledge of TSD with no significant 
difference in knowledge between carriers and non-carriers 
was 82%, and 83% of respondents were happy with the 
timing and high school setting of the screening and thought 
that this approach should continue. There was no significant 
difference in negative psychological consequences between 
carriers and non-carriers as assessed by validated anxiety and 
decision regret scales. Screened individuals were supportive 
of the program.
The Dor Yeshorim screening 
program – an alternative  
approach in ultraorthodox  
Jewish communities
The Dor Yeshorim screening program was estab-
lished in 1983 to provide access to TSD screening to 
the ultra-orthodox Jewish community in the USA in a 
format culturally acceptable to this demographic. A branch 
of this program has been operating in Israel since 1986.19 
The program has since been expanded to test for other 
significant recessive conditions at higher than background 
frequencies in Jewish populations, and can be accessed 
by request by ultra-orthodox AJ individuals around the 
world, including Australians. This program differs from 
mainstream genetic screening programs in several ways. 
Individual genetic results are not disclosed; instead, the 
point of interest is a potential couple’s genetic compat-
ibility. Non-compatible carrier couples not introduced as 
a suitable match. This mode of screening is designed to 
prevent disease and to avoid the stigma that may be associ-
ated with the knowledge of individual carrier status within 
relatively small ultra-orthodox communities.
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Pros and cons of TSD genetic 
screening in an adolescent 
population
The ideal setting in which to screen for TSD is an informed 
adult couple planning a future pregnancy.26 Unfortunately, 
this demographic often do not access preconception test-
ing for many reasons, including low knowledge of carrier 
risk, low knowledge of screening options, low motivation, 
cost of testing, or unplanned pregnancy.27,28 A factor that 
has most successfully increased uptake of preconception 
genetic screening for TSD internationally has been the 
i mplementation of screening programs that target an adoles-
cent population.15 Screening of senior high school students, 
as occurs in Australian AJ TSD genetic screening programs, 
captures a large proportion of the target population in an 
environment where both pre-test education and testing can 
be facilitated with relative ease. Senior high school students 
are mature minors, and are generally able to understand the 
implications of testing and provide informed consent.29,30 
Students educated prior to testing and then screened for 
TSD in a high school setting have been found to retain more 
information at the time of testing and 3–6 years following 
testing than adults screened in other settings.13,17,22,23 In order 
to be optimally relevant, TSD carrier screening must occur 
in a window before conception, with all reproductive options 
accessible, allowing couples to make informed choices 
in planning their family.31 Carrier testing in an adolescent 
population addresses the issue of TSD screening prior to 
pregnancy planning, thus allowing future informed access 
to a full range of reproductive options for at-risk families.32
TSD screening and diagnosis:  
assays and strategies
HEXA enzyme assay
In 1971 an assay for HEXA protein was developed, allowing 
the possibility of TSD antenatal testing and carrier screening.33 
HEXA enzyme testing remains the accepted gold standard 
for TSD screening and diagnosis. HEXA testing has 98% 
sensitivity, and can be used in pan-ethnic populations and in 
the presence of rare and/or founder mutations.34 TSD carri-
ers have enzyme activity 52% compared to non-carriers 
where enzyme activity is 60%.34 However, HEXA enzyme 
testing has several pitfalls. Testing requires venepuncture, 
which can lead to lower acceptance and participation rates in 
community screening. Technical limitations in overlapping 
reference intervals mean that there is an inconclusive range 
of enzyme activity (52% to 60%) in which it is difficult to 
distinguish TSD carriers from non-carriers.35 Rarely, false 
negative and false positive results can occur (eg, B1 allele36,37 
and pseudodeficiency alleles,38 respectively). Medications 
including oral contraceptives may affect detected enzyme 
levels.39
Traditional HEXA DNA testing
DNA molecular testing for a panel of known mutations is 
highly sensitive and specific when applied to an appropriately 
selected population.
In AJ populations, several mutant HEXA alleles have been 
demonstrated.40 Ninety-six percent of Jewish TSD carriers 
have one of three common mutations.6,7 c.1278insTATC, 
the most common mutation in AJ populations, is a frame-
shift mutation due to a four-base-pair insertion in exon 11, 
introducing a premature stop codon and causing protein 
truncation;41 c.14211GC, the second most common 
mutation in AJ populations, is a GmC transversion in the 
donor splice site of intron 12,40,42,43 and p.Gly269Ser is a 
rarer missense mutation.44
In AJ populations it has been shown that DNA mutation 
testing is the most accurate and cost-effective assay for TSD 
population genetic screening.5,45 DNA testing of mouthwash/
cheek brush samples improves participation rates compared 
with blood sampling required for biochemical testing.23 
Successful DNA testing of hair root specimens offers a 
sample amenable to extreme ease of transport, and potential 
use for outreach screening.46
Massively parallel DNA sequencing
Massively parallel DNA sequencing (MPS) has been shown 
to be superior to HEXA enzyme-based screening and tradi-
tional DNA genotyping methodologies in research settings.47 
MPS-based genetic screening can be applied to TSD, but 
also has the potential to simultaneously offer screening for 
high numbers of targeted genetic conditions in non-selected 
populations.48 The costs of MPS technology are reducing, but 
remain significant. Another limiting factor in the application 
of MPS-based genetic screening strategies is the unresolved 
issue of the interpretation and reporting of incidental find-
ings and variants of unknown significance.47,49 The Sydney 
AJ Community Genetic Screening program is currently 
conducting a pilot study using an expanded MPS panel for 
up to 26 recessive conditions as part of AJ preconception 
genetic screening (L  Burnett and A Proos, unpublished data, 
2014). Ioannou et al found that increasing the number of 
conditions included in the Melbourne AJ Community Genetic 
 Screening program from TSD alone to seven conditions 
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resulted in a decrease in knowledge and increase in predicted 
negative feelings if found to be a carrier of one or more of 
the conditions.18 Other studies are underway assessing the 
psychological impact of an expanded screening menu incor-
porating seven recessive conditions. Further research will be 
needed to ensure that MPS screening is conducted in a way 
that maintains ethical principles of autonomy, beneficence, 
non-maleficence, and justice. Information derived from 
MPS sequencing may have additional longitudinal benefits 
for patients as data collected may be re-interrogated in the 
future.50
Cost of testing
The costs of enzyme-, DNA-, and MPS-based assays are all 
similar in the range of $100 to $500 AUD (L Burnett and A 
Proos, unpublished data, 2014).
Following TSD enzyme testing (serum enzyme activ-
ity p leukocyte enzyme activity), DNA testing may also 
be required to address some of the technical limitations 
described above.
In addition to reagent costs, MPS sequencing will have 
supplementary costs for bioinformatics interpretation and 
reporting, which are yet to be formally assessed.
Models of screening
Screening models to identify carrier couples include one-step 
models where both partners undertake screening immediately 
and two-step models where partners are screened  sequentially. 
Under most circumstances,  two-step carrier screening is the 
most cost-effective option for at-risk couples. In the two-step 
screening model, the second partner is tested only where the 
first partner was confirmed by screening to be a TSD carrier. 
One-step carrier screening is appropriate in settings where 
the results of screening are urgently required (eg, during a 
pregnancy). The Dor-Yeshorim model also utilizes one-step 
carrier screening.51
Reproductive options  
for carrier couples
Options to avoid TSD-affected pregnancies in a couple at risk 
include using assisted reproductive technologies, including in 
vitro fertilisation/intracytoplasmic sperm injection with pre-
implantation genetic diagnosis or use of a donor gamete to 
achieve healthy embryos. In spontaneous pregnancies, ante-
natal diagnosis can be availed with the possibility of selective 
termination of TSD-affected pregnancies. Invasive methods 
of fetal diagnostic testing include chorion villus sampling 
and amniocentesis. Both these methods carry a test-related 
risk of miscarriage (0.5% to 1%) and are offered from the 
late first trimester of pregnancy onward.52  Detection of free 
fetal DNA in a maternal blood sample offers a promising 
non-invasive option for future fetal diagnosis that could 
potentially be offered from the very early first trimester of 
pregnancy onward.53 Other options for couples at risk include 
the use of donor gametes, adoption, making a decision to 
remain childless, leaving the pregnancy outcome to fate, or 
(as with the Dor Yeshorim program) avoiding the issue by 
having chosen a partner who was already known not to be a 
potential “at-risk” couple partnership.
Success of Australian TSD  
screening programs
Measures of the success of a genetic screening program 
include uptake within the target population, percentage of 
the target population offered access to screening, the level of 
informed consent among individuals screened, the reduction 
of target disease incidence over time through the uptake of 
assisted reproductive technologies, and selective pregnancy 
termination and economic outcomes.54
In world Jewish communities, TSD carrier screening 
programs have reduced the births of infants with TSD 
by 90%.6,17,18 Prior to 1970, 85% of TSD affected infants 
were born to Jewish parents. TSD frequency in non-Jewish 
populations has, during the same time-frame, remained stag-
nant. Currently the majority of TSD affected infants are born 
to non-Jewish parents.6,55 Studies of the allele frequencies of 
several genes in the Australian Jewish population in Sydney 
including HEXA, BRCA1, BRCA2, and APC indicate the 
Australian Jewish population is not statistically different 
from Jewish populations in Israel, USA, and Canada and 
is therefore comparable to international Jewish populations 
with regard to the burden of genetic diseases.11,56 The impact 
of wide reaching TSD screening programs targeting Jewish 
communities in Australia can, in the long-term, be expected 
to have similar implications for reducing TSD incidence as 
international programs have demonstrated. In 2011, a com-
prehensive and consecutive audit of all TSD cases diagnosed 
in Australia from 1995 onward was conducted.55 Fewer than 
expected numbers of Jewish TSD cases were noted within 
the audit, corresponding to the period where Jewish com-
munity TSD preconception genetic screening programs were 
operating in Sydney and Melbourne. The majority of TSD 
cases were found to have occurred in non-Jewish Australian 
 families. No AJ TSD preconception genetic screening 
 program participant over the past 18 years has gone on to 
have a TSD-affected child. Two cases of TSD have occurred in 
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Australia since 1995 affecting two different AJ families. None 
of the four AJ parents of the two AJ TSD-affected infants had 
previously undergone TSD genetic screening.
A major pitfall in Australian AJ genetic screening 
is low participation rates outside of adolescent-focused 
high school screening programs, with fewer than 50% of 
Australian Jewish individuals of reproductive age having 
accessed these programs (Eckstein, unpublished data, 
2006).51 This residual target population relies on personal 
request or health care clinician referral for TSD screening. 
Barriers to clinician referral include costs, time constraints, 
and availability of supporting services, as well as patient and 
clinician education.57 In Israel, clinicians are instructed to 
offer access to genetic screening for TSD to all AJ women 
of reproductive age, ideally prior to pregnancy, but also 
during pregnancy. The Israeli system is an example of how 
clinicians can effectively facilitate preconception genetic 
screening strategies to prevent the targeted condition/s.31,58 
The Human Genetics Society of Australasia is currently 
formulating guidelines to assist Australian healthcare 
providers in implementing this  practice (I Stechiwskyj, 
unpublished data, 2014).
As MPS-facilitated genetic screening technology 
evolves and costs reduce over time, it is highly likely that 
genetic screening for a large range of serious rare genetic 
diseases will become routine in antenatal care in pan-ethnic 
populations. As has been demonstrated with TSD in AJ com-
munities that have been intensively studied, genetic screening 
can be expected to have a net health benefit to families and 
communities. Further research is needed to understand how 
expanded genetic screening for a greater number of condi-
tions will impact screened individuals psycho-socially to 
optimize the potential nethealth benefit of screening.
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Chapter 4 reports allele specific TSD carrier frequencies from longitudinal  
Australian TSD preconception screening program data (1995 to 2007) and 
correlates self-reporting of Ashkenazi Jewish heritage with TSD carrier risk 
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Abstract The Australasian Community Genetics Program
provided a preconception screening for Tay-Sachs disease
(TSD) to 4,105 Jewish high school students in Sydney and
Melbourne over the 12-year period 1995–2007. By corre-
lating the frequencies of mutant HEXA, MIM *606869
(gene map locus 15q23-q24) alleles with subjects’ nomi-
nated ethnicity (Ashkenazi/Sephardi/Mixed) and grandpa-
rental birthplaces, we established that Ashkenazi ethnicity
is a better predictor of TSD carrier status than grandparental
ancestral origins. Screening self-identified Ashkenazi sub-
jects detected 95% of TSD carriers (carrier frequency 1:25).
Having mixed Ashkenazi and non-Ashkenazi heritage
reduced the carrier frequency (1:97). South African heritage
conveyed a fourfold risk of c.1421+1G>C mutation
compared with other AJ subjects (odds ratio (OR), 4.19;
95% confidence interval (CI), 1.83–9.62, p=0.001), but this
was the only specific case of ancestral origin improving
diagnostic sensitivity over that based on determining
Ashkenazi ethnicity. Carriers of c.1278insTATC mutations
were more likely to have heritage from Western Europe
(OR, 1.65 (95% CI, 1.04–2.60), p=0.032) and South
Eastern Europe (OR, 1.77 (95% CI, 1.14–2.73), p=0.010).
However, heritage from specific European countries inves-
tigated did not significantly alter the overall odds of TSD
carrier status.
Keywords Tay-Sachs disease . Australia . South Africa .
Jewish . Screening
Abbreviations
AJ Ashkenazi Jewish
TSD Tay-Sachs Disease
Introduction
Tay-Sachs disease (TSD) is a fatal neurodegenerative
lysosomal sphingolipid storage disorder caused by muta-
tions of HEXAMIM *606869 (gene map locus 15q23-q24).
The HEXA gene product is the α-subunit of β-
hexosaminidase, a dimeric enzyme involved in the lyso-
somal degradation of GM2 gangliosides. TSD carrier
frequency is approximately 1:25 in individuals of Ashke-
nazi Jewish (AJ) descent (Kolodny 2009). TSD incidence
in Jewish people is one in 3,900 births, compared to one in
320,000 births in the general population (Triggs-Raine et al.
2001). Several mutantHEXA alleles have been demonstrated
in the AJ population (Arpaia et al. 1988).
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The Australian Jewish community (estimated population
104,000) mainly reside in Melbourne and Sydney (Rubinstein
1995). The majority of Australian Jews have Ashkenazi
heritage (Rutland 2005).
The Australasian Community Genetics Program (Labo-
ratory and Community Genetics Department, Pacific
Laboratory Medicine Services [PaLMS, Pathology North],
Royal North Shore Hospital, Sydney) facilitates senior high
school student and young adult outreach preconception
genetic screening for TSD and other recessive diseases
common in the AJ community (Gaucher disease, cystic
fibrosis, mucolipidosis type IV, Fanconi anemia, familial
dysautonomia, Canavan disease, Bloom syndrome) (Barlow-
Stewart et al. 2003). Over 50% of Jewish adolescents in
Melbourne and Sydney attend Jewish high schools that
access TSD screening programs (Australian Bureau of
Statistics 2006).
From 1995 to 2007, we conducted in Sydney TSD
genetic screening tests for 4,105 Jewish high school
students from Sydney and Melbourne. The Melbourne
subgroup have previously been reported in part (Gason et
al. 2005), and the design of the Sydney program has also
been described (Barlow-Stewart et al. 2003). These screen-
ing programs are based on established best-practice
principles, and the program design draws on the experience
of overseas TSD screening programs (Ekstein and Katzen-
stein 2001; Bach et al. 2007; Lowden and Davidson 1977;
Kaback et al. 1977). However, over time, individuals
screened are becoming drawn from a population that is
demographically different from any preceding generation.
Social change such as intermarriage, both within the Jewish
community (Ashkenazi/Sephardi) and within the general
Australian community (Jewish/non-Jewish) may be chang-
ing their risk profiles. It is therefore possible that strategies
of offering screening to the entire Jewish community
through high school and adult preconception access points
may become less effective over time due to lack of
identification of subjects as being at risk for TSD carrier
status.
Our study has reviewed key demographic and gene-
alogical parameters of subjects and correlated them with
the encountered TSD carrier frequencies of different
mutant HEXA alleles in the modern Australian AJ
community, with respect to self-recognition of being AJ,
and with grandparental country of origin. We separately
compared findings from Australia’s two largest cities,
Sydney and Melbourne, to maximize the likelihood of
detecting local community trends or differences. From
these studies, we sought to clarify the risk profiles of the
current generation of Jewish youth choosing preconcep-
tion TSD carrier screening in the context of planning
screening strategies for the future.
Materials and methods
The study was approved by the Hawkesbury Human
Research Ethics Committee of the Northern Sydney Central
Coast Area Health Service of the New South Wales
Government Department of Health.
Between 1995 and 2007, TSD carrier screening was
offered through a community-funded program to 16–18-
year-old students attending Jewish high schools in both
Sydney and Melbourne. Participation was voluntary and
informed through pretest genetic counseling. Participants
provided written consent for TSD genetic testing, with
optional additional consent for involvement in further
research and development. In Sydney, all students also
answered a demographic questionnaire at the time of
testing. Data collected included nominated ethnicity (Ash-
kenazi/Sephardi/mixed Jewish/non-Jewish), the country of
birth of the participants, of their two parents, and their four
grandparents. In Melbourne, this questionnaire was an-
swered only by participants screened between 1997 and
2002. Data from all subjects who answered the question-
naire have been included in the study. Further follow-up
contact with individual subjects was limited to only those
subjects who had consented to involvement in research and
development.
TSD carrier screening was performed using DNA
extracted either from venous blood samples (1995–2004)
or from buccal cell wash sample (2005–2007). Results of
testing were entered into a secure database system and de-
identified prior to this study. Our laboratory methods were
as described previously (Warren et al. 2005); note that our
laboratory protocol requires HEXA mutations identified by
enzyme analyses to be confirmed by HEXA DNA analysis
before inclusion in our database. HEXA enzyme testing
was replaced by HEXA DNA-only testing from 2005
onwards. DNA-only-based testing is designed to detect
the three common HEXA mutations in the AJ population
(Table 1). DNA-only testing has been shown to be a highly
sensitive and cost-effective method at detecting heterozy-
gotes in an orthodox AJ cohort of 38,197 individuals in
Israel (Bach et al. 2001), with equivalent specificity
compared to enzyme-based testing. In Bach’s cohort,
enzyme testing had variable sensitivity (93.1–99.1%) and
specificity (88.1–98.8%) and, amongst 151 obligate carriers
tested, no low-prevalence mutations were found. Enzyme
testing in theory affords the possibility of detecting low-
prevalence HEXA DNA mutations (Triggs-Raine et al.
1990). In contrast to the findings of Bach et al., we
identified in our cohort two low-prevalence HEXA DNA
mutations by enzyme testing and confirmed by DNA
sequencing. However, due to the low prevalence of these
mutations, our group agrees with the finding of Bach et al.
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that DNA-only testing is currently the most cost-effective
method in a heterozygote AJ population.
Published analysis of this screening program found it to
be effective, with high uptake, low negative perceptions,
and high knowledge levels amongst participants. (Ioannou
et al. 2010a, b)
Demographic classification as to whether the subjects
considered themselves to be AJ, Sephardi, or mixed was by
self-declaration from the questionnaire responses provided.
Grandparents’ country of birth was also obtained from
the subjects’ questionnaires. Responses were stratified into
regions (Table 2), based on political geographic boundaries
and language to reflect Jewish community life in Europe
prior to World War II (WWII), with additional reference to
the Australian Bureau of Statistics Standard Australian
Classification of Countries (second edition) (Harper 2008).
The resultant geographic groupings we used were compa-
rable to those used in past published papers investigating
the frequencies of TSD carriers amongst AJ and non-AJ
groups during the premolecular and molecular era (Risch et
al. 2003; Peleg et al. 1994; Myrianthopoulos and Melnick
1977).
We also regrouped the data on grandparents’ birthplaces
so that individuals were categorized into only two groups:
having no grandparent or else having at least one
grandparent from any specific region/country. Using this
classification schema, note that individuals could belong to
more than one ancestral group.
All statistical analyses were conducted using the SPSS
v15.0 (IBM SPSS, Inc., Somers, NY, www.spss.com). P
values less than 0.05 were considered statistically significant.
Logistic regression analyses were performed to deter-
mine if country groups or individual countries were
significant predictors of carrier status. In the series of
logistic regression analyses, the dependent variables were
either c.1278insTATC mutation status (carrier/noncarrier) or
c.1421+1G>C mutation status (carrier/noncarrier). The
small sample size and number of cases of p.Gly269Ser
Table 1 Common HEXA mutations and their frequencies in Jewish populations previously studied (National Centre for Biotechnology
Information gene and protein sequence reference NM_000520.4: NP_000511.2)
Common HEXA
mutations in AJ
populations
Description of mutation Myerowitz and
Costigan 1988
(20 AJ carriers)
Peleg et al.
1994 (152
AJ carriers)
Grebner and
Tomczak 1991
(148 AJ carriers)
Paw et al.
1990 (156
AJ carriers)
Average of
these results
c.1278insTATC 4-base pair insertion in exon 11→
frame shift→stop codon (Myerowitz
and Costigan 1988)
14 (70%) 125 (82%) 108 (73%) 114 (73%) 361/476 (76%)
c.1421+1G>C G→C transversion in the donor splice
site of intron 12 (Arpaia et al. 1988;
Ohno and Suzuki 1988)
– 15 (10%) 26 (18%) 24 (15%) 65/456 (14%)
p.Gly269Ser Missense mutation (Ohno et al. 1988) – 6 (4%) 5 (3%) 6 (4%) 17/456 (4%)
Other – 6 (4%) 9 (6%) 12 (8%) 27/456 (6%)
Table 2 Geographic country groupings (constructed to study differential HEXA allele carrier frequencies by region of grandparents’ birthplace)
Country groupings Member countries (for purposes of this table)
Western Europe Austria, Belgium, Denmark, Finland, France, Germany, Holland/Netherlands, Italy, Norway, Portugal, Spain,
Sweden, Switzerland
North Eastern Europe Belarus, Estonia, Latvia, Lithuania, Moldova, Poland, Russia, Ukraine, Siberia
South Eastern Europe Bulgaria, Croatia, Czechoslovakia, Hungary, Romania, Serbia, Slovakia, Yugoslavia
UK England, Ireland, Scotland, Wales, UK (unspecified)
Southern Africa Mozambique, Namibia, South Africa, Zambia, Zimbabwe
North Africa and the
Middle East
Egypt, Iran, Iraq, Lebanon, Libya, Morocco, Syria, Tunisia, Turkey, Yemen, Middle East (unspecified)
Australia/New Zealand Australia, New Zealand
Israel/Palestine Israel, Palestine
Other countries Afghanistan, Argentina, Armenia, Azerbaijan, Barbados, Bolivia, Brazil, Burma, Canada, Chile, China, Cyprus, Fiji,
Greece, India, Indonesia, Japan, Kazakhstan, Malaysia, Mexico, Mongolia, Pakistan, Peru, Philippines, Singapore,
Sri Lanka, Trinidad and Tobago, USA, Uzbekistan, West Indies
Unknown Unknown, entry blank
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mutations prevented a similar analysis for p.Gly269Ser
mutation status. Either a country group or else an individual
country was entered as a covariate using a forced method of
entry. The logistic regression analyses generated odds ratios
with 95% confidence intervals, and absence of a grandpar-
ent from the major country group or individual country was
considered the reference category. Data from the Sydney
and Melbourne groups were initially analyzed separately
and, where no statistically significant difference of results
was found, results were then pooled and reanalyzed.
Results
Nominated ethnicity amongst AJ subjects studied is
expressed in Table 3. Table 4 describes the proportion of
subjects studied with at least one grandparent from each
predefined geographical region (Table 2) and from the nine
most common countries of origin. Table 5 describes the
relative proportions of common and de novo HEXA
mutations found in our study population. The two most
prevalent mutations seen, c.1278insTATC and c.1421+1G>
C, were further classified into ancestral regional groupings
(Table 6).
AJ ethnicity is a good predictor of being a TSD mutation
carrier (X2=69.07, df=1, p<0.001). Students with Europe-
an ancestry were more likely to be TSD carriers (X2=
2,247.24, df=9, p<0.001); however, further analysis by
individual European country of origin did not increase the
predictive power. Melbourne had a significantly higher
proportion of AJ subjects, compared with Sydney (X2=
10.48, df=1, p=0.001) (Table 3), and the two cities also had
differences in the relative proportions of subjects whose
ancestors were from different European geographic origins
(Table 4). South African ancestry conveyed a fourfold
increased likelihood of carrying the mutation c.1421+1G>
C (OR, 4.19 (95% CI, 1.83–9.62), p=0.001) compared with
other AJ subjects. Odds generated from logistic regression
analysis comparing c.1278insTATC and c.1421+1G>C
carrier status and grandparents’ birthplace for AJ subjects
are summarized in Table 7.
Discussion
The most likely explanation for the origin of multiple
HEXA mutations in AJ populations is that they arose
around 1100 AD by founder effect and genetic drift (Slatkin
2004; Durst et al. 2001; Risch et al. 1995; Goldstein et al.
1999; Niell et al. 2003; Frisch et al. 2004). Four
independent sphingolipid storage diseases have arisen in
the AJ population (TSD, Niemann-Pick disease, Gaucher
disease, and mucolipidosis type IV) leading some inves-
tigators to hypothesize a heterozygote advantage (Zlotogora
et al. 1988; Motulsky 1995; Myrianthopoulos and Melnick
1977).
The geographic ancestral origins of the Jewish popula-
tion screened for TSD carrier status in our study were
Ethnic group Sydney, N=2,846% (n) Melbourne, N=1,259% (n) Combined, N=4,105% (n)
Ashkenazi 76.9 (2,186) 81.3 (1,024) 78.2 (3,210)
Sephardi 3.2 (92) 1.8 (23) 2.8 (115)
Mixed 13.7 (391) 7.5 (94) 11.8 (485)
Unknown 6.2 (177) 9.4 (118) 7.2 (295)
Table 3 Nominated ethnicity
amongst Australian Jewish sub-
jects studied
Table 4 Individuals with at least one grandparent from defined geographic groupings (regions/countries)
Region Sydney,
N=2,846% (n)
Melbourne,
N=1,259% (n)
Country Sydney,
N=2,846% (n)
Melbourne,
N=1,259% (n)
Europe (unspecified) 68.6 (1,953) 87.2 (1,098) Ukraine 3.8 (107) 4.7 (59)
Western Europe 19.5 (554) 19.8 (249) Lithuania 9.7 (276) 4.4 (56)
North Eastern Europe 47.0 (1,337) 71.2 (897) Czechoslovakia 8.0 (227) 10.0 (126)
South Eastern Europe 21.8 (620) 22.0 (277) Germany 11.7 (332) 12.6 (159)
South Africa 32.2 (916) 11.0 (138) England 16.3 (464) 9.8 (124)
UK 18.3 (522) 11.0 (139) Hungary 11.8 (337) 10.1 (127)
North Africa+Middle East 7.8 (221) 5.6 (71) Russia 12.9 (366) 17.2 (217)
Australia/New Zealand 22.7 (646) 23.6 (297) Poland 26.2 (747) 54.6 (687)
Israel/Palestine 4.7 (133) 6.8 (86) South Africa 32.0 (910) 11.0 (138)
Other 9.8 (279) 7.0 (88)
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extremely diverse. When grandparents’ country of birth
was examined, 86 countries and five continents were
represented. North American demographic studies of AJ
TSD carrier frequency have identified varying carrier
frequencies between AJ communities founded by immi-
grants from different regions of Europe (Toronto, 1:14;
Baltimore, 1:22; and Washington D.C., 1:28; Average USA,
1:30) (Lowden and Davidson 1977). However, these studies
were based on results of enzyme-based carrier testing and
therefore made no distinction between individual AJ HEXA
allele frequencies among the subpopulations studied.
Although a small AJ community has existed in Australia
since the time of European colonization of Sydney in 1788,
the majority of the Australian AJ population was founded
by immigration subsequent to WWII. Similar to American
AJ immigration patterns, focussed communities of immi-
grants with shared recent language and heritage settled
separately in both Melbourne and Sydney, resulting in
slightly different subpopulation profiles. Significantly, more
subjects from Melbourne identified as AJ than from Sydney
(81.3% vs. 76.8%), correlating to reports of more grand-
parents born in Russia (17.2% vs. 12.9%) and Poland
Sydney Melbourne Combined
Sample size 2,186 1,024 3,210
Total TSD carriers 95 42 137
Noncarriers 2,091 982 3,073
Mutation-specific carrier absolute number/frequencies:
Total TSD carriers 95 (43:1,000) 42 (41:1,000) 137 (43:1,000)
c.1278insTATC 67 (31:1,000) 34 (33:1,000) 101 (32:1,000)
c.1421+1G>C 20 (9:1,000) 5 (5:1,000) 25 (8:1,000)
p.Gly269Ser 4 (2:1,000) 2 (2:1,000) 6 (2:1,000)
p.Arg24Tryp 2 (1:1,000) 0 2 (1:1,000)
p.Phe304del 0 1 (1:1,000) 1 (<1:1,000)
Private mutations
p.Arg499Cys 1 (1:2,000) 0 1 (<1:1,000)
p.His204Pro 1 (1:2,000) 0 1 (<1:1,000)
Table 5 Australian AJ mutation
profile; HEXA mutations identi-
fied in our study population
Table 6 AJ origin of grandparents by region, carrier status, and allele frequency of two common HEXA mutations (N=12,840)
Regional
groups
Total (N=12,840),
n (% of N)
Non-carrier
(N1=12,332),
n (% of N1)
Carrier (N2=508),
n (% of N2)
Absolute carrier
frequency ratio
(%)
c.1278insTATC
(N3=376),
n (% of N3)
c.1278insTATC
carrier frequency
ratio (%)
c.1421+1G>C
(N4=96),
n (% of N4)
c.1421+1G>C
carrier frequency
ratio (%)
Europe (all) 7,005 (54.5) 6,740 (54.7) 265 (52.1) 1: 26 (3.8) 217 (57.8) 1:32 (3.1) 22 (22.9) 1:318 (0.3)
North Eastern
Europe
4,310 (33.6) 4,166 (33.8) 144 (28.3) 1:30 (3.3) 113 (30.1) 1:39 (2.6) 20 (20.8) 1:215 (0.5)
Southern Africa 2,672 (20.8) 2,534 (20.5) 138 (27.2) 1:19 (5.2) 75 (19.9) 1:36 (2.8) 55 (57.3) 1:49 (2.1)
South Eastern
Europe
1,489 (11.6) 1,428 (11.6) 61 (12.0) 1:24 (4.1) 59 (15.7) 1:25 (4.0) 2 (2.1) 1:745 (0.1)
Western Europe 969 (7.5) 919 (7.5) 50 (9.8) 1: 19 (5.2) 38 (10.1) 1:26 (3.9) 0 (0.0) Unknown (0)
Australia/New
Zealand
1,172 (9.1) 1,134 (9.2) 38 (7.5) 1:31 (3.2) 34 (9.0) 1:34 (2.9) 4 (4.2) 1:293 (0.3)
UK 785 (6.1) 762 (6.2) 23 (4.5) 1:34 (2.9) 17 (4.5) 1:46 (2.2) 4 (4.2) 1:196 (0.5)
Uncertain 606 (4.7) 590 (4.8) 16 (3.1) 1:38 (2.6) 9 (2.4) 1:67 (1.5) 7 (7.3) 1:87 (1.2)
Other 350 (2.7) 335 (2.7) 15 (3.0) 1:23 (4.3) 13 (3.5) 1:27 (3.7) 2 (2.1) 1:175 (0.6)
Unspecified
Europe
237 (1.8) 227 (1.8) 10 (2.0) 1:24 (4.2) 7 (1.9) 1:34 (3.0) 0 (0.0) Unknown (0)
North Africa/
Middle East
53 (0.4) 45 (0.4) 8 (1.6) 1:7 (15.1) 8 (2.1) 1:7 (15.1) 0 (0.0) Unknown (0)
Israel/Palestine 197 (1.5) 192 (1.6) 5 (1.0) 1:39 (2.5) 3 (0.8) 1:66 (1.5) 2 (2.1) 1:99 (1.0)
N.B. The carrier category contains n=376 grandparents of a c.1278insTATC carrier, 96 grandparents of a c.1421+1G>C carrier and 40
grandparents of subjects with other mutations
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(54.6% vs. 24.2%). A larger proportion of Sydney
compared with Melbourne AJ subjects had grandparents
from South Africa (32.0% vs. 11.0%).
Demographic differences within the Sydney and Mel-
bourne communities did not affect overall TSD carrier
frequency in our study, which was 3.3% in both cities with
no significant difference between the cities (Table 5). AJ
TSD carrier frequencies were also comparable (Melbourne,
4.1%; Sydney, 4.3%) and similar to other AJ populations
worldwide (Kaback et al. 1977), suggesting participants
correctly identified their AJ origins. Self-identification of
AJ ethnicity correlated statistically with a higher proportion
of grandparents from North Eastern Europe, South Africa,
and South Eastern Europe (X2=2,247.24, df=9, p<0.001).
Confirmation of subjects’ correct self-identification of AJ
heritage and TSD carrier risk has not been previously
reported in a screened Jewish population outside of Israel
and USA in the current at-risk generation.
Variation in the frequencies of the c.1278insTATC and
c.1421+1G>C mutations was seen in the Sydney and
Melbourne subpopulations, mirroring demographic differ-
ences by grandparents’ country of birth demonstrated in
these cities.
Uptake of screening in individuals approached by our
group in Sydney and the Melbourne branch has been very
high (approaching 100%) since the advent of cheek brush/
mouthwash sampling. Ioannou et al. published a paper in
2010 evaluating TSD screening in Melbourne using a
purpose-designed questionnaire exploring student knowl-
edge (disease and genetics), reasons for screening, anxiety,
and predicted negative feelings if found to be a carrier. Two
hundred seventy-three students were offered screening and
272 (99.6%) completed the questionnaire. Only two
students chose not to have screening (Ioannou et al.
2010a, b). Unfortunately, demographic information on our
questionnaire has only been collected from study partic-
ipants. Although it is therefore not possible to determine the
ethnicity of any students who may have refused testing,
given the very small number of students declining testing
the potential for a negative ascertainment bias on this basis
is extremely unlikely to have influenced our findings.
Frisch et al. (2004) identified a conserved c.1278insTATC
haplotype in 55 unrelated AJ individuals, suggesting the
occurrence of a common founder in Central Europe. The
c.1278insTATC mutation was diagnosed in 73.2% of
Australian carriers (Sydney, 69.8%; Melbourne, 81.0%),
comparable to the figure of 70–82% reported in other AJ
populations (Peleg et al. 1994; Grebner and Tomczak 1991;
Paw et al. 1990; Myerowitz and Costigan 1988). However,
grandparents’ birthplace in specific European countries or
regions showed no significant relationship with grand-
children’s risk of c.1278insTATC carrier status (Table 7).
The c.1421+1G>C mutation was diagnosed in 18.9% of
Australian TSD carriers (Sydney, 21.1%; Melbourne,
11.9%), compared with 13% of American AJ TSD carriers
(Arpaia et al. 1988).The c.1421+1G>C mutation carrier
frequency was 1:49 in subjects with grandparents from
South Africa (OR, 4.19 (95% CI, 1.83–9.62), p=0.001),
compared to 1:129 in all Australian AJ subjects. The
increased proportion of Sydney AJ subjects with grand-
parents from South Africa (32.0% vs. 11.0%) mirrored
c.1421+1G>C increased frequency in Sydney vs. Mel-
bourne subpopulations (0.00915, 1:109 vs. 0.00488, 1:204).
The Jewish community in South Africa is of Eastern
European AJ origin (Meiner et al. 1991; Levin 2001),
overwhelmingly originally from Lithuania (Tatz et al.
2007). The AJ population in Lithuania plummeted from
the 755,000 recorded in Lithuania’s 1897 census to 153,743
Table 7 Odds of being a c.1278insTATC/c.1421+1G>C carrier considering grandparents’ birthplace for Ashkenazi subjects: none versus at least
one
Regional groups Zero grandparents ≥1 Grandparent
Total c.1278insTATC
carrier
c.1421+1G>
C carrier
Total c.1278insTATC
carrier
c.1278insTATC carrier
OR (95% CI)
P value c.1421+1G>C carrier
OR (95% CI)
P value
Europe (all) 732 17 14 2,478 77 1.35 (0.79–2.30) 0.270 0.21 (0.09–0.47) <0.001
North Eastern
Europe
1,327 40 14 1,883 54 0.95 (0.63–1.44) 0.808 0.50(0.22-1.13) 0.096
Southern Africa 2,286 70 9 924 24 0.84 (0.53–1.35), 0.480 4.18 (1.82–9.57) 0.001
South Eastern
Europe
2,473 62 22 737 32 1.77 (1.14–2.73) 0.010 0.30 (0.071–1.29) 0.11
Western Europe 2,570 67 24 640 27 1.65 (1.04–2.60) 0.032 0.00 (0.00) 0.99
Australia/New
Zealand
2,511 70 22 699 24 1.24 (0.77–1.99) 0.37 0.33 (0.076–1.38) 0.128
UK 2,698 82 21 512 12 0.77 (0.42–1.41) 0.393 0.75 (0.22–2.53) 0.64
North Africa/
Middle East
3,172 89 24 38 5 5.24 (2.00–13.77) 0.001 0.00 (0.00) 0.99
Israel/Palestine 3,068 92 23 142 2 0.46(0.11–1.90) 0.284 0.94 (0.13–7.00) 0.95
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in its 1923 census (Lane et al. 1985), caused by emigration
to South Africa, USA, and Canada. From 1941, Nazi
genocide achieved near complete annihilation of the Jews
of Kaunas and Vilnius provinces in Lithuania, the relatively
small area from which more than half of the South African
AJ population trace their ancestry (Lane et al. 1985). As a
result, there is now no surviving European reference
population. In a published survey conducted between
2003 and 2004, 608 Australian and New Zealand recent
South African AJ immigrants made 697 mentions of
ancestral homes in Kaunas (Kovno) province and 65 in
the Vilnius (Vilna) province (Tatz et al. 2007). The South
African AJ community expanded from 10,000 members in
1890 (Jenkins et al. 1977a, b; Lane et al. 1985) to 120,000
in the early 1980s. By 2007, an estimated 40% of South
Africa’s AJ population (47,000) had emigrated for social
and political reasons (Tatz et al. 2007).
It has been postulated that c.1421+1G>C mutations
may have existed at a higher allele frequency in a relatively
small area of Lithuania by founder effect and might be
preserved in individuals with grandparents from South
Africa. In data analyzed from the Dor Yeshorim TSD
screening program in New York and Jerusalem; Risch et al.
(2003), demonstrated a higher c.1421+1G>C allele fre-
quency in subjects with at least one grandparent from
Lithuania (0.0113) compared with mixed AJ group
(0.0041), where 3,718 of 249,372 grandparents with
Lithuanian origins. Risch et al. (2003) included an
unspecified number of subjects with South African ancestry
in the Lithuanian group but did not report of a significant
result in the subjects with South African heritage as a
subgroup. In our study, c.1421+1G>C mutation carrier
frequency was not increased among the small sample of
Australian subjects identifying at least one grandparent
from Lithuania (1:300).
In 1985, the TSD carrier frequency among the Jews of
South Africa was estimated to be 1:23 (Lane et al. 1985).
The National Health Laboratory service (previously the
South African Institute for Medical Research) has offered a
genetic screening service for TSD since the 1970s which
can be availed by individuals at risk (personal communi-
cation Dr. Amanda Krause and Ms. Fahmida Essop 2009).
Six of 43 AJ individuals screened by them for TSD were
c.1421+1G>C carriers (14% of individuals tested, 18% of
33 TSD carriers identified) a proportion greater than the
13% of TSD carriers expected for American AJ popula-
tions. This result is not directly comparable to our data,
given the different mode of patient selection and small
sample size. Further evaluation is undoubtedly required;
however, the trend is in the same direction as our Australian
data. AJ ancestry in our cohort was a risk factor for TSD
inheritance (X2=69.07, df=1, p<0.001). Mixed heritage
(AJ/Sephardi/non-Jewish) was shown to dilute this risk.
One hundred thirty out of 137 of the HEXA mutation
carriers detected through screening in our study were in AJ
self-identifying individuals. A policy of screening individ-
uals with AJ ethnicity would detect the majority of HEXA
mutation carriers with sensitivity of 95%. Amongst 895
individuals tested who did not self-identify as AJ, but as
“Sephardi,” “uncertain,” “Jewish,” or “mixed” ethnicity,
seven carriers were identified. The majority of these non-AJ
carriers (five of seven) were found in individuals with
“mixed” ethnicity (carrier frequency, 1:97; 1%) representing
3.6% of all carriers. All five mixed ethnicity carriers were
found to express the c.1278insTATC mutation. One carrier
of the c.1278insTATC mutation identified origins as
uncertain, and one carrier of the c.1421+1 G>C identified
as Jewish.
Two AJ individuals screened by enzyme analysis prior to
2005 were found to carry private mutations. One individual
carried the p.Arg499Cys mutation with grandparents from
Poland. The p.Arg499Cys mutation has been previously
seen in several ethnic groups including Polish (Mules et al.
1992).
The second mutation p.His204Pro has not been previ-
ously described, and we are in the process of characterizing
this (unpublished data). Grandparental ancestry of this
subject was Dutch and English.
Our research strategy involved the use of a de-identified
database of results. De-identification of data resulted in the
possibility of non-acknowledgment of familial relationships
within the database for both carriers and noncarriers.
c.1278insTATC carrier status was observed in five individ-
uals with at least one grandparent from the North African/
Middle Eastern region (OR, 5.25; 95% CI, 2.00–13.76, p=
0.001). These individuals all nominated their ethnicity as
AJ, suggesting European ancestry. The five subjects, all of
whom consented for their results to contribute to research
and development, were re-identified at arm’s length by a
secondary investigator post-analysis, and a familial rela-
tionship was confirmed in two of the five cases.
A strategy of investigating the relationship between
grandparent’s birthplace and TSD carrier status has some
inherent weaknesses. Without family pedigree testing, the
grandparent from whom an identified mutation was
inherited remains uncertain. Grandparent and parent carriers
with noncarrier offspring are undetected.
In countries like Australia which have become adopted
homes to immigrant Jewish communities, new generations
of AJ descent are experiencing continuing evolution of
cultural history and identity. Demography of the generation
we studied revealed the effect of the Australian “melting
pot,” with a large proportion of Jewish subjects identifying
as having mixed ethnicity. Our program was successful in
identifying its target population as 78.6% of subjects
screened identified as AJ. However, students attending
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non-Jewish high schools were not able to be offered cohort
TSD screening, representing a significant proportion of
young people remaining without access to screening and
thus at risk for being TSD carriers with decreased
opportunity to gain that knowledge.
Despite postulated demographic changes that have been
occurring since earlier studies of HEXA mutation frequen-
cies of AJ populations were undertaken (Lowden and
Davidson 1977; Kaback et al. 1977), the risk profile of
AJ individuals in our study regarding TSD carrier status
remains undiluted (carrier frequency, 1/25).
Conclusions
Nominated AJ ethnicity was the single best predictor of
TSD carrier risk in our study. Screening only those
individuals identified as having AJ heritage would identify
95% of all Australian Jewish TSD carriers.
Individuals of mixed AJ and non-AJ heritage have
reduced risk of being TSD carriers (1:97). Individuals with
one or more grandparents from South Africa had a fourfold
greater risk of being a carrier of c.1421+1G>C mutation,
compared with other AJ subjects.
The TSD carrier frequency for all mutations in Austra-
lian Jewish subjects is 1:30. The TSD carrier frequency for
all mutations in Australian AJ subjects is 1:25. This
proportion of AJ subjects who are TSD carriers is
unchanged from previous international studies despite
widespread demographic change and social influences such
as intermarriage in the wider community.
These findings suggest that the policy approach remains
sound in encouraging access to high school and precon-
ception TSD carrier testing for all members of the Jewish
community. However, should funding or resources limit the
ability to undertake full community screening, then the
alternative of screening only those subjects who identified
themselves as being AJ would identify 95% of carriers.
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Chapter 5: 
 
 
Chapter 5 reports the result of a complete and consecutive audit of all 
diagnosed cases of TSD in Australia and longitudinal TSD carrier frequencies 
in Australian AJ communities in the era of TSD preconception genetic 
screening program operation. It examines Australian Jewish community 
demographic data from Australian Bureau of Statistics assessments and 
reflects that fewer than expected Jewish TSD cases have occurred in the 
genetic screening era.  
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ay Sachs disease (TSD) is an
autosomal recessive lysosomal
storage disorder caused by
mutations of the HEXA gene1 (Men-
delian Inheritance in Man [MIM]
number,*606869; gene map locus,
15q23-q24)2 that cause hexosamini-
dase A enzyme deficiency.3 It is 100
times more common in Ashkenazi
(European) Jews (carrier frequency, 1
in 27) than in general populations
(carrier frequency, 1 in 250).4 Affected
babies appear normal at birth, then
experience slow neurological decline
and death in infancy (infantile TSD)
or early childhood (intermediate
TSD). No cure or effective treatment
exists.
Preconception genetic screening
programs for TSD have been intro-
duced in Jewish communities world-
wide to determine individuals’ carrier
status.5-8 Ninety-nine per cent of TSD
cases among Jewish people are caused
by three known HEXA mutations.9
Prospective identification of risk
allows individuals and couples to
make informed decisions about
reproduction.
Based on international best-practice
principles,8,10,11 Australian genetic
screening programs for TSD12 have
targeted senior Jewish high school
students in Sydney (from 1995 to 2012
through the Australasian Community
Genetics Program, Laboratory and
Community Genetics Department,
Pacific Laboratory Medicine Services
[PaLMS], Pathology North) and in
Melbourne (from 1998 to 2011
through Victorian Clinical Genetics
Services [VCGS]; and in 2012 through
Austin Health). Sydney and Mel-
bourne are home to Australia’s two
largest Jewish communities, where
50%–70% of Jewish high school stu-
dents attend schools that access
screening (Eckstein G. Demography of
the Sydney Jewish community: an
overview of information from the 2006
Census. Unpublished report commis-
sioned by the Jewish Community
Appeal (JCA); copies available on
request from http://www.jca.org.au).
The design of the Sydney program, on
which the Melbourne program is
based, has previously been described.7
Jewish-community-funded screening
is free to students and uptake is high
(99.6%).13 Screening programs offer
testing for additional conditions rele-
vant to the target community, includ-
ing Fanconi  anaemia ,  famil i al
dysautonomia, Canavan disease,
Bloom syndrome, glycogen storage
disease type 1a, mucolipidosis type IV,
Niemann–Pick disease type A and
cystic fibrosis.
An important measure of the suc-
cess of a genetic screening program is
the reduction of target disease inci-
dence over time. Other measures of
success include access to and uptake
of screening in the target popula-
tion.14 Here, we report the outcomes
of Jewish screening programs for TSD
on the incidence of TSD-affected
births in Sydney and Melbourne from
1995 to 2011, inclusive.
Methods
We retrospectively audited all TSD
cases diagnosed in Sydney and Mel-
bourne from 1995 through 2011. All
samples were processed by one or
more of three Australian laboratories
(PaLMS, Pathology North, NSW
Health Pathology, Sydney; VCGS,
Melbourne; and SA Pathology,
Adelaide). Laboratory records from
these centres pertaining to each case
were reviewed. Records of cascade
screening (ie, systematic screening
of relatives of affected infants) were
identified. We audited all laboratory
testing for TSD case diagnosis and
carrier screening during the study
period. This included diagnosis of
TSD cases, cascade screening and
s cr ee n i n g  p ro g r am  re f e r ra l s .
Between 50% and 70% of Jewish
high school students attend Jewish
high schools that participate in TSD
screening programs. Within TSD
screening programs, there is 99%
Tay Sachs disease in Australia: reduced 
disease incidence despite stable carrier 
frequency in Australian Jews
T Objectives: To evaluate the outcomes of preconception screening of Jewish Australians for Tay Sachs disease (TSD) carrier status on Jewish TSD-affected 
births.
Design, participants and setting:  Epidemiological observational study involving 
a complete retrospective audit of infantile and intermediate TSD cases 
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in our finding of fewer than expected Jewish babies with TSD. Ongoing outcome 
monitoring must continue.
AbstractRaelia M LewMB BS(Hons) MMed,
Postgraduate Research
Student1
Anne L Proos
MSc, FFSc(RCPA),
Scientist2
Leslie Burnett
MB BS, PhD, FRCPA,
Pathologist,2 and Clinical
Professor in Pathology3
Martin Delatycki
MB BS, FRACP, PhD,
Director4,5
Agnes Bankier
MB BS, FRACP,
Clinical Geneticist5
Michael J Fietz
PhD,
Senior Medical Scientist6
1 Department of
Obstetrics, Gynaecology
and Neonatology,
University of Sydney,
Sydney, NSW.
2 Pacific Laboratory
Medicine Services,
Pathology North,
NSW Health Pathology,
Royal North Shore Hospital,
Sydney, NSW.
3 Northern Clinical School,
Royal North Shore Hospital,
University of Sydney,
Sydney, NSW.
4 Bruce Lefroy Centre for
Genetic Health Research,
Murdoch Childrens
Research Institute,
Melbourne, VIC.
5 Department of Clinical
Genetics, Austin Health,
Melbourne, VIC.
6 Department of
Biochemical Genetics,
SA Pathology,
Adelaide, SA.
rlew2064@
uni.sydney.edu.au
MJA 2012; 197: 652–654
doi: 10.5694/mja12.11010
Research
653MJA 197 (11/12) · 3/17 December 2012
uptake among students offered
screening.
Parents of a child with TSD are
routinely asked about Jewish heritage,
and this information was obtained
from laboratory records, medical
records and clinical genetics files. Data
from testing laboratories and medical
records were cross-referenced to elim-
inate duplication of cases.
We identified all TSD cases diag-
nosed and obtained the medical and
laboratory records for audit. For all
TSD cases identified, parental TSD
carrier results were on record. We
cross-referenced case and cascade
screening results with screening pro-
gram data. Although our audit of lab-
oratory results identified family
members of TSD-affected Jewish chil-
dren who chose to undertake cascade
screening and were found to be TSD
carriers, no further analysis was per-
formed on the results of extended
cascade screening.
Statistical analysis
We obtained summary statistics for
births registered in Sydney and Mel-
bourne in 1995–2010.15-17 Births for
2011 (Australian Bureau of Statistics
[ABS] unpublished data) were esti-
mated based on consecutive data for
the previous 15 years.15-17 Jewish
births for 1995–2010 were proportion-
ally estimated from the 2006 Austral-
ian census report,18,19 and we used the
number of 0–4-year-olds identified as
Jewish as a proxy measure for births
during this 5-year census period.
De-identified data relating to all
students screened for TSD in Sydney
in 1995–2011 and Melbourne in 1998–
2011 were used to calculate TSD car-
rier frequency among Jewish students.
This was used to model expected
TSD-affected births among Jewish
Australians. Carrier frequency for TSD
in the general Australian population
has not been measured. We used the
World Health Organization estimate
for TSD carrier frequencies in mixed
populations (1 in 250 or 0.4%)20 to
model expected TSD-affected births
among non-Jewish Australians.
The predicted numbers of infants
born with TSD in Jewish and non-
Jewish Australians were calculated
using the Hardy–Weinberg equation.21
All statistical analyses were con-
ducted using SPSS version 15.0 (IBM
SPSS Statistics). 
Ethics approval
Ethics approval was obtained from
the Northern Sydney Local Health
District Human Research Ethics
Committee (HREC) and the Royal
Children’s Hospital  Melbourne
HREC.
Results
In the 2006 census, 88 826 of a total
19 855 288 Australians (0.45%) iden-
tified themselves as Jewish; 46% of
Jewish Australians lived in Melbourne
and 40% in Sydney.
Box 1 shows that the 7756 Jewish
high school students screened had a
TSD carrier rate of one in 31 (3.26%);
rates were similar in Sydney (3.39%)
and Melbourne (3.15%).
Box 2 shows ABS births data for
Melbourne and Sydney in 1995
through 2011.15-17
The 2006 Austral ian census
recorded 4394 Jewish children aged
0–4 years in Melbourne and Sydney.18
The census-based estimate of Jewish
births in Melbourne and Sydney in
1995–2011 was 14 940. Box 3 shows
numbers of observed and predicted
TSD-affected babies born in Sydney
and Melbourne in 1995–2011; a total
of 12 babies with TSD were born in
this period — four in Sydney and
eight in Melbourne — of whom two
were Jewish.
The observed ratio of Jewish to
non-Jewish TSD-affected births was
1:5 compared with the expected ratio
of 1:2. No Jewish TSD carrier identi-
fied through screening has had a
TSD-affected child.
Our audit showed that no parents
of TSD-affected Jewish children had
participated in screening, and no
screening program participants were
parents of TSD-affected children.
Discussion
Twenty years after the introduction of
TSD carrier testing in Australia,13 there
have been fewer than expected Jewish
TSD-affected births (Box 3). Further,
no genetic carrier identified through
screening has had a TSD-affected
child. As many of these individuals,
now aged 16–38 years, have not com-
menced and/or completed their fami-
lies, the full impact of the screening
program is yet to be realised.
3 Expected and observed Tay Sachs disease-affected births in Sydney and 
Melbourne, 1995–2011
Jewish Non-Jewish Total
Overall ratio of Jewish 
to non-Jewish 
TSD-affected births
Expected births 4.1 7.4 11.5 1:2
Observed births 2 10 12 1:5
Rate ratio 
(95% CI)
0.49 
(0.06–1.76)
1.35 
(0.65–2.49)
2 Summary of Australian Bureau of Statistics births data for Sydney, New South 
Wales, Melbourne and Victoria, 1995–2010
Year Sydney
New South 
Wales Melbourne Victoria
1995–1999 Unpublished 433 833 Unpublished 303 833
2000–2004 285 037 430 151 224 458 302 750
2005–2009 303 045 450 887 257 095 340 931
2010 65 106 95 918 54 023 70 568
2011 Unpublished Unpublished Unpublished Unpublished
Estimated births 1995–2011 1 009 470 1 499 000 827 700 1 081 700
1 Summary of results from Tay Sachs disease (TSD) screening programs in 
Melbourne and Sydney, 1995–2011
TSD screening 
program
Total students 
screened Carriers Carrier frequency 95% CI 
Melbourne 4097 129 1 in 32 (3.15%) 2.66%–3.73%
Sydney 3659 124 1 in 30 (3.39%) 2.85%–4.03%
Total 7756 253 1 in 31 (3.26%) 2.89%–3.68%
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During the study period, most
extended families of TSD-affected
infants underwent cascade genetic
screening, and no parents of an infant
with TSD had further TSD-affected
children. This is a strong demonstra-
tion of the effectiveness of community
genetic screening for TSD, supported
by appropriate laboratory testing
infrastructure.
Current Jewish Australian screen-
ing program carrier frequencies are
comparable to international Jewish
carrier frequencies from 1970 to the
present.5 TSD predominantly affects
those of Ashkenazi Jewish ancestry.
Of 4105 Australian Jewish high school
students screened for TSD in 1995–
2007, 78% of participants and 95% of
carriers were Ashkenazi.22 TSD carrier
f requenc ies were  1 in 25 for
Ashkenazi Jews and 1 in 97 for those
of mixed and non-Ashkenazi Jewish
heritage.22 No distinction is made in
census data between Ashkenazi and
other Jewish Australians, so subpopu-
lation analysis was not performed.
The ABS and Jewish community
organisations estimate that Jewish
Australians underreport their religion
in the census, and usually apply a
correction factor of 20% (Eckstein G.
Unpublished report; copies available
on  request  f rom h t tp : / /ww w.
jca.org.au) We did not apply any cor-
rection factor to estimates of Jewish
births or expected numbers of Jewish
TSD cases.
Our study has limitations relating
to the rarity of TSD, the low disease
frequency and the small size of the
Australian Jewish population. These
factors prevented the reduction in
observed Jewish TSD cases reaching
statistical significance in our study. To
demonstrate a significant reduction in
cases, it would take 70 years to
observe around 12 Jewish TSD cases,
using the Poisson model.23
TSD testing is now less invasive,24
and the cost of laboratory testing has
fallen over the 16-year period
described in this study. Outreach
screening strategies to extend the
benefits of TSD preconception
screening to a wider target population
should be considered.
Overall, we found that since TSD
screening commenced in Australia,
the number of observed TSD cases in
Jewish Australians has halved com-
pared with predictions, while carrier
frequency remains high (1 in 31). Pre-
conception carrier screening, sup-
ported by community education and
the appreciation of autosomal reces-
sive inheritance are the likely key fac-
tors explaining the fewer than
expected Jewish babies born with
TSD.
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Chapter 6: 
 
 
Chapter 6 reports the results of a systematic review of the literature relating to 
TSD screening in AJ communities. It reports the Australian experience and 
derives evidence based TSD screening protocols and clinical 
recommendations. 
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Ashkenazi Jewish population screening for Tay–Sachs disease:
The International and Australian experience
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Agnes Bankier,5 Harry Aizenberg,7 Michael J Field,8 Yemima Berman,2,8 Ronald Fleischer8 and Michael Fietz9
1Department of Obstetrics and Gynaecology, QEII Research Institute for Mothers and Infants, 2Sydney Medical School-Northern, Royal North Shore Hospital
E25, University of Sydney, 3Pacific Laboratory Medicine Services (PaLMS), NSW Health Pathology North, 4NSW Centre for Genetics Education, 8Department of
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Abstract: Internationally, Tay-Sachs disease (TSD) preconception screening of Ashkenazi Jewish (AJ) individuals and couples has led to
effective primary prevention of TSD. In Australia, adolescent preconception genetic screening programs operate mainly in Jewish community
high schools. These existing programs offer an effectivemeans of primary prevention of TSD, are cost effective and safe. However, in the broader
Australian community TSD screening is not systematically performed and cases still occur in unscreened AJ individuals. In order to improve the
effectiveness of Australian screening, there is a need for definitive guidelines for healthcare professionals to facilitate extension of the proven
benefits of preconception TSD screening to all AJ individuals at risk. We performed a systematic review of the relevant literature relating to AJ
pre-conception and antenatal screening for TSD. The evidence was assessed using an established National Health and Medical Research Council
evidence grading system. Evaluations of efficacy of TSD screening programs design and execution, cost-benefit and cost-utility health economic
evaluation, and population outcomes were undertaken. The results have been used to propose a model for universal AJ TSD preconception and
antenatal screening for the primary care setting.
Key words: adolescent; education; genetics; metabolic.
Introduction
Tay–Sachs disease
Tay–Sachs disease (TSD) is a neurodegenerative disorder caused
by congenital deficiency of β-hexosaminidase enzyme due to
mutations in the HEXA gene (OMIM *606869 gene map locus
15q23-q24). TSD exhibits autosomal recessive inheritance, in
which heterozygous genetic carriers are phenotypically normal.
In a couple where both partners are carriers, 25% of pregnancies
will be affected. Most infants with TSD appear healthy at birth.1
After a 3- to 6-month period of normal development, TSD-
affected infants regress neurologically secondary to neuronal
accumulation of sphingolipid GM2 gangliosides. Most motor and
social skills are lost by 18 months of age. Children rarely survive
beyond 5 years of age. No effective treatment exists.2 In Ashke-
nazi Jews (AJ; Jews of Central/Eastern European descent), TSD
incidence is one in 2500 (carrier frequency one in 25).3 A total of
93.1–99.1%of Jewish TSD carriers are found to have one of three
common HEXA mutations: c.1278insTATC, c.1421+1G>C and
c.805G>A.4–6 In non-AJ populations, TSD incidence is one in
250 000 (carrier frequency one in 250).7
International practice
Strong international consensus supports universal TSD AJ
preconception/antenatal screening.8–11 In the United States,1
Canada12 and Israel,13 TSD screening of AJ individuals has
resulted in >90% reduction in TSD incidence.
Key points
1 Tay–Sachs disease (TSD) carrier screening should be offered to
Ashkenazi Jewish (AJ) individuals of reproductive age in order
to provide informed reproductive choice. Primary care clini-
cians’ inquiry of ethnic background is required on history
taking to identify AJ individuals who will be at high risk of
having children with TSD.
2 Timing of genetic screening should ideally be conducted prior
to conception.
3 Primary health providers should be aware of different strat-
egies of TSD screening. Partners of TSD carriers should be
offered screening, regardless of heritage. Screening stra-
tegies for one- and two-step screening are summarised in
Figures 1–3. In order to minimise delay to diagnosis, one-step
screening (Fig. 2) is recommended where screening is under-
taken during a pregnancy.
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1
The following international bodies recommend that TSD
preconception/antenatal screening should be offered to all indi-
viduals with AJ heritage:
• The American Congress of Obstetricians and Gynecologists9
• The American College of Medical Genetics11
• Society of Obstetricians and Gynaecologists of Canada10
• United Kingdom National Screening Committee8
• State of Israel Ministry of Health14
Australian practice
Despite strong international support of universal AJ preconcep-
tion TSD screening, no Australian guideline exists, and AJ TSD
screening is not publicly funded.
Cost–benefit and ethical considerations
In terms of direct monetary cost, preconception or antenatal
screening for TSD is superior to retrospective identification of
carrier parents following the birth of an affected infant. The
direct tangible monetary costs have been analysed in an Aus-
tralian cost–utility study, which found in favour of screening.15
Important ethical benefits of TSD carrier screening include
informed reproductive choice16 and a net increase in health of
carrier couples and families by preventing the profound psycho-
logical costs of having a TSD-affected infant. These additional
benefits are difficult to quantify in terms of monetary value.17
Objective
Australia is a good model for evaluating the effectiveness of high
school TSD screening programmes. Australia has a relatively
static Jewish population strongly concentrated to two major
centres (Sydney and Melbourne).18,19 Australian screening pro-
grammes are well funded, have high uptake of services by AJ
high school students targeted (>8000 student participants to
date) and are highly collaborative with the ongoing analysis of
more than 17 years of data.20
This paper aims to systematically review the international
evidence base supporting universal preconception TSD screen-
ing for AJ individuals, to present the Australian experience and
to examine the case for supporting universal AJ TSD screening
in Australia. Our data and resultant conclusions may be of
assistance for screening AJ communities in other countries.
Australian TSD population genetic
screening programmes
Based on international best practice principles,6,21–23 Australian
genetic screening programmes for TSD24 have targeted senior
Jewish high school students in Sydney and Melbourne since
1995.20 The design of the Sydney programme, on which the
Melbourne programme is based, has been described previously.25
Screening programmes were developed in consultation with the
local communities and consist of mandatory on-site education
followed by voluntary on-site genetic carrier testing (originally
by venepuncture but more recently by mouthwash sampling).
Participants may request immediate or deferred disclosure of
results.26 Screening is cost free to participants (philanthropically
funded), and participation rates are high (99.6%).27
An alternative approach to screening is that of Dor
Yeshorim,22 an international Jewish genetic screening pro-
gramme accessible to Australians. Dor Yeshorim targets ultra-
orthodox Jewish communities world-wide. The programme is
accessed prior to marriage to advise on the genetic compatibility
of a proposed match. Individuals’ results remain anonymous. A
small minority of Jewish Australians identify as ultra-orthodox.
Dor Yeshorim is unaffiliated with Australian TSD screening pro-
grammes. Dor Yeshorim screening records were unavailable to
authors of this paper, so they could not be used for analysis.
In addition to TSD, both Australian Jewish genetic screening
programmes and Dor Yeshorim now offer testing for other con-
ditions relevant to the target community.3,22,27
TSD population genetic screening programmes have proved a
successful strategy for primary prevention of TSD.1,20,23,28 Over
the 17 years so far evaluated in health outcome studies, no
Australian TSD screening programme participant has had an
affected child – representing complete prevention in the 7756
screened between 1995 and 2011.20 In follow-up analysis five-
to 11-year post-high school, screening programme participants
were supportive of the programme, retained good knowledge of
TSD and were happy with the timing of screening.29
An absolute reduction in Australian AJ TSD incidence of
approximately 50% occurred between 1995 and 2011, a period
corresponding to the introduction and operation of Australian
Jewish community population genetic screening programmes in
Sydney and Melbourne.20
Access to TSD screening in Australia is incomplete
The most frequent route of access to TSD screening in Australia
is by participation in organised screening programmes in senior
high schools and associated outreach programmes. However,
even taking into account those who have accessed these pro-
grammes, the majority of Australians with AJ heritage of repro-
ductive age have not accessed TSD screening..20 From Australian
Bureau of Statistics and Australian Jewish Community data, it
is estimated that approximately 50% of current Australian
Jewish high school students attend schools that do not cur-
rently participate in TSD screening programmes. (Eckstein G.
Demography of the Sydney Jewish community: an overview of
information from the 2006 Census. Unpublished report com-
missioned by the Jewish Community Appeal (JCA); copies
available on request from http://www.jca.org.au). AJ individ-
uals who completed high school prior to 1995 in Sydney and
1998 in Melbourne (predating TSD screening programmes) did
not have access to any TSD population genetic screening; a
subset of this group remains in the reproductive age bracket.
Outside of screening programmes, TSD genetic preconception
screening can in theory be accessed through primary care clini-
cian referral.16 In the Australian context, the primary care cli-
nician is usually a patient’s general practitioner or obstetrician/
gynaecologist. In practice, such referral for TSD screening is
uncommon (Anné L Proos, unpublished data, 2013). Barriers
include lack of clinician education, omission of genetic risk
identifying enquiry during medical history taking,30,31 lack of
patient knowledge,32 unplanned pregnancy (accounting for
30–50% of all pregnancies in developed countries)33 and cost of
testing.34 In Sydney, laboratory testing for TSD currently incurs
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an out-of-pocket cost to patients of approximately $A100
(L Burnett, AL Proos, pers. comm., 2013).
Methods
Identification of studies
A Medline-Pubmed, Embase and Google scholar advanced
search was conducted using MeSH topics ‘Tay Sachs disease’
AND (‘screening’ OR ‘genetic counselling’ OR ‘cost’ OR ‘GM2’
OR ‘genetic diseases’ or ‘Ashkenazi Jewish’). A Cochrane col-
laboration review was also conducted. A manual review of
abstracts identified articles relevant to genetic screening for TSD
in individuals with AJ heritage. These were subsequently
reviewed in full. No language restrictions were applied.
Inclusion criteria: all research and review articles reporting
experience of AJ TSD screening, including clinical, laboratory,
cost analysis and psychological aspects of TSD screening. Exclu-
sion criteria: articles related to non-human subjects, experimen-
tal laboratory methods, genetic screening in non-Jewish
populations and articles where no online abstract was available.
Formulation of evidence-based recommendations
The evidence supporting the proposed guidelines was appraised
with reference to the Australian National Health and Medical
Research Council (NHMRC) evidence grading system.35
Results
The Medline-Pubmed, Embase and Google scholar advanced
search identified 288 articles. A manual review of abstracts
identified 85 articles relevant to AJ TSD preconception and
antenatal screening of which all were reviewed in full. No
randomised controlled trials relating to TSD carrier screening
were identified. No Cochrane review or meta-analysis of TSD
genetic screening has been conducted. Some papers had
findings relevant to more than one body of evidence. NHMRC
grading system utilised is summarised in Appendix I. Papers
included in the review are listed in Appendix II. Grades of
recommendations for bodies of evidence are reported in Table 1.
The evidence summary is reported in Table 2.
Alternative models of TSD screening are depicted in
Figures 1–3.
Test Partner A
(usually female)
Is Partner A 
TSD carrier?
Offer Partner B TSD testing
Discuss cascade screening of As relatives
Is Partner B
 Jewish?
HEXA 
enzyme
HEXA
DNA 
mutations
Is Partner B 
TSD carrier?
YES
YES No
Negligible residual risk of TSD for offspring
(Ensure couple understands that negligible TSD risk 
applies ONLY in current partnership.
Future partnerships will need to be retested:
Note that the risk in a different future partnership remains 
low for the individual who has tested negative)
No referral for genetic counselling required
No referral for specialist reproductive medicine required
No
No
Each pregnancy of this partnership has 25% risk of TSD
As appropriate, refer for:
- Genetic counselling advice or clinical geneticist opinion
- Specialist reproductive medicine opinion
Discuss:
- Access to educational resources
- Cascade screening of relatives
YES
Fig. 1 Two-step screening.
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Discussion
Evidence from 17 years experience of TSD screening pro-
grammes in Australian Jewish high schools has shown screen-
ing to be both effective in TSD primary prevention20 and also
cost-effective.15 However, reliance solely on high school-based
programmes is an inadequate strategy for population-wide
screening as less than half the at-risk target population (AJ
individuals of reproductive age) is within this screened cohort
(Eckstein G. Demography of the Sydney Jewish community: an
overview of information from the 2006 Census. Unpublished
report commissioned by the Jewish Community Appeal (JCA);
copies available on request from http://www.jca.org.au).
The results of this review found level III-3 evidence for each
of the criteria analysed (Table 1). Based on these findings,
recommendations for TSD screening were developed (Table 3).
Primary care clinician referral for TSD screening is the pragmatic
solution to reach this remaining community sector and to facili-
tate universal access. Challenges to implementation of this strat-
egy include improving clinician and patient education31,36,37 and
funding of supporting laboratory testing and health infrastruc-
ture.34 Creation of Australian guidelines for AJ preconception
genetic screening in the primary care context would assist in
realising universal access, and the process of developing such
guidelines is underway (Human Genetics Society of Australasia,
Joint Human Genetics Society of Australasia/Royal Australian
and New Zealand College of Obstetricians and Gynaecologists
Prenatal Diagnosis and Screening Committee).
Performing this screening prior to pregnancy should be con-
sidered the gold standard as prospective diagnosis allows carrier
couples access to a wider range of reproductive options.38,39 As
many pregnancies are unplanned,33 clinicians should consider
and offer TSD screening opportunistically when at-risk patients
present for other reasons (e.g. general or sexual health check).31
Presentation for screening may commonly occur in early
pregnancy.31 Where an at-risk couple is identified during preg-
nancy (both biological parents are found to be TSD carriers),
prompt referral for appropriate genetic counselling and mater-
nal fetal medical review should be undertaken. Management
may include fetal diagnostic testing.9
Good pre-test education is imperative to achieve informed
consent. In Australian TSD screening programmes, pre-test edu-
cation is delivered by a qualified genetic counsellor.25,27 Sessions
include the delivery of written and multimedia presentations.
Test both Partner A and B
 simultaneously
Are 
both A and B 
TSD carriers?
Negligible residual risk of TSD for offspring
(Ensure couple understands that low TSD risk applies ONLY in 
current partnership)
No referral for genetic counselling required
No referral for specialist reproductive medicine required
Each pregnancy of this partnership has 25% risk of TSD
Explain results and, as appropriate, refer for:
- Genetic counselling advice or clinical geneticist opinion
- Specialist reproductive medicine opinion
Discuss:
- Access to educational resources
- Cascade screening of relatives
YES
Is 
exactly ONE of
 A or B 
TSD carrier?
(Only if consented):
- Disclose individual results
- Cascade screening of relatives
No
YES
Nothing further indicatedNo
Fig. 2 One-step couple screening.
RM Lew et al.Screening for Tay–Sachs disease
Journal of Paediatrics and Child Health (2014)
© 2014 The Authors
Journal of Paediatrics and Child Health © 2014 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
4
Multimedia educational presentations are highly effective in
conveying pre-test information in the context of TSD screening
programmes.40 On-line education tools made freely available to
primary care clinicians and patients may cost-effectively achieve
consistent and quality-assured patient education.41
Figures 1–3 summarise the recommended screening path-
ways applicable to AJ individuals and their partners. These
pathways are derived from international best practice screening
strategies6,21–23,25,27 and offer alternative approaches to different
preconception and antenatal scenarios. The Dor Yeshorim
model was designed to provide culturally acceptable access to
screening for an ultra-orthodox Jewish demographic.22
Current practice recommends DNA-based testing for common
AJ mutations as the most cost-effective method to identify AJ
TSD carriers.5,6 Partners of AJ carriers should also be offered TSD
preconception screening, with any such non-AJ individuals
being tested with enzyme-based assays42 rather than DNA-based
testing, due to the wider range of HEXA variants found in
non-AJ heterozygote carriers.43
Hexasominidase A enzyme (Hex A) activity analysis detects
98% of TSD carriers from all ethnic backgrounds.11 TSD carriers
have enzyme activity <52% compared with non-carriers where
enzyme activity is >60%.11 Hex A testing has limitations, which
is why this diagnostic technique is not preferred for AJ TSD
screening. A blood sample is required, and medications includ-
ing oral contraceptives and anti-hypertensives may affect
detected enzyme levels.32 There is an inconclusive range in
which it is difficult to distinguish carriers from non-carriers,
mandating further testing with HEXA DNA testing and/or
sequencing. False negative and false positive results can occur
with Hex A testing in the presence of B1 and pseudodeficiency
alleles, respectively.
Genetic laboratory testing methodology is rapidly advancing.
In the immediate future, massively parallel (‘next generation’)
DNA sequencing will likely replace the conventional testing
methods for conditions screened in AJ preconception pro-
grammes including TSD.44–46 This will expand the scope and
menu of preconception genetic screening exponentially and
pose challenges for the traditional notions of informed
consent.47 Evidence regarding the safety and ethical impact of
these developments is currently lacking.
Referral of clients to a local national and regional genetic
services may be appropriate; within Australia, a directory of
such resources is offered by the Centre for Genetics Education
(www.genetics.edu.au), and similar referral directories have
been established in many other regions and countries.
Test both prospective 
Partners A and B
 simultaneously
Are 
both A and B 
TSD carriers?
Negligible residual risk of TSD for offspring (in this partnership)
(Ensure couple [or agreed third party] understands that low TSD risk 
applies ONLY in current partnership)
No referral for genetic counselling required
No referral for specialist reproductive medicine required
Each pregnancy of this partnership has 25% risk of TSD
Couple may be deemed unsuitable for introduction/marriage
If non-disclosure of results requested, nothing further is indicated.
Note that deidentified risk for couple may be disclosed to third parties
Only if consented: As appropriate, refer for:
- Genetic counselling advice or clinical geneticist opinion
- Specialist reproductive medicine opinion
Discuss:
- Access to educational resources
- Cascade screening of relatives
YES
Is 
exactly ONE of
 A or B 
TSD carrier?
If non-disclosure of results requested, 
nothing further is indicated.
Otherwise, and only if consented:
- Disclose individual results
- Cascade screening of relatives
No
YES
Nothing further indicatedNo
Fig. 3 One-step couple screening (ultra-orthodox unmarried couple).
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Table 2 Evidence summary
1. Ethical and health economic aspects of TSD screening
Evidence summary
TSD preconception screening of Ashkenazi Jewish individuals
results in effective primary prevention of TSD, does not cause
prolonged psychological harm and is cost-effective.
2. Australian Jewish high school screening programmes for TSD and
serious autosomal recessive disorders of reproductive significance
Evidence summary
Australian Jewish high school screening programmes for TSD are
effective and appropriate. One in 25 Australian Jewish high
school students are TSD carriers. Uptake of screening by
students is high (99.6%). Disclosure of results may be immediate
or deferred. Fewer than 50% of Australian Jewish individuals of
reproductive age have accessed existing programmes.
3. Timing of Screening
Evidence summary
Preconception screening facilitates informed access to more
reproductive strategies for TSD prevention and is associated
with less anxiety than testing in pregnancy. For Australians,
self-declaration of Ashkenazi Jewish heritage correlates with high
risk of TSD. Outside of screening programmes, patient access to
screening requires clinician referral. Clinicians’ failure to identify
at-risk patients on history taking is a barrier to screening.
4. Pre-test education and genetic counselling
Evidence summary
Pre-test education in screening programmes has been validated.
Genetic education is provided by a qualified health professional
1 week prior to screening, encompassing TSD clinical features,
mode of inheritance, sensitivity and limitations of laboratory
testing, implications of positive and negative results, and
reproductive options. Written educational material is provided.
Multimedia resources have been effective in conveying pre-test
information. High knowledge levels correlate with reduced
anxiety in TSD carriers. Effective education facilitates informed
consent.
5. Models of TSD screening, management of carriers and carrier
couples
Evidence summary
TSD screening may be conducted using one-step or two-step
models (Figures 1–3). Clinician awareness of the pros and cons
of different screening strategies maximises cost benefit.
6. Laboratory testing methodology
Evidence summary
In Jewish individuals, DNA-based testing has a carrier detection
sensitivity of 93.1–99.1% and is the most cost-effective testing
method. The small residual risk relates to other HEXA mutations.
Most non-Jewish populations exhibit TSD carrier frequencies of
one in 250–300. French Canadian, Pennsylvania Dutch and Cajun
heritage may convey higher a priori risk. Non-Jewish TSD carriers
are most effectively identified by enzyme-based testing for which
false negative rate is minimal. HEXA mutations may be
characterised by DNA sequencing.
TSD, Tay–Sachs disease.
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Conclusion
TSD screening programmes targeting an adolescent AJ popu-
lation are a highly effective and cost-effective primary preven-
tion strategy. Routine implementation of recommendations
summarised in Table 3 by primary care clinicians would optimise
informed reproductive choice in AJ individuals and would result
in near complete TSD case prevention. The recommendations in
Table 3 have been developed through evidence-based review of
all published studies irrespective of country of origin and should
be portable and applicable to other national jurisdictions. Uni-
versal access to TSD genetic screening for all AJ Australians is
clinically achievable in the primary care setting using simple
practice workflows (Figs 1–3). The conclusions reached based on
this Australian data are likely to be transferrable and applicable to
other countries and communities.
Multiple Choice Questions
Question 1 Choose the INCORRECT answer. TSD is
a. A neurodegenerative disorder
b. An autosomal recessive condition (heterozygous
carriers are unaffected)
c. Less common in AJ populations
d. Lethal in infancy or early childhood
e. Usually diagnosed during the first 6 months of
life
Answer 1: c. Less common in AJ populations. TSD was first
described in affected individuals of AJ descent. TSD is 100
times more common in AJ populations (carrier frequency one
in 25) than in general populations (carrier frequency one in
250). French Canadian populations are also at increased risk
of TSD.
Question 2 Choose the CORRECT answer: TSD preconception
screening
a. Does not reduce TSD incidence
b. Is not cost-effective in AJ populations
c. Is accessed poorly outside of established Jewish
high school-based screening programmes
d. Does not significantly enhance informed repro-
ductive choice
e. Has poor uptake following pre-test counselling
Answer 2: c. Is accessed poorly outside of established Jewish
high school-based screening programmes. The most frequent
route of access to TSD screening in Australia is by participa-
tion in organised screening programmes in senior high
schools and associated outreach programmes. However, even
taking into account those who have accessed these programmes,
the majority of Australians with AJ heritage of reproductive age
have not accessed TSD screening. Within established screening
programmes, uptake following pre-test counselling is 98%.
Question 3 A couple have undergone preconception screening
for TSD. Both partners have been found to be TSD
carriers. They have been counselled by their doctor
that, in each pregnancy, their baby will have a one
in four chance of having TSD. Their reproductive
options include
a. Using donor sperm or donor egg from a TSD
non-carrier
b. First trimester chorion villus sampling for fetal
diagnosis
c. Elective IVF with embryo biopsy and pre-
implantation genetic diagnosis
d. Adoption
e. All of the above
Answer 3: e. All of the above. Preconception timing of TSD
screening optimises the range of reproductive options open to
TSD carrier couples.
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Appendix I
NHMRC evidence grading framework
NHMRC evidence hierarchy
Key question(s) Evidence
table
reference
Evidence base (number of studies, level of
evidence and risk of bias in the included
studies)
A One or more level I studies with a low risk of bias or several level II studies with a low risk
of bias
B One or two level II studies with a low risk of bias or SR/several level III studies with a low risk
of bias
C One or two level III studies with a low risk of bias or level I or II studies with a moderate risk
of bias
D Level IV studies or level I–III studies/SRs with a high risk of bias
Consistency (if only one study was available,
rank this component as ‘not applicable’)
A All studies consistent
B Most studies consistent and inconsistency can be explained
C Some inconsistency, reflecting genuine uncertainty around question
D Evidence is inconsistent
NA Not applicable (one study only)
Clinical impact (indicate in the space below if
the study results varied according to some
unknown factor (not simply study quality
or sample size) and thus the clinical impact
of the intervention could not be
determined)
A Very large
B Substantial
C Moderate
D Slight/restricted
Generalisability (How well does the body of
evidence match the population and clinical
settings being targeted by the guideline?)
A Evidence directly generalisable to target population
B Evidence directly generalisable to target population with some caveats
C Evidence not directly generalisable to the target population but could be sensibly applied
D Evidence not directly generalisable to target population and hard to judge whether it is sensible
to apply
Applicability (Is the body of evidence relevant
to the Australian health-care context in
terms of health services/delivery of care
and cultural factors?)
A Evidence directly applicable to Australian health-care context
B Evidence applicable to Australian health-care context with few caveats
C Evidence probably applicable to Australian health-care context with some caveats
D Evidence not applicable to Australian health-care context
Definition of NHMRC grades of recommendation
Grade of recommendation Description
A Body of evidence can be trusted to guide practice
B Body of evidence can be trusted to guide practice in most situations
C Body of evidence provides some support for recommendation(s), but care should be taken in its application
D Body of evidence is weak, and recommendation must be applied with caution
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Chapter 7: 
 
Transition to performing Ashkenazi Jewish population genetic 
screening using community centred screening strategies and 
Massively Parallel Sequencing Technologies  
 
Introduction 
 
Tay Sachs disease (TSD), results from a critical deficiency in ß-hexosaminidase 
enzyme. TSD has genetic recessive inheritance and is more common in Ashkenazi 
Jewish (AJ) populations (carrier frequency 1 in 25). TSD has historically been the 
prototype genetic condition amenable to preconception screening. 1  
 
TSD single condition genetic screening  
 
Routine preconception and antenatal screening of AJ individuals for TSD has been 
offered in centres around the world since the 1970s.1 Over time and with 
technological advancement, the method of laboratory diagnosis of carrier risk has 
changed.  
 
TSD carriers were at first diagnosed by ß-hexosaminidase HEXA enzyme assay, 
most commonly using synthetic fluorimetric substrates. In the 1980s, the HEXA gene 
was identified and specific genetic mutations common in AJ populations were 
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characterised.2 DNA testing later emerged as the most cost-effective method of TSD 
screening for AJ populations.3, 4 Enzyme methods remain in limited use, primarily for 
non-AJ screening and for functional characterisation of low prevalence and newly 
described HEXA variants. 
 
TSD screening programs are effective in TSD prevention, cost effective and well 
accepted. 2, 5-7 In AJ populations, disease incidence has reduced by over 90% since 
the introduction of preconception and antenatal genetic screening.1, 6, 7 8-10 In 
reference to best practice criteria for justification of screening for disease prevention, 
the case for TSD genetic screening in AJ populations is clear (Table 1). 11 
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Table 1: Wilson and Jungner classic screening criteria as applied 
to TSD 
 
Wilson and Jungner Criteria TSD 
1. Important health problem Yes 
2. Intervention possible Yes 
3. Diagnosis/Intervention infrastructure 
available 
Yes 
4. Carrier state detectable Yes 
5. Suitable test Yes 
6. Acceptable test Yes 
7. Condition understood Yes 
8. Target group identifiable Yes 
9. Cost balanced Yes 
10. Ongoing strategy possible Yes 
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Expanded Ashkenazi Jewish preconception screening: beyond 
TSD  
 
Over the passage of time, concurrent screening for both TSD and also a limited and 
increasing number of other genetic conditions common to AJ populations became 
technically feasible. Commercially produced multi-disease screening panels, 
including TSD, became widely used in AJ preconception and antenatal genetic 
screening to detect known disease-causing founder mutations.12 For reasons of 
laboratory reagent costs, it can now paradoxically be more expensive to test for a 
single condition e.g. TSD than for a panel of multiple conditions.12 When given the 
choice of limited screening vs. screening using an expanded panel, after counselling 
95% of Jewish individuals opt for an expanded panel.13 Conditions included in 
expanded panels can vary in disease severity and penetrance, making pre-test 
genetic counselling more complex, a barrier to community based screening 
strategies initiated by primary health care clinicians.  In the genomic era, genetic 
screening performed using Massively Parallel Sequencing (MPS) technologies 
presents the option to expand AJ screening panels further still. MPS also presents 
the possibility to offer preconception genetic screening for carrier trait diagnosis of 
rare genetic diseases in unselected general populations. Algorithms to assist 
clinicians in choosing the most appropriate method of genetic testing and screening 
have been proposed.14 For Australian AJ individuals, primary health care clinicians 
are now supported by the HGSA AJ genetic screening position paper, presented in 
Chapter 8 of this thesis. Conditions recommended for AJ preconception genetic 
screening in the HGSA ratified AJ panel are recommended for screening based on 
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their clinical impact and relatively high carrier frequencies.  Patient demand for 
genetic screening technologies is however unprecedented, including direct to 
consumer (DTC) screening models which screen for more than 100 conditions.15 
 
  
 80 
Transitioning AJ genetic screening from local screening programs 
to a broader clinical practice setting 
 
Chapter 8 of this thesis represents an important resource to educate and empower 
primary health care clinicians with confidence in offering preconception genetic 
screening to AJ patients. Remaining barriers requiring future redress include the lack 
of Medicare funding item numbers for preconception genetic screening as a health 
promotion initiative and a relative lack of clinical genetic literacy amongst primary 
health care clinicians. This is in part explained by the rapid expansion and evolution 
of genetic diagnostic technologies and test menu that has occurred within the 
working lifetime of a single generation of practitioners.      
 
Massively Parallel Sequencing (MPS) 
 
Genetic diagnosis by MPS is now possible due to several scientific developments of 
the 21st century. The Human Genome Project provided a complete reference 
genome for comparison with test sequences. Large databases of genomic 
information from healthy individuals and patients with disease have been 
interrogated to contextually assess observed genetic variants. Technologies and 
platforms have been developed, at reducing cost to facilitate simultaneous 
sequencing of multiple regions of fragmented RNA or DNA in a single assay.  
 
To perform MPS16, a typical workflow would involve DNA from a patient is being 
fragmented. Common adapters are ligated to the fragment ends. DNA fragments are 
amplified by Polymerase Chain Reaction (PCR). Sequencing-by-synthesis then 
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occurs, where as each base is added, a signal is generated and read by software – 
recording the genetic sequence of each PCR fragment. The sequence of each 
fragment is mapped against the human genome. This allows identification of genetic 
variants present in the test subject’s DNA. Databases of genetic variation now exist 
allowing characterization of the “human variome”, observed genetic variability within 
human populations.17-20 These include ethnically matched reference genome 
sequences. Novel and rare variants may be more likely to be pathogenic, while 
common variants can more often be characterized as normal population genetic 
variability.21 The data generated from MPS is then analyzed and interpreted in 
context of the patient’s family history and the disease prevalence and pattern of 
inheritance.   
 
“Third generation” technologies are developing methods of MPS without a preceding 
step of DNA amplification, aiming to improve MPS speed and accuracy.22 
 
  
MPS was developed as a research tool for whole-genome sequencing (WGS).23 The 
sequenced genome of an individual can be regarded as a personal reference library 
that could be re-interrogated over an individual’s lifetime as a diagnostic tool. This 
concept has generated many complex clinical, ethical and bioinformatics challenges, 
which are yet to be fully addressed.24 The American College of Medical Genetics 
and Genomics recommends that the application of exome or whole genome 
sequencing should be limited to clinical cases which elude targeted interrogation.25 
For clinical applications in genetic screening and diagnosis, targeted sequencing 
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may be faster, more cost-effective and less likely to result in the detection of 
secondary or incidental findings (IFs) of uncertain significance.26  
 
In targeted MPS, prior to amplification, a library of DNA or RNA fragments containing 
regions of particular interest may be selected. Probes are designed to anneal to 
specific chromosomal regions of interest. Targeted regions are identified and 
isolated for PCR amplification and sequencing.  
 
 
 
Massively Parallel Sequencing for Genetic Screening: Supporting 
evidence guiding current practice 
 
Preconception genetic screening is a natural application of MPS technology. MPS 
methods permit screening for an expanded panel of genetic disorders 
simultaneously and with high fidelity, quick turnaround time, and reducing costs.27 
Studies are needed to provide evidence of net benefit and to reassure clinicians that 
the practice of MPS based targeted genetic screening does not cause harm.  
 
The selection of disorders on expanded carrier screening panels should be 
rigorously based on health promotion principles.28 The basis for which disorders 
were selected for inclusion should be disclosed to screening participants.  
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Prevalence and severity of diseases phenotypes should be considered when 
assessing whether a condition should be included in a screening panel.  Inclusions in 
screening panels of disorders with mild phenotypes, variable expression, low 
penetrance, or with an adult onset of disease manifestations is controversial. Where 
such conditions are included, patients should be fully informed of the nature of these 
conditions and be given the option to “opt out” of receiving specific test results.  
 
 
 
Direct to Consumer MPS Screening 
 
Currently, MPS screening technology is available commercially “direct to consumer” 
and has been utilised widely, despite the fact that there exists no expert consensus 
regarding whether MPS expanded screening is on balance medically indicated in 
general populations and, if so, which genetic conditions should be included in 
screening panels.29 In the USA, the Food and Drug Administrative authority (FDA) 
have defined some DTC genetic testing platforms in the category of “medical device” 
(e.g. 23andMe) and have thus restricted company marketing for medical genetic 
screening (marketing of DTC genetic sequencing for genealogical applications is 
unrestricted).30 Internet based marketing and sales give DTC genetic screening 
models the potential to have global reach and transcend regulation in any single 
jurisdiction. /unregulated DTC genomic testing could potentially result in misuse and 
even fraud or non-consensual testing. In response, there have been calls for 
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countries, including Australia to legislate a criminal offence relating to non-
consensual genetic testing, although currently no such legal framework exists.31 In 
May 2014, the Australian National Pathology Accreditation Advisory Council 
published a position paper to guide providers of DTC testing in Australia.32 In June 
2014, the National Health and Medical Research Council published a draft statement 
for DTC providers and a statement of information to guide consumers of DTC 
genetic testing.33   
  
 
Is MPS based pre-conception genetic screening warranted in 
general populations? 
 
In 2008 Andermann et al. revisited the longstanding screening criteria proposed by 
Wilson and Jungner and proposed additional screening criteria for the genomic era 
(Box 1);34 While these criteria have not been universally ratified, they form a valid 
framework within which general population genetic screening may be considered.   
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Box 1: Andermann et al., Synthesis of emerging screening criteria 
1. The screening programme should respond to a recognized need. 
2. The objectives of screening should be defined at the outset.  
3. There should be a defined target population.  
4. There should be scientific evidence of screening programme effectiveness.  
5. The programme should integrate education, testing, clinical services and 
programme management.  
6. There should be quality assurance, with mechanisms to minimize potential risks of 
screening.  
7. The programme should ensure informed choice, confidentiality and respect for 
autonomy.  
8. The programme should promote equity and access to screening for the entire 
target population.  
9. Programme evaluation should be planned from the outset.                                  
10. The overall benefits of screening should outweigh the harm.  
 
Criterion 4 states that scientific evidence of screening program effectiveness is 
required. Evidence of genetic screening program effectiveness using a limited 
screening panel in ethnically identifiable sub-populations such as AJ genetic 
screening programs is strong. In these populations, in which carrier frequencies of 
particular serious genetic diseases (e.g. TSD) are high, the effectiveness of limited 
screening for specific mutations is high.  In an unselected general population, carrier 
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frequencies for specific inherited single targeted mutations, as are targeted in AJ 
screened populations, would be expected in many cases to be reduced. However 
the reality remains that all humans carry several recessive lethal or disease causing 
genetic mutations. While the majority of recessive mutations are inherited, a 
proportion of these may arise spontaneously in an individual.35 These mutations are 
responsible for a significant proportion of human disease.36 A given individual – 
regardless of their ethnic origin has a strong chance of carrying one or more serious 
genetic mutations that has been either inherited or acquired. In a general population 
as compared to an AJ population, we are less likely to prospectively predict the 
specific nature of these mutations. Thus highly limited DNA screening has limited 
clinical application in the prevention of disease in general populations. Casting a 
wider net using MPS expanded genetic screening has promising utility in the 
reduction of genetic disease, with the potential, if routinely used in the future, to have 
net health benefit on a population level. While on a population level, carrier 
frequencies for specific gene mutations are low, at-risk couples may have a 1 in 4 
chance of having severely affected children. 
 
 
Table 2 examines the compliance of MPS expanded panel genetic screening to 
Andermann et al adapted criteria.  
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Table 2: Andermann criteria applied to MPS expanded genetic 
screening 
 
Andermann criteria MPS screening 
1.Recognised need Yes, and consumer demand 
2.Defined objectives at outset Yes, but strong potential for unexpected 
results exists 
3. Defined target population Yes (Direct to consumer genetic 
screening targets a general population) 
4. Evidence of program effectiveness Limited. Existing evidence relates to 
existing genetic screening programs for a 
more limited number of conditions 
5. Integrated program: Education, 
testing, follow-up, management. 
Variable: Structured screening program 
vs. DTC models  
6. Quality Assurance Variable 
7. Informed choice, confidentiality, 
autonomy 
Changing notions of the meaning of 
informed consent in the genomic era 
8. Promote equity for target population Variable 
9. Planned evaluation  Variable 
10. Benefits>harm Unknown 
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Challenging Andermann et al. proposed criteria: MPS expanded 
panel genetic screening  
 
Preventative medicine and health promotion 
 
Genetic screening for serious recessive genetic conditions allows couples to have 
advanced warning of their risk of having a child affected with a lethal or severely 
debilitating genetic illness. These couples have the potential to have healthy, 
unaffected children. Reproductive technologies exist to assist an at-risk couple to 
achieve this. Without advanced knowledge of their genetic risk and treatment 
options, individuals and couples are denied access to the full range of existing 
reproductive options. These include antenatal diagnosis in the first trimester of 
pregnancy, pre-implantation genetic diagnosis prior to conception (through IVF with 
embryo biopsy), the use of donor oocyte or sperm to achieve a healthy pregnancy, 
or adoption.  
 
The need for this intervention is to improve the quality of life of individuals and 
couples by improving their chances of having a healthy child. Even when no 
intervention is pursued, couples benefit from their reproductive choices being 
informed.37 
 
Arguments in favour of MPS expanded panel genetic screening include long-term 
population level cost-benefit. By accessing reproductive technologies to assist at-risk 
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couples to have healthy families, on a health system level, fewer resources will be 
required to treat and palliate children with lethal and severely debilitating genetic 
disease. Fewer support services will be required to assist families of affected 
children (e.g. respite, counsellor services, carer pensions) and fewer families will be 
forced to leave the workforce.38 
 
With MPS technologies, a pan-ethnic approach to accessing preconception genetic 
screening strategies will be feasible in the future. This will potentially extend the 
benefits of preconception genetic screening strategies demonstrated in small 
ethnically defined populations to all Australians.  
 
As genetic sequencing technology evolves and costs reduce, in the future it is 
foreseeable that an argument will be made for pan-ethnic preconception genetic 
screening strategies as part of the movement for preventive medicine and health 
promotion.38     Evidence from expanded panel screening within Ashkenazi Genetic 
screening programs is an important resource to guide the development of future 
screening protocols and extend benefits to people of all ethnic origins. When 
mainstream pan-ethnic screening strategies are adopted, knowledge of personal 
genetic heritage will become less important in assessing genetic risk. This will be 
timely in the context of our multicultural “melting pot” Australian society, where ethnic 
origins are often mixed and carrier status for recessive conditions will be less reliably 
predicted by health care providers.      
 
 
 90 
MPS in Personalised Medicine: Changes to our medical paradigm 
 
The aim of evidence-based medicine is to determine therapy for a patient’s treatment 
that has been validated to be the most effective, safe and cost efficient on the basis 
of expert consensus and trial data. In the past, we have relied on clinicians and 
researchers experience of the effectiveness of interventions in groups of patients 
with a common diagnosis, based on disease phenotype or syndrome. 
 
The gold standard interrogation of an intervention’s validity has been the double 
blinded randomised controlled trial.39 In this model, patients are normally analyzed 
within the treatment group to which they were randomly allocated, irrespective of 
whether they experienced the intended intervention (intention to treat analysis).40 
 
Despite inclusion and exclusion criteria for studies, multifactorial individual patient 
differences exist, meaning that the intervention and control groups are never 
identical. We also now know that due to genetic and epigenetic differences, no two 
individuals are identical. In acknowledgement of this, the concept of blinded 
randomisation aims to minimise potential biases that might obscure the findings of a 
study for or against the benefit of an intervention.  
 
This concept is based on the ideal of choosing interventions that are the most likely 
to be of benefit in the majority of cases to have an optimised net effect on a 
population level. 
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Personalised medicine is a concept that challenges the normalised “best fit” aims of   
population based studies. The aim is to analyse the genetic (and it the future 
potentially the epigenetic) make up of an individual, or disease process (e.g. genetic 
sequencing of cancer clone populations) and target therapy for the individual based 
on these findings. In this scenario, interventions selected to target disease ontologies 
based on genetic classification may replace interventions selected based on 
syndromic phenotype.41 Future individual-specific targeting of intervention strategies 
in this way will be hoped to have positive effects on patient outcomes and quality of 
life. With continued progress in our collective understanding on the effect of our 
genetic make-up on disease outcomes, pan-ethnic population screening may play a 
role in health promotion, disease prevention and more effective treatment strategies 
in multifactorial genetic disease, beyond it’s current application in the detection and 
management of Mendelian genetic disease associated risk. This concept challenges 
the notion of defining a “target population” for screening strategies (Table 2, Criterion 
3), as we consider each individual as a target for genetic screening and health 
promotion strategies.   
        
MPS: Secondary and Incidental findings (IFs) 
 
As exome and genome sequencing become integrated into mainstream medical 
care, genetic changes that predispose a healthy individual to develop diseases will 
be better understood. While instituting MPS technologies to answer specific 
diagnostic questions, the potential exists for recognition and reporting of findings 
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unrelated to the indication for ordering the sequencing (incidental or secondary 
findings) that may be of medical value for patient care.42 
 
The American College of Medical Genetics and Genomics (ACMG) in 2013 
published a policy statement for the clinical application of whole exome or whole 
genome sequencing that emphasized the importance of prospectively explaining the 
possibility of MPS derived unexpected findings. ACMG initially recommended that 
clinical laboratories actively search and evaluate for certain pathogenic variants in 56 
genes and advised these should be reported, regardless of patient preference for 
results disclosure.42 24 of these IFs related to genes predisposing to cancers or 
cardiovascular disease.  ACMG recommended that those who did not agree to learn 
of these IFs could choose to forego the entire test. This statement was subsequently 
modified in March 2014 to align with European guidelines and to address concerns 
about preserving patient autonomy.43 
 
The ultimate goal of ACMG recommendations is to positively impact patient care. To 
prioritize incidental reporting on gene variants of potential benefit to patients, while 
also allowing personal choice in decisions of IFs disclosure. Bioinformatics systems 
can apply data processing filters, limiting data analysis to the portion of the genome 
that the patient has chosen to learn about. Filters can be tailored to reflect individual 
patient choices. There may be great variability regarding the breadth of genomic 
disclosure individuals request.44   
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Informed consent in the genomic era 
 
Informed consent describes the goal that patients are aware of the potential risks 
and benefits of a test, treatment or study and that the voluntarily consent to 
participate.   MPS based genetic screening prompts a review of traditional notions of 
informed consent.45 MPS generates a large amount of data, with a wide range of 
potential results. MPS has the capacity to detect nearly any disease-causing gene 
variant, imparting a broad range of relative risks for disease vary from high to zero. 
However, it will take time and collaborative scientific effort to definitively categorize 
all disease variants and to clarify the clinical importance of Variants Of Unknown 
Significance (VOUS).46 The novel aspect of MPS based testing is the generation of 
genomic data of enormous scale and scope, which is of potential medical relevance 
to a patient. 47 Rapid technological progress and expansion of scientific and medical 
knowledge make it impossible to give a detailed explanation of or even to predict all 
the ways that stored genomic data might be used in the future at the time that bio-
specimens are collected.   
 
In traditional genetic screening programs, screening objectives, risks and outcomes 
have been satisfactorily discussed in the context of screening for a limited range of 
conditions. Informed consent for genetic screening using MPS may only be achieved 
in a more generic sense than has previously been the accepted standard in genetic 
counselling and testing. Depending on the number of conditions screened for, the 
majority rather than a minority of participants can be expected to be diagnosed as a 
carrier of one or more conditions.48 
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Many groups around the world are working on models for optimising the process of 
informed consent in the genomic era.45 No consensus exists on how this can best be 
achieved. Studies documenting the experiences of medical professionals and 
patients using exome sequencing in diagnostics will provide insight into the next 
steps needed to optimise the informed consent procedure in this context.49  
  
 
Sydney Community Genetics Ashkenazi Jewish Preconception 
Screening: Evolution of a TSD screening program 
 
In Sydney, an AJ preconception genetic screening program targeting senior Jewish 
high school students has been operating since 1995. The original program design 
was based on international best-practice principles and screened for TSD only.  
Between 1996 and 2004, screening was conducted for TSD +/- cystic fibrosis. 
From 2005 onwards, screening was conducted for five genetic conditions (TSD, 
cystic fibrosis, Fanconi anaemia, Canavan Disease, familial dysautonomia), with 
carrier 12% detection rate for one or more conditions. 
 
In 2013, a pilot study was proposed using an AJ MPS expanded screening panel, 
now underway. MPS screening was conducted in parallel to the existing screening 
program. The MPS panel studied consists of 25 genetic conditions (Table 3). The 
Sydney Community Genetics MPS screening panel design was based on 
International AJ screening program practice50, 51 52-54 and PaLMS (later acquired by 
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Pathology North) Department of Laboratory and Community Genetics infrastructure 
and MPS testing capabilities.  
 
The 2015 routine clinical panel (non MPS) is aligned to the HGSA recommended 
panel (Chapter 8).  
. 
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Table 3: Current and pilot MPS panels for AJ preconception genetic 
screening 
 
Disease 
(* = Included in current 
screening panel) 
 
Gene 
 
 
No of 
mutations 
 
 
Jewish Carrier 
Frequency 
 
 
Disease phenotype 
Tay Sachs disease 
(TSD)* HEXA 14 1 in 27  
Lethal in infancy/early childhood 
Canavan disease (CD)* ASPA 4 1 in 55 
Lethal in infancy/early childhood 
Familial dysautonomia 
(FD)* IKBKAP 2 1 in 31 
Severe disability 
Bloom disease* BLM 1 1 in 134 Severe disability, cancer susceptibility 
Fanconi anaemia (FA)* FANCC 4 1 in 100 Various birth defects, cancer susceptibility 
Niemann-Pick disease 
(A&B)* SMPD1 4 1 in 115 
Lethal in childhood 
Mucolipidosis type 4* 
MCOLN
1 2 1 in 89 
Severe psychomotor retardation 
Glycogen storage disease 
1a G6PC 2 1 in 64 
Severe metabolic dysfunction; early diagnosis 
improves outcomes ++ 
Cystic fibrosis (CF)* CFTR 11 1 in 29 
Spectrum of severe to milder disease. 
Reduced life expectancy 
Gaucher disease GBA 6 1 in 15 
Multi-organ system disease. Treatment 
improves outcomes ++ 
Maple syrup urine disease 
Type 1B 
BCKDH
B 3 1 in 97 
Lethal in infancy if metabolic crisis untreated. 
Treatment improves outcome ++ 
Hyperinsulinism ABCC8 2 1 in 68 
Lethal in infancy if untreated. Treatment 
improves outcome +  
Dihydrolipoamide 
dehydrogenase deficiency  
(E3) DLD 1 1 in 107 
Lethal in infancy if metabolic crisis untreated. 
Treatment sometimes improves outcome  
Usher syndrome type 3 CLRN1 1 1 in 120 
Progressive visual and hearing loss with 
vestibular dysfunction 
Usher syndrome type 1F 
PCDH1
5 1 1 in 147 
Progressive visual and hearing loss, vestibular 
dysfunction 
Nemaline myopathy (NM) NEB 1 1 in 168 Neuromuscular dystrophy. Severe disability 
Joubert syndrome T2 
TMEM2
16 1 1 in 92 
Motor disability +/- mental retardation 
Spinal muscle atrophy SMN1 1 1 in 41 
Progressive muscle weakness, severe 
disability 
Walker Walburg 
syndrome FKTN 1 1 in 149 
Severe psycho-motor retardation 
Haemophilia C F11 3 1 in 23 Mild haemophilia. 
Familial Mediterranean 
fever MEFV 15  1 in 5 
Painful attacks, AA amaloidosis / chronic renal 
failure 
Deafness GJB2 2 1 in 25 Deafness 
Glycogen storage disease 
Type 3 
GDE/A
GL 1 1 in 35 
Organomegally, variable psycho-motor 
retardation, hypotonia, cardiovascular 
abnormalities 
Alpha-1 antitrypsin 
deficiency 
SERPI
NA1 4  1 in 30 
Lung and liver failure. Reduced life expectancy 
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Australian AJ Preconception genetic screening programs provide an environment to 
assess the clinical and psychosocial impact of using MPS-based genetic screening 
in a pilot study. Multiple studies are underway assessing the clinical, psychosocial, 
safety implications of MPS based screening in an Australian adolescent AJ target 
population. Preliminary results are expected to be available in late 2016, however 
ongoing assessment of this cohort will continue into the future to assess longer-term 
impacts and reproductive outcomes. 
 
In the planning phase of this study, I undertook research to model the predicted 
diagnostic and medical workforce implication of switching from targeted genetic 
testing for the 5 recessive conditions included in routine screening until 2015, to an 
expanded MPS based panel for 25 conditions in an AJ cohort (Appendix 1).  This 
research assisted in planning of the AJ MPS pilot study currently underway.   
 
MPS expanded screening differs from previous AJ screening program models in 
three ways; 
1. A greater number of genetic conditions are screened for simultaneously.  
2. Targeted conditions are serious, but many are of relatively low prevalence 
compared to TSD and cystic fibrosis.   
3. Targeted genomic data is recorded; this resource could be subject to 
reinterpretation and discovery of unexpected results that fall outside of the original 
screening objectives.  
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Whether and how unexpected results should be reported has been the subject of 
vigorous debate.55-57 Informatics tools are currently being developed to assist in 
management of result reporting.58 59 In Appendix 1 modelling of primary, secondary 
and incidental findings expected in a 25 condition AJ MPS screening panel are 
explored. A summary of the major findings reported in this work is outlined below. 
 
Modelling of primary, secondary and incidental findings expected in a 25 
condition AJ MPS screening panel 
 
Massively Parallel DNA Sequencing for Ashkenazi Jewish community pre-
conception genetic screening programs: Predicted outcomes, ethical and workforce 
implications (Poster 1) 
 
I estimated the clinical impact of AJ preconception genetic screening using an MPS 
panel, designed to include 25 autosomal recessive (AR) genetic conditions where 
the homozygous phenotype has serious health implications. Conditions included 
those having an AJ carrier frequency ranging from 1 in 5 (MEFV Familial 
Mediterranean fever, variable penetrance) to 1 in 168 (NEB Nemaline myopathy). 
The panel was designed based on international practice, principles for screening and 
the diagnostic capabilities at PaLMS Pathology North, Royal North Shore Hospital.  
 
In the modelling, the average number of AJ individuals screened per annum was 
estimated from AJ screening program data. Internationally published AJ allele 
prevalence for conditions (Appendix 1, Poster 1) were used to calculate the 
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predicted number of carriers of one or more conditions that would be detected using 
the expanded MPS panel versus the current screening method targeting five 
conditions (TSD (carrier frequency 1 in 27), cystic fibrosis (carrier frequency 1 in 29), 
Canavan disease (carrier frequency 1 in 55), Fanconi anaemia (carrier frequency 1 
in 100), familial dysautonomia (carrier frequency 1 in 31)).    
 
It was found that while the five conditions AJ panel has an a priori carrier risk for at 
least one condition of 12%, the expanded MPS panel has an a priori carrier risk for 
at least one condition of 51%. The probability calculation used was 1-[(1-P1)*(1-
P2)*…(1-Px)], where P1 to P25 refer to the carrier frequency  of conditions listed  in 
Poster 1, presented below in Figure 1. 
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Figure 1: Outcome Summary Data, Sydney Jewish community genetic screening 
programs (presented in Poster 1) 
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 INTRODUCTION 
Ashkenazi Jewish (AJ) individuals are at high risk of several genetic conditions.1  
Preconception genetic screening programs were introduced in Jewish high schools in 
Sydney (1995)2 and Melbourne (1998)3 to detect asymptomatic Tay Sachs disease 
carriers. The scope of these screening programs has expanded to now assess for 
multiple relevant autosomal recessive conditions (Table 2).4  
Effectiveness in primary prevention5, safety4 and cost effectiveness6 of these 
programs have been validated. Conditions screened for and method of laboratory 
testing has changed over time (1995-2004 TSD: Enzyme testing + Restriction Length 
Fragment Polymorphism (RFLP), 2005-2012: Amplification Refractory Mutation 
System(ARMS)).7  
In Sydney, future testing may be conducted using massively parallel DNA sequencing 
technologies  (MPS) as the routine modality,  extending screening to  a broader range 
of conditions.  
  
METHODS 
A panel of conditions was designed for use in AJ preconception genetic screening for 
common autosomal recessive conditions.  
Criteria for inclusion was according to accepted principles for screening.8 
For modelling, the average number of students screened per annum was based on 
actual screening program data. 
The known AJ prevalence of conditions included in the current and expanded panel  
(Table 1) was used to calculate the predicted number of carriers of one or more 
conditions that would be detected using the expanded panel, vs. the current screening 
method.  
The probability calculation used was 1- [(1-P1)*(1-P2)*…(1-Px)], where p1 to p25 refer 
to the carrier frequency of each condition referenced 1 to 25 in Table 1. 
The proportion of individuals screened that would require referral for genetic 
counselling services for both screening models was calculated.  
RESULTS 
DISCUSSION 
1) Zlotogora J. Population programs for the detection of couples at risk for severe monogenic genetic diseases. Hum Genet. 2009; 126: 247-53. 2) Burnett L, Proos AL, Chesher D, et al. The Tay-Sachs disease prevention program in Australia: Sydney 
pilot study. Med J Aust. 1995; 163: 298-300. 3) Gason AA, Sheffield E, Bankier A, et al. Evaluation of a Tay-Sachs disease screening program. Clin Genet. 2003; 63: 386-92. 4) Ioannou L, Massie J, Lewis S, et al. Evaluation of a multi-disease carrier 
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Nucleic Acids Res. 1989; 17: 2503-16. 8) Wilson JM and Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968; 65: 281-393.9) Raffan E and Semple RK. Next generation sequencing--implications for clinical 
practice. British medical bulletin. 2011;  
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AIM 
To estimate the clinical impact of  AJ preconception genetic screening using an MPS 
expanded panel.  
TABLE 1: Current and proposed expanded AJ 
panel for preconception genetic screening 
Conventional DNA testing for 5 conditions (Table 1, marked with *)  has an AJ calculated 
a priori risk carrier risk (for at least 1 condition) of 12%. In the Sydney program's 
experience implementing this model (2005-12), the observed number of carrier 
participants (12% - see Table 2) was in agreement with this predicted number, and 
these were referred for genetic counselling. 
In the proposed MPS screening model, ((Table 1, conditions 1 to 25), the a priori risk of 
being diagnosed a carrier for at least 1 condition is 50.8%. 
 
Some 50% (1 in 2) AJ individuals screened with the proposed MPS panel would be diagnosed a carrier for ≥ 1 recessive condition, which 
predicts a more-than-four-fold (12% to 50%) increase in referrals for genetic counselling. This escalation highlights future workforce 
demands predictable with whole population uptake of genomic preventative medicine.  
MPS also poses challenges to traditional concepts of informed consent.Currently, Jewish Community Genetic screening programs target 
Senior high school students.2, 4, 5 Mature minors6, can provide informed consent for conventional DNA testing for a limited number of 
conditions.4Studies are now underway to ensure that informed consent is achievable in Community Genetics screening programs utilising 
MPS for multiple conditions simultaneously 
TABLE 2: Outcome summary Sydney Jewish 
community genetic screening programs  
Development of health policy regarding ethical, legal and workforce implications of the implementation of diagnostic genome sequencing 
technology must be addressed with some urgency. 
Probability*
Disease*
(**=*Included*in*current*screening*panel)* Gene*
No*of*
muta=ons*
Jewish*
Carrier*
Frequency
(P)** 1EP*
P1* Tay*Sachs*disease*(TSD)** HEXA* 14* 1*in*27** 0.96*
P2* Canavan*disease*(CD)** ASPA* 4* 1*in*55* 0.98*
P3* Familial*Dysautonomia*(FD)** IKBKAP* 2* 1*in*31* 0.97*
P4* Bloom*disease* BLM* 1* 1*in*134* 0.99*
P5* Fanconi*Anaemia*(FA)** FANCC* 4* 1*in*100* 0.99*
P6* NiemannEPick*(A&B)* SMPD1* 4* 1*in*115* 0.99*
P7* Mucolipidosis*type*4*
MCOLN
1* 2* 1*in*89* 0.99*
P8* Glycogen*storage*disease*1a* G6PC* 2* 1*in*64* 0.98*
P9* Cys=c*ﬁbrosis*(CF)** CFTR* 11* 1*in*29* 0.97*
P10* Gaucher*Disease* GBA* 6* 1*in*15* 0.93*
P11* Maple*Syrup*disease*Type*1B* BCKDHB* 3* 1*in*97* 0.99*
P12* Hyperinsulinism* ABCC8* 2* 1*in*68* 0.99*
P13*
Dihydrolipoamide*Dehydrogenase*
Deﬁciency**
(E3)* DLD* 1* 1*in*107* 0.99*
P14* USH3* CLRN1* 1* 1*in*120* 0.99*
P15* USH1F* PCDH15* 1* 1*in*147* 0.99*
P16* Nemaline*Myopathy(NM)* NEB* 1* 1*in*168* 0.99*
P17* Joubert*Syndrome*T2*
TMEM2
16 1 1*in*92* 0.99*
P18* Spinal*Muscle*atrophy* SMN1 1 1*in*41* 0.98*
P19* Walker*Walburg* FKTN* 1* 1*in*149* 0.99*
P20* Haemophilia*C* F11* 3* 1*in*23* 0.96*
P22* Familial*Mediterranean*fever* MEFV* 15* *1*in*5* 0.80*
P23* Deafness* GJB2* 2* 1*in*25* 0.99*
P24* Glycogen*storage*disease*T3*
GDE/
AGL* 1* 1*in*35* 0.97*
P25* Alpha*1*an=trypsin*Deﬁciency*
SERPINA
1* 4* *1*in*30* 0.98*
Year Participants Carriers Disorders  
1995 170 6 TSD 
1996 123 13 TSD, CF 
1997 181 4 TSD 
1998 178 13 TSD, CF 
1999 175 11 TSD, CF 
2000 166 13 TSD, CF 
2001 172 6 TSD 
2002 192 4 TSD 
2003 215 10 TSD 
2004 242 6 TSD 
2005 245 28 CF,TSD,CD,FD,FA 
2006 298 34 CF,TSD,CD,FD,FA 
2007 254 32 CF,TSD,CD,FD,FA 
2008 281 22 CF,TSD,CD,FD,FA 
2009 252 43 CF,TSD,CD,FD,FA 
2010 220 23 CF,TSD,CD,FD,FA 
2011 278 37 CF,TSD,CD,FD,FA 
2012 252 28 CF,TSD,CD,FD,FA 
Carriers detected(%) TSD TSD,CF CF,TSD,CD,FD,FA 
 36(3%) 50(8%) 247(12%) 
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Figure 2: Projected a priori carrier detection risk with an expanded screening panel  
(presented in Poster 1) 
 
Current practice is to offer all identified carriers a referral for genetic counselling. If 
this practice were to continue with the introduction of MPS based expanded 
screening, a more-than-four-fold increase in referrals for genetic counselling would 
be generated from screening of the same target population.  
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Ashkenazi Jewish (AJ) individuals are at high risk of several genetic conditions.1  
Preconception genetic screening programs were introduced in Jewish high schools in 
Sydney (1995)2 and Melbourne (1998)3 to detect asymptomatic Tay Sachs disease 
carriers. The scope of these screening programs has expanded to now assess for 
multiple relevant autosomal recessive conditions (Table 2).4  
Effectiveness in primary prevention5, safety4 and cost effectiveness6 of these 
programs have been validated. Conditions screened for and method of laboratory 
testing has changed over time (1995-2004 TSD: Enzyme testing + Restriction Length 
Fragment Polymorphism (RFLP), 2005-2012: Amplification Refractory Mutation 
System(ARMS)).7  
In Sydney, future testing may be conducted using massively parallel DNA sequencing 
technologies  (MPS) as the routine modality,  extending screening to  a broader range 
of conditions.  
  
METHODS 
A panel of conditions was designed for use in AJ preconception genetic screening for 
common autosomal recessive conditions.  
Criteria for inclusion was according to accepted principles for screening.8 
For modelling, the average number of students screened per annum was based on 
actual screening program data. 
The known AJ prevalence of conditions included in the current and expanded panel  
(Table 1) was used to calculate the predicted number of carriers of one or more 
conditions that would be detected using the expanded panel, vs. the current screening 
method.  
The probability calculation used was 1- [(1-P1)*(1-P2)*…(1-Px)], where p1 to p25 refer 
to the carrier frequency of each condition referenced 1 to 25 in Table 1. 
The proportion of individuals screened that would require referral for genetic 
counselling services for both screening models was calculated.  
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While it has been recognised that traditional notions of informed consent are 
challenged by the magnitude of genetic information generated by MPS based 
screening, no consensus exists as to how this issue should be navigated. While 
there is robust evidence supporting the safety, efficacy and cost efficiency of 
targeted genetic screening in mature minors, prior to pregnancy planning, 
translational research is needed to assess the safety and ongoing psychosocial 
impacts of MPS based expanded genetic screening in adolescent populations.    
 
Reporting findings of Massively Parallel Sequencing: A model for genetic screening 
of autosomal recessive conditions in at-risk communities (Poster 2) 
 
MPS based genetic screening was arbitrarily limited in our previous work to 
encompass 25 autosomal recessive conditions (Poster 1). However as MPS 
technology attains greater speed, greater accuracy and lower cost, parallel 
screening for an even broader range of conditions may be expected to become 
routine.  
 
We developed and validated a mathematical model to predict the AR genetic carrier 
rate in a dataset or population as the testing panel expands. This model was used to 
study the effects of increasing the number of AR conditions included in population 
screening programs, using data from Australian AJ genetic screening program as a 
prototype.   
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To simulate the effect of increasing the number of conditions tested for, each carrier 
frequency for the 26 genetic conditions most prevalent in the AJ community was 
added to the model one-by-one from most to least frequent, an the cumulative AR 
carrier rate was calculated. The simulation panel represented the 25 AR conditions 
listed in Figure 2, with the addition of one semi-dominant condition, familial 
hypercholesterolaemia (LDLR). There was good agreement between the predictions 
of our model and the actual rate of AR genetic carriers detected in the Australian AJ 
community genetic screening program. Expansion of the AJ testing menu to include 
26 conditions was predicted to result in 58% of the AJ screened population to be 
diagnosed as a carrier for one or more conditions (Appendix 1, Poster 2). We 
showed the primary driver of the AR genetic carrier rate is the number of tested 
conditions. A mathematical model was developed based on the binomial distribution: 
p(X) = 1- [(1-P1) • (1-P2) •...(1-Pn)], where P1 to Pn are the carrier frequencies of 
various genetic conditions and p(X) is the probability of being a genetic carrier for 
any one of these conditions (assuming all conditions are inherited independently). 
The model was validated in silico using the testing panels and data from Australian 
AJ community genetics screening programs. Known or best estimate carrier 
frequencies for the 26 most prevalent AR conditions in the AJ community were 
obtained from published literature. The predicted annual detection rate of AR genetic 
carriers was compared to the actual number of carriers. 
To simulate the effect of increasing the number of tested conditions, each carrier 
frequency was iteratively added to the model one by one, from the most to least 
frequent, to calculate the cumulative AR carrier rate. The carrier frequency was 
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varied over a 4-fold range to simulate the effect of uncertainty in carrier prevalence 
or errors in sequencing on the predicted AR carrier rate. 
This is in contrast to autosomal dominant conditions where the proportion of 
individuals with a pathogenic variant plateaus as the number of conditions tested for 
increases.6     
Figure 3: Predicted and actual rates of AR genetic carriers (Number of conditions 
tested for: 1(1995,1997,2001-2004), 2(1996, 1998-2000) or 5 (2004-2013).)  
(Presented in Poster 2) 
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Massively parallel sequencing (MPS) has dramatically lowered the cost 
of genomic sequencing for multiple genetic conditions. Best ethical and 
clinical practice for clinical diagnostic testing using traditional targeted 
sequencing technologies requires informed consent and availability of 
genetic counselling.  
High infant mortality from severe autosomal recessive (AR) childhood 
conditions has led to the establishment of genetics screening programs in 
communities with increased risk of AR conditions due to ancestral origins. 
For example, Australian Ashkenazi Jewish (AJ) preconception and carrier 
screening programs test for conditions relevant to the AJ community and 
have been effective in decreasing the incidence of AR-affected births (1).
The greater speed, lower costs and parallel nature of genetic testing 
using MPS technologies allows the testing panel of screening programs 
to be expanded to encompass a broader range of conditions. The effects 
of broader testing on carrier detection rates are yet to be fully evaluated. 
INTRODUCTION 
A simple mathematical model was developed based on the binomial 
distribution: p(X) =  1- [(1-P1) • (1-P2) •…(1-Pn)], where P1 to Pn are the 
carrier frequencies of various genetic conditions and p(X) is the 
probability of being a genetic carrier for any one of these conditions 
(assuming all conditions are inherited independently). 
The model was validated in silico using the testing panels and data from 
Australian AJ community genetics screening programs. Known or best 
estimate carrier frequencies for the 26 most prevalent AR conditions in 
the AJ community were obtained from published literature (2,3). The 
predicted annual detection rate of AR genetic carriers was compared to 
the actual number of carriers.  
To simulate the effect of increasing the number of tested conditions, each 
carrier frequency was iteratively added to the model one by one, from the 
most to least frequent, to calculate the cumulative AR carrier rate. The 
carrier frequency was varied over a 4-fold range to simulate the effect of 
uncertainty in carrier prevalence or errors in sequencing on the predicted 
AR carrier rate. 
METHODS 
We validated the model using data from an Australian AJ community genetics screening program. Our model closely predicts the observed 
rates of AR genetic carriers detected in the Sydney AJ community screening program over an 18-year period.  
 
Using our model, we studied the likely impact on carrier detection rates of the introduction of MPS into screening. We show that the primary 
driver of the AR genetic carrier rate is the number of tested conditions. This is in contrast to autosomal dominant conditions where the 
proportion of individuals with a pathogenic variant plateaus as the number of tested conditions is increased (4). Increasing the number of AR 
conditions screened from the current panel of 5 up to 26 would result in a 4-fold increase in the proportion of AR genetic carriers detected.  
 
Jewish Australians represent a population minority and, in clinical terms, this projected increase in total community genetics services use is 
modest. It does however highlight important workforce issues that health systems will face as the rapidly evolving field of genomic preventative 
medicine becomes more mainstream. Future increases in the number of included conditions will increase the number of genetic carriers 
detected and have implications for downstream health costs and resources. 
DISCUSSION 
Figure 1: Predicted and actual rates of AR genetic carriers 
 Number of conditions tested for: 1 (1995, 1997, 2001-2004), 2 (1996, 
1998-2000) or 5 (2004-2013) 
To develop and validate a model to predict the AR genetic carrier rate in a 
dataset or population as the testing panel expands. This model was used 
to study the effects of increasing the number of AR conditions included in 
population screening programs.  
AIM 
For further information please contact: leslie.burnett@sydney.edu.au HGSA Annual Scientific Meeting 2014 
REFERENCES 
1.  Lew, R.M., et al., Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Med J Aust, 2012. 197(11): p. 652-4. 
2.  Scott, S.A., et al., Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat, 2010. 31(11): p. 1240-50. 
3.  Strom, C.M., et al., Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med, 
2004. 6(3): p. 145-52. 
4.  Ding, L.C., et al., The impact of reporting incidental findings from exome and whole genome sequencing: Predicted frequencies based on modelling. Genet Med, 2014 (in press) 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0 5 10 15 20 25 30 
Proportion of carriers (100% detection) given the number of conditions included 
Proportion of carriers (current detection rates) given the number of conditions 
included 
Carriers at 1/2 rate 
Carriers at 2x rate 
Proportion of  carriers (100% detection) 
Proportion of carriers (current detection rate 90%) 
½ carrier fr quency 
2x carrier frequency 
Figure 2: Predicted proportion of AR genetic carriers with 
increasing number of AR conditions tested   
RESULTS 
There was good agreement between the predictions of our 
model and the actual rate of AR genetic carriers detected in the 
community screening program (Figure 1). Expansion of the 
testing menu to screen for 26 conditions is predicted to increase 
the proportion of AR genetic carriers to 58% (Figure 2). 
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Figure 4: Predicted proportion of AR genetic carriers with increasing number of AR 
conditions tested for (Presented in Poster 2) 
 
Individuals of AJ heritage represent a minority of Australians, and health system 
implications due to the expected increased number of AJ genetic carriers identified 
by MPS based screening will be modest overall. However our mathematical models, 
validated with data generated from longitudinal experience of Australian AJ genetic 
screening programs, highlight important workforce and health system infrastructural 
implications expected when MPS based genetic testing and screening become 
integrated into mainstream genomic preventative medicine. 
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Massively parallel sequencing (MPS) has dramatically lowered the cost 
of genomic sequencing for multiple genetic conditions. Best ethical and 
clinical practice for clinical diagnostic testing using traditional targeted 
sequencing technologies requires informed consent and availability of 
genetic counselling.  
High infant mortality from severe autosomal recessive (AR) childhood 
conditions has led to the establishment of genetics screening programs in 
communities with increased risk of AR conditions due to ancestral origins. 
For example, Australian Ashkenazi Jewish (AJ) preconception and carrier 
screening programs test for conditions relevant to the AJ community and 
have been effective in decreasing the incidence of AR-affected births (1).
The greater speed, lower costs and parallel nature of genetic testing 
using MPS technologies allows the testing panel of screening programs 
to be expanded to encompass a broader range of conditions. The effects 
of broader testing on carrier detection rates are yet to be fully evaluated. 
INTRODUCTION 
A simple mathematical model was developed based on the binomial 
distribution: p(X) =  1- [(1-P1) • (1-P2) •…(1-Pn)], where P1 to Pn are the 
carrier frequencies of various genetic conditions and p(X) is the 
probability of being a genetic carrier for any one of these conditions 
(assuming all conditions are inherited independently). 
The model was validated in silico using the testing panels and data from 
Australian AJ community genetics screening programs. Known or best 
estimate carrier frequencies for the 26 most prevalent AR conditions in 
the AJ community were obtained from published literature (2,3). The 
predicted annual detection rate of AR genetic carriers was compared to 
the actual number of carriers.  
To simulate the effect of increasing the number of tested conditions, each 
carrier frequency was iteratively added to the model one by one, from the 
most to least frequent, to calculate the cumulative AR carrier rate. The 
carrier frequency was varied over a 4-fold range to simulate the effect of 
uncertainty in carrier prevalence or errors in sequencing on the predicted 
AR carrier rate. 
METHODS 
We validated the model using data from an Australian AJ community genetics screening program. Our model closely predicts the observed 
rates of AR genetic carriers detected in the Sydney AJ community screening program over an 18-year period.  
 
Using our model, we studied the likely impact on carrier detection rates of the introduction of MPS into screening. We show that the primary 
driver of the AR genetic carrier rate is the number of tested conditions. This is in contrast to autosomal dominant conditions where the 
proportion of individuals with a pathogenic variant plateaus as the number of tested conditions is increased (4). Increasing the number of AR 
conditions screened from the current panel of 5 up to 26 would result in a 4-fold increase in the proportion of AR genetic carriers detected.  
 
Jewish Australians represent a population minority and, in clinical terms, this projected increase in total community genetics services use is 
modest. It does however highlight important workforce issues that health systems will face as the rapidly evolving field of genomic preventative 
medicine becomes more mainstream. Future increases in the number of included conditions will increase the number of genetic carriers 
detected and have implications for downstream health costs and resources. 
DISCUSSION 
Figure 1: Predicted and actual rates of AR genetic carriers 
 Number of conditions tested f r: 1 (1995, 1997, 2001-2004), 2 (1996, 
1998-2000) or 5 (2004-2013) 
To develop and validate a model to predict the AR genetic carrier rate in a 
dataset or population as the testing panel expands. This model was used 
to study the effects of increasing the number of AR conditions included in 
population screening programs.  
AIM 
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RESULTS 
There was good agreement between the predictions of our 
model and the actual rate f AR genetic carriers detected in the 
community screening program (Figure 1). Expansion of the 
testing menu to screen for 26 conditions is predicted to increase 
th  proportion of AR et  carriers to 58% (Figure 2). 
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The ACMG has recently published recommendations for the clinical reporting of 24 
specific genetic conditions if diagnosed incidentally during MPS based testing. 7, 8 
We applied our mathematical modelling to a simulated MPS diagnostic panel to 
calculate the proportion of individuals screened who would require supplementary 
consultation and genetic counselling due to the detection of 1 or more of the ACMG’s 
24 incidental findings (IFs) recommended to be reported (Figure 5).  
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Figure 5: Carrier frequency estimates of recommended conditions 
 
We found approximately 2.7% (1.5 to 6.5%) of individuals screened would require 
supplementary counselling because of the detection of IFs. As the list of IFs 
recommended for clinical reporting is likely to expand over time, the issue of MPS 
identified IFs of clinical relevance is likely to result in major net increases in health 
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Probability Disease Phenotype Carrier Frequency 
Low estimate 
Carrier Frequency 
Most likely 
estimate 
Carrier Frequency 
High estimate 
P1 Hereditary Breast and Ovarian Cancer 0.1060% 3,4 0.4589% 2.8820%4,5 
P2 Li-Fraumeni Syndrome 0.0050%6 0.0100% 0.0200%6 
P3 Peutz-Jeghers Syndrome 0.0004%7 0.0012% 0.0040%7 
P4 Lynch Syndrome 0.0500%8 0.1066% 0.2273%8 
P5 Familial adenomatous polyposis 0.0023%9 0.0027% 0.0032%9 
P6 
MYH-Associated Polyposis; Adenomas, multiple 
colorectal, FAP type 2, Colorectal adenomatus 
polyposis, autosomal recessive, with pilomatricomas 1.0000%10 1.4142% 2.0000%10 
P7 Von Hippel Lindau syndrome 0.0014% 0.0028%11 0.0056% 
P8 Multiple Endocrine Neoplasia Type 1 (MEN1) 0.0017% 0.0033%12 0.0067% 
P9 Multiple Endocrine Neoplasia Type 2 (MEN2) 0.0014% 0.0029%13 0.0057% 
P10 Familial Medullary Thyroid Cancer (FMTC) * * * 
P11 PTEN Hamartoma Tumor Syndrome 0.0003% 0.0005%14 0.0010% 
P12 Retinoblastoma 0.0067%15 0.0058% 0.0050%15 
P13 
Hereditary Paraganglioma-Pheochromocytoma 
Syndrome 0.0001%16 0.0003% 0.0009%16 
P14 Tuberous Sclerosis Complex 0.0086% 0.0172%17 0.0345% 
P15 WT1-related Wilms tumor 0.0005%18 0.0006% 0.0006%18 
P16 Neurofibromatosis type 2 0.0025%19 0.0028% 0.0030%19 
P17 EDS - vascular type 0.0005%20 0.0010% 0.0020%20 
P18 
Marfan Syndrome, Loeys-Dietz Syndromes, and 
Familial Thoracic Aortic Aneurysms and Dissections 0.0102%21,22,23 0.0144% 0.0205%21,22,23 
P19 Hypertrophic cardiomyopathy, Dilated cardiomyopathy 0.1100%24 0.1241% 0.1400%24 
P20 Catecholaminergic polymorphic ventricular tachycardia 0.0050%25 0.0058% 0.0066%25 
P21 Arrhythmogenic right ventricular cardiomyopathy 0.0800%26 0.2530% 0.8000%26 
P22 
Romano-Ward Long QT Syndromes Types 1, 2, and 3, 
Brugada Syndrome 0.0143%27 0.0218% 0.0333%27 
P23 Familial Hypercholesterolemia 0.1500% 0.3000%28 0.6000% 
P24 Malignant hyperthermia susceptibility 0.0010% 0.0071%29 0.0500% 
Each probability, P1 – P24, represent the combined probabilities of the conditions listed. E.g. P1 represents the combined 
probabilities of BRCA1 and BRCA2. 
Frequency estimates with a white background represent values found in the literature, while those with grey backgrounds 
indicate calculated estimates (see Methods). 
* Probabilities for FMTC included with those of the related syndrome MEN2 
Massively parallel sequencing (MPS), also called next generation 
sequencing, has dramatically lowered the cost of nucleic acid sequencing 
for multiple genetic conditions.  
Best ethical and clinical practice for clinical diagnostic testing using 
traditional targeted sequencing technologies requires obtaining informed 
consent and ensuring availability of genetic counselling. 
Testing for specific genetic conditions using MPS may incidentally 
discover off-target genetic conditions. The American College of Medical 
Genetics and Genomics (ACMG) has recently published 
recommendations for the clinical reporting of incidental findings for a list 
of 24 specific conditions.1,2 
INTRODUCTION 
A diagnostic panel was simulated based on the ACMG recommended 
minimum list of genes to be reported, regardless of the original indication 
for the clinical sequencing (incidental findings). 
The number of patients with significant variants in one or more conditions 
that would be detected using the screening panel was calculated from 
known (or best estimate) prevalence. Where a range of variant 
prevalence data was available, we selected the lowest and highest 
values, and calculated the most-likely estimate as the geometric mean. 
Alternatively, where only a single datum was available, we selected half 
and twice this prevalence as the low and high estimates.  
 
Assuming all disorders were inherited independently, the probability 
calculation used was 1- [(1-P1)*(1-P2)*…(1-P24)], with P1 to P24 as the 
carrier frequencies of the 24 proposed ACMG conditions. Calculations 
were repeated separately for the lower and higher limits.  
 
The proportion of individuals screened who would require supplementary 
consultation and genetic counselling was calculated. 
METHODS 
Our modelling of the ACMG Recommendations for Clinical Reporting of Incidental Findings has shown that a non-trivial percentage (1.5% - 6.5%) of screened 
individuals will have a significant reportable finding. These individuals would require confirmatory testing, education, counselling and potentially treatment but 
might derive significant benefit from the incidental findings. 
 
All the conditions on the current ACMG list are relatively rare. Information about the population carrier frequencies of such rare conditions is necessarily limited, 
and calculations based on such limited information must be regarded with caution. Many of the estimates of carrier frequency are based on the prevalence of a 
particular disorder. The true carrier frequency may be much higher if the disorder has incomplete penetrance; this would lead to a falsely low estimation of the 
predicted number of incidental findings. Similarly, some pathogenic phenotypes will be due to genetic variations not yet described or currently considered of 
uncertain significance; these will lead to a falsely high estimation of the number of true incidental findings. However, over time, with increasing experience and 
larger population sample numbers, the true rate of incidental findings will become apparent. 
 
Ongoing research continues to reveal the genetic basis for more and more conditions. The ACMG list of Recommendations is likely to grow, not shrink, over time. 
The implementation of the ACMG Recommendations for Clinical Reporting of Incidental Findings will require major increases in resources for the health system. 
To adopt the ACMG Recommendations, these increased resource requirements need to be identified, costed and addressed. The costs to implement the 
recommendations need to be compared to the potential benefits, cost offsets and utility of reporting and acting on these findings. 
DISCUSSION 
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TABLE 1: Carrier Frequency Estimates of Recommended Conditions 
The proposed ACMG recommen d screening panel w uld 
require supplementary consultation and genetic counselling for 
approximately 2.7% (range 1.5%-6.5%) of screened individuals. 
RESULTS 
To predict the clinical impact of expanded genomic testing with MPS 
using the ACMG Recommendations for Clinical Reporting of Incidental 
Findings. 
AIM 
TABLE 2: Expected Incidental Findings Using ACMG Panel 
Carrier Frequency Estimate Low Most likely High 
Percentage of individuals who screen positive 
for at least one of the 24 conditions 1.52% 2.70% 6.48% 
For further information please contact: leslie.burnett@sydney.edu.au 
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care resources. Further studies, medical infrastructure and workforce planning 
around this issue should be considered. 
 
Implications of Massively Parallel Sequencing in screening for Autosomal Recessive 
conditions: the risk of being a “genetic wallflower” (Poster 4) 
 
We undertook mathematical modelling to better understand the impact of expanded 
AJ MPS genetic screening on the number of at-risk carrier couples expected to be 
identified via screening. We also explored the likelihood of genetic wallflowers 
emerging (Appendix 1, Poster 4). Mathematical modelling based on binomial 
distribution was used to predict the number of AR carriers based on prevalence of 
pathogenic variants and number of tested conditions. Monte Carlo simulation was 
used to calculate the probability of any two individuals in this screened population 
being carriers of exactly the same AR genetic conditions.  
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Figure 6: 
A. Predicted rate of AR genetic carriers with increasing number of AR conditions 
tested 
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Genetic screening for autosomal recessive (AR) genetic carriers is available in 
many communities “at risk” due to high prevalence of pathogenic variants. 
Examples include Tay-Sachs disease testing in the Ashkenazi Jewish (AJ) 
community. The range of tests included in screening programs is broadening, 
and will accelerate with the introduction of Massively Parallel Sequencing.  
We recently modelled the frequency of autosomal dominant (AD) genetic 
conditions arising as Incidental Findings (IF) in Whole Genome Sequencing. We 
found that the proportion of tested individuals with significant IFs plateaus to a 
limit even as the number of genes tested increases beyond those in the ACMG 
IF Recommendations (1).  
In contrast, modelling of AR conditions showed that the carrier rate continues to 
increase with the number of genes tested (2). As more gene panels are included 
in screening programs, a risk emerges of being a “genetic wallflower”, someone 
rejected by every suitor because of the common AR variants they carry. 
INTRODUCTION 
We developed a computer simulation model to create a virtual population of 
individuals with randomised genomes. The simulation model could be adjusted 
to vary population size (we used 103-104), the number of genes tested (each 
genome consisted of 1-27 genes of known AJ prevalence, supplemented by 
102 - 104 simulated genes, so that at maximal values, the simulated genome 
approximated the size of the human exome), the prevalence of pathogenic AR 
variants (using actual gene prevalence for known AJ genes, and 10-2 - 10-4 for 
simulated genes) and number of iterations (range 10-100). Random couples 
were then chosen from each population to ‘mate’. The average AR genetic 
carrier rate, number of variants present per individual and proportion of at-risk 
couples (i.e. both partners being carriers for the same pathogenic AR genetic 
condition) for a population were calculated.  
The simulation model was validated using actual testing panels and data from 
Australian AJ community genetics screening programs. Known or best estimate 
carrier frequencies for the 26 most prevalent AR conditions in the AJ community 
were obtained from published literature (3,4). The simulated annual rate of AR 
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B. Average number of variants in an individual with increasing number of AR 
conditions tested 
 
 
While the number of genetic carriers for AR conditions is expected to expand quickly 
with expanded MPS based screening panels, the expansion of the number of at-risk 
carrier couples is predicted to expand more slowly (Figure 7). We are currently 
undertaking work to further quantify this. These findings have significant implications 
for health economic evaluation and planning.      
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Genetic screening for autosomal recessive (AR) genetic carriers is available in 
many communities “at risk” due to high prevalence of pathogenic variants. 
Examples include Tay-Sachs disease testing in the Ashkenazi Jewish (AJ) 
community. The range of tests included in screening programs is broadening, 
and will accelerate with the introduction of Massively Parallel Sequencing.  
We recently modelled the frequency of autosomal dominant (AD) genetic 
conditions arising as Incidental Findings (IF) in Whole Genome Sequencing. We 
found that the proportion of tested individuals with significant IFs plateaus to a 
limit even as the number of genes tested increases beyond those in the ACMG 
IF Recommendations (1).  
In contrast, modelling of AR conditions showed that the carrier rate continues to 
increase with the number of genes tested (2). As more gene panels are included 
in screening programs, a risk emerges of being a “genetic wallflower”, someone 
rejected by every suitor because of the common AR variants they carry. 
INTRODUCTION 
We developed a computer simulation model to create a virtual population of 
individuals with randomised genomes. The simulation model could be adjusted 
to vary population size (we used 103-104), the number of genes tested (each 
genome consisted of 1-27 genes of known AJ prevalence, supplemented by 
102 - 104 simulated genes, so that at maximal values, the simulated genome 
approximated the size of the human exome), the prevalence of pathogenic AR 
variants (using actual gene prevalence for known AJ genes, and 10-2 - 10-4 for 
simulated genes) and number of iterations (range 10-100). Random couples 
were then chosen from each population to ‘mate’. The average AR genetic 
carrier rate, number of variants present per individual and proportion of at-risk 
couples (i.e. both partners being carriers for the same pathogenic AR genetic 
condition) for a population were calculated.  
The simulation model was validated using actual testing panels and data from 
Australian AJ community genetics screening programs. Known or best estimate 
carrier frequencies for the 26 most prevalent AR conditions in the AJ community 
were obtained from published literature (3,4). The simulated annual rate of AR 
genetic carriers was compared to the actual rate of carriers and our previous 
mathematical modelling results (2). 
The effect of increasing the number of genes tested on the overall carrier rate 
and on the proportion of at-risk couples was simulated on a population of 
10,000 individuals and averaged from 100 iterations. 
METHODS 
As the number of AR conditions included in testing panels is increased, the 
number of AR genetic carriers identified in a population will increase. This 
behaviour is in marked contrast to that for AD conditions, where the proportion 
of a population with a reportable IF will plateau. These findings have significant 
implications for health economic evaluation and planning.  
However, regardless of the number of AR conditions tested, the number of “at-
risk” carrier couples increases more slowly, lessening the risk of emergence of 
genetic wallflowers. We are currently quantifying this risk. 
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Figure 7: Average proportion of couples at-risk of an AR affected child with 
increasing number of AR conditions tested 
 
 
Education strategies for AJ preconception screening programs are highly effective.  
Participants understand in depth the natural history and recessive inheritance of 
screened conditions and are introduced to potential reproductive interventions. 
Knowledge has been demonstrated to be well retained in 5 to 11 year follow-up 
studies.8  The same depth of understanding for a panel of 25+ inherited conditions 
may not be a reasonable expectation. Studies of participants’ knowledge and 
perceptions prior to and after pre-test education, as well as longer-term studies of 
knowledge retention and quality of life impacts are needed.  
 
Should MPS screening pilot studies support the further application of MPS based 
genetic screening programs to an expanded target group, longitudinal access 
planning (including costing and potential health budget funding) and ongoing impact 
evaluation will be mandated in the future.  
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The planning and primary analysis of MPS based pre-conception genetic screening 
strategies represents a first step in adapting this technology to diagnostic 
applications to benefit individuals and population health. The publications described 
in Appendix 1 outline work undertaken in the planning phase of the MPS AJ 
preconception screening pilot study. Expansion of this work is underway, and will 
progress beyond the scope of this thesis.    
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Chapter 8 Human Genetics Society of Australasia position 
paper: Australasian Ashkenazi Jewish genetic screening 
 
 
These guidelines were prepared by invitation for the Joint Human Genetics 
Society of Australasia/Royal Australian and New Zealand College of 
Obstetricians and Gynaecologists Prenatal Diagnosis and Screening 
Committee. They are designed to support the transition of AJ preconception 
genetic screening strategies to universally accessible primary health care 
settings.   
 
As chairperson and first author of these guidelines I convened a committee 
with multidisciplinary expertise to devise a framework to devise and to debate 
these guidelines. I then wrote the guidelines and brought them back to the 
committee for review. I instituted suggested revisions from both the committee 
and peer review. 
 
 Recommendations are designed to be relevant for all individuals who are 
involved in pre-pregnancy and antenatal care, including, but not limited to 
General Practitioners, Obstetricians and Gynaecologists, Clinical Geneticists 
and Genetic Counselors. 
 
In 2015, this guideline was ratified by the HGSA, and published with 
unrestricted access (https://www.hgsa.org.au/documents/item/6092). 
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Summary of Recommendations 
 
The HGSA TSD Population Screening Committee recommends that: 
1. All AJ individuals of reproductive age should be made aware of the availability of AJ 
preconception genetic screening for severe monogenetic conditions and offered access to 
screening for TSD, CF, FD, FA NPD, BLM, CD and MPLIV.  
2. For all screened conditions except TSD, screening is by mutation detection.  For TSD, 
screening can be by mutation detection or enzyme analysis for AJ individuals but should be 
by enzyme analysis for non-AJ individuals screened. 
3. The gold standard should be considered to be a combination of high school genetic 
screening programs, outreach community programs, opportunistic screening by medical 
practitioners and preconception screening. No single approach is likely to be sufficient in 
providing a comprehensive screening strategy for the Australian AJ population. 
4. Preconception screening is preferable to antenatal screening. Where screening is 
conducted during pregnancy, screening of both parents concurrently and without delay is 
preferred.  
5. Where an AJ individual is diagnosed as a carrier for one or more severe monogenetic 
conditions, their partner should be offered screening for the condition(s) in question, 
regardless of AJ heritage. Residual risk counselling is required when screening indicates 
that a non-AJ partner is a non-carrier for the condition(s) in question. 
6. Best practice testing methodology will differ for AJ and non-AJ individuals, as will test 
sensitivity and residual risk. AJ/non-AJ patient background and any known family history of 
AJ genetic disease should be documented on pathology requests and communicated to the 
testing laboratory. Testing laboratories should comply with international best-practice 
standards and quality assurance procedures. 
7. Primary care clinicians, including but not limited to General Practitioners,  and Obstetricians 
and Gynaecologists, are encouraged to provide access to genetic screening in AJ patients. 
Enquiry of ethnic background should be made on medical history taking. Clinicians should 
consider and offer AJ genetic screening opportunistically when at-risk patients present for 
other reasons (i.e. general or sexual health check). 
8. Primary health care providers should be aware of different screening strategies to maximise 
cost-benefit. 
9. Pre-test education should be delivered by a qualified health professional. Details of 
conditions screened for including clinical features, mode of inheritance and implications for 
relatives should be discussed. Information should be imparted regarding reproductive 
options for at-risk couples. Voluntary informed consent should be obtained from the patient 
and should be documented. 
10. Carriers of one or more conditions detected by AJ genetic screening should be fully 
informed of the significance of their results. Current and future partners of carriers should be 
offered screening. Cascade screening should be offered to relatives of these genetic 
carriers. 
11. Carrier couples should be referred for specialist genetic counselling. In the context of 
pregnancy, carrier couples should be referred for Obstetrician +/- subspecialist Maternal 
Fetal Medicine review without delay. 
12. These recommendations should be promulgated to relevant learned Medical Colleges and 
health care professional Associations and Societies, as well as to genetic support groups 
and consumer health organisations (section 10). 
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2. Introduction 
 
2.1 Background 
Population screening refers to testing for heterozygous carrier status in individuals without a family 
history of disease. The health implications are not for the individuals tested but for their children. 
For serious monogenetic diseases, knowledge of carrier status prior to pregnancy allows carrier 
couples to be informed and exercise reproductive choice. Classic principles of population genetic 
screening (Wilson & Jungner), reviewed for the genomic age (World Health Organization) are 
relevant to preconception and antenatal genetic screening.(1)  
 
The 2011 Australian Bureau of Statistics (ABS) census estimates the current overall population of 
Jewish Australians to be 97,335 representing a 9.58% increase from the previous 5-year census 
period.(2) The term ‘Ashkenazi’ describes Jewish populations with ancestry from Central and 
Eastern Europe. The majority of Jewish Australians have AJ heritage. Disease-causing founder 
mutations for a range of recessive genetic conditions have been identified in AJ populations. These 
conditions may be more common in AJ populations (e.g. Tay Sachs disease, AJ carrier frequency 
1 in 25), almost exclusive to AJ individuals (e.g. familial dysautonomia, AJ carrier frequency 1 in 
40) or present at similar prevalence in AJ individuals to other communities (e.g. cystic fibrosis, AJ 
carrier frequency 1 in 23). In AJ individuals, however, a small number of identified AJ founder 
mutations are responsible for the vast majority of disease. This small number of founder mutations 
simplifies many of the technical complexities involved in laboratory testing and screening. Genetic 
carrier screening for severe monogenetic conditions is well accepted by AJ communities worldwide 
(reviewed below). Although individual conditions screened for may be rare in themselves, about 1 
in 5 AJ individuals screened with an AJ mutation panel will be carriers for one or more of these 
conditions.(3)    
 
2.2 International Practice 
Tay Sachs disease (TSD) screening of AJ individuals has resulted in >90% reduction in TSD 
incidence in the United States(4), Canada(4, 5), Israel.(6) Most recently, a reduction in AJ TSD 
case frequency has been documented in Australia.(7) The success of TSD preconception and 
antenatal screening programs has led to the expansion of screening programs over time to offer 
simultaneous screening for TSD and a range of other severe monogenetic conditions with known 
causative AJ founder mutations.  
   
The American Congress of Obstetricians and Gynecologists (ACOG)(8), the American College of 
Medical Genetics and Genomics (ACMG)(9), the Society of Obstetricians and Gynaecologists of 
Canada (SOGC)(10), the United Kingdom National Screening Committee (UK NSC) (11) and the 
State of Israel Ministry of Health(12) all recommend that TSD preconception/antenatal screening 
should be offered to all individuals with AJ heritage. 
 
In addition to screening for TSD, ACOG further recommends routine AJ screening for cystic fibrosis 
(CF), Canavan disease (CD) and familial dysautonomia (FD)(8), while ACMG endorses routine 
screening for 9 conditions; TSD, CF, CD, FD, Niemann Pick disease type A (NPDA), Bloom 
syndrome (BLM), Mucolipidosis Type IV (MLIV), Fanconi anaemia (FA) and Gaucher disease 
(GD).(3) (9) Centres in the United States (e.g. Mt Sinai Centre for Jewish Genetic Diseases, Tufts 
Medical Centre Victor Outreach and Screening Program for Ashkenazi Jewish Genetic Diseases) 
routinely offer screening for 16 to 19 conditions, including TSD, BLM, CD, CF, FD, FA, GD, MPIV, 
NP, dihydrolipoamide dehydrogenase deficiency, familial hyperinsulinism, glycogen storage 
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disease type 1A, Joubert syndrome, maple syrup urine disease, nemaline myopathy, spinal 
muscular atrophy, Usher syndrome type 1F, Usher syndrome type III and Walker Warburg 
syndrome.(13-16)    
 
Table 1: International Practice for AJ carrier screening 
 
Country UK  USA Israel Canada Australia*  
Supporting guideline NHS ACO
G 
ACM
G 
Private**
* 
ACMG*
* 
SOCG None 
TSD X X X 
 
X X X X 
CD  X X X X X X 
NP  X X X X  X 
FD  X X X X X X 
CF  X X X X  X 
BLM   X X X   
MLIV   X X X   
FA   X X X   
GD   X X    
Dihydrolipoamide 
dehydrogenase 
deficiency 
   X    
Familial 
hyperinsulinism 
   X    
Glycogen storage 
disease type 1A 
   X    
Joubert syndrome    X    
Maple syrup urine 
disease 
   X    
Nemaline myopathy    X    
Spinal muscular 
atrophy 
   X    
Usher syndrome type 
1F 
   X    
Usher syndrome type 
III 
   X    
Walker Warburg 
syndrome 
   X    
 
*    Non-government funding 
**   Endorsed for all conditions other than GD 
***  Mt Sinai Centre for Jewish Genetic Diseases, Tufts Medical Centre Victor Outreach and  
      Screening Program for Ashkenazi Jewish Genetic Diseases 
 
In 2013, the ACMG published a position statement(17) on prenatal/preconception expanded carrier 
screening, endorsing the concept of screening for a far wider range of conditions, made possible 
by next-generation genetic sequencing technology (NGS, now increasingly known as Massively 
Parallel Sequencing [MPS]). MPS genetic screening offers high test fidelity, lower costs and 
reduced laboratory turn-around time, compared to previous diagnostic techniques.(17) The ACMG 
position statement stipulates that the basis for selection of disorders for inclusion in expanded 
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screening panels should be disclosed completely and transparently. Disorders with mild 
phenotypes, variable expression, low penetrance, and/or characterised by an adult onset may be 
included in screening panels where the implications of screening for such conditions are fully 
understood. Patients must be able to selectively opt out of receiving results of these tests and be 
fully informed of the concept of residual risk where test results are negative. (17) 
 
2.3 Health economic considerations 
An Australian study found pre-conception or antenatal screening for CF and TSD to be cost-
effective when compared to retrospective identification of carrier parents following the birth of an 
affected infant.(18) It is difficult to assign a monetary value to other significant but intangible 
benefits, such as informed reproductive choice(19) and a net increase in health of families by 
preventing the profound psychological costs of having an infant affected by a fatal or severely 
debilitating genetic condition.  
 
2.4 Outcomes of screening 
The Australian evidence for AJ preconception screening derives predominantly from evaluation of 
TSD screening programs. These programs target senior students at Jewish high schools. Within 
existing Australian TSD screening programs, AJ individuals self-identify correctly.(20) Testing has 
been demonstrated to be acceptable to students with extremely high levels of participation (>98%) 
and low levels of anxiety associated with diagnosis of TSD carrier status.(21-24)  
 
Over 17 years evaluation by health outcome studies to date, no Australian screening program 
participant has had a TSD affected child, representing 100% disease prevention in this cohort.(7) 
As expected, AJ heterozygous genetic carrier frequencies for TSD in the screened cohort 
remained high and were not impacted by screening. The implication is that the Australian AJ 
community remains at high risk without ongoing intervention.   Access to TSD screening programs 
is limited to less than half their ideal target population. The ideal target population for AJ genetic 
screening would include all AJ individuals of reproductive age.(25) Two AJ infants were diagnosed 
with TSD during the study period. None of their four AJ parents had participated in Jewish 
community high school based genetic screening programs, or been screened privately for TSD 
carrier status.(7)  
 
3. The recommended Australasian AJ screening panel (version 2014) 
 
The rationale for AJ carrier testing is to identify carriers and to provide individuals and couples with 
optimised reproductive choice. Care must be taken to do no harm. Based on international 
experience and recommendations(1, 3, 6, 8, 9, 17, 26), this committee has deliberated that, at this 
time, evidence from TSD screening programs support preconception/prenatal genetic screening of 
AJ individuals and their partners for conditions that meet the following criteria: 
1. A high AJ carrier frequency due to founder mutations (>1%) 
2.  Severe monogenetic condition of juvenile onset at the latest 
3. >90% diagnostic sensitivity 
4. Limited or no available treatment 
 
Following review of potential genetic conditions meeting these criteria, as well as review of 
International practice (see 2.2, above), AJ carrier screening for the following conditions is 
recommended (Table 2): 
Table 2: HGSA recommended panel for AJ carrier screening 
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Condition AJ Carrier 
frequency 
Clinical features Life expectancy 
Tay-Sachs 
disease 
(TSD) 
1 in 25 Progressive neurodegeneration Infancy to early childhood 
Cystic fibrosis 
(CF) 
1 in 25 Pulmonary disease, pancreatic 
insufficiency, reduced fertility 
Variable childhood to mid-
adulthood 
Bloom 
syndrome 
(BLM) 
1 in 102* Dysmorphic features, reduced 
intellect, cancer susceptibility, 
low fertility 
Childhood to young adulthood 
Familial 
dysautonomia 
(FD) 
1 in 30 Progressive neurodegeneration, 
autonomic dysfunction 
Childhood to young adulthood 
Niemann-Pick 
disease 
type A (NPD) 
1 in 80 Progressive neurodegeneration Infancy to early childhood 
Canavan 
disease (CD) 
1 in 40 Progressive neurodegeneration Infancy to early childhood 
Fanconi 
anaemia (FA) 
1 in 80 Dysmorphic features, cancer 
susceptibility, pancytopaenia 
Childhood to young adulthood 
Mucolipidosis 
type IV 
(MLPIV) 
1 in 100 Dysmorphic features, 
progressive neurodegeneration 
Childhood to young adulthood 
 *Bloom syndrome has been included (AJ carriers frequency 1.02%).  
  Severe phenotype with reduced life expectancy. 
 
4. Expanded summary of conditions in the recommended AJ screening panel  
 
4.1. Tay-Sachs disease 
TSD is due to congenital deficiency of ß-hexosaminidase enzyme, caused by mutations of HEXA 
OMIM *606869 (gene map locus 15q23-q24). TSD has autosomal recessive inheritance. 93.1 to 
99.1% of Jewish TSD carriers are found to have one of three common HEXA mutations: 
c.1278insTATC, c.1421+1G>C and p.Gly269Ser.(27-34). Heterozygous carriers are unaffected.  
Where both parents are carriers, 25% of pregnancies will be affected. Most infants with TSD 
appear healthy at birth and develop normally for three to six months.(4) Neuronal accumulation of 
sphingolipid GM2 gangliosides then is associated with progressive neurological regression. Most 
motor and social skills are lost by 18 months of age. Children rarely survive beyond 5 years of age. 
No effective treatment exists.(35-37)  
 
1 in 25 AJ Australians is a heterozygous carrier for TSD.(20) In general populations TSD carrier 
frequency is 1 in 250.(38) French Canadian, Pennsylvania Dutch, Irish, and Cajun heritage may 
convey higher a priori risk. TSD population genetic screening programs have proved a successful 
strategy for primary prevention of TSD.(4, 7, 39, 40) 
 
4.1.1. TSD carrier detection 
DNA testing for AJ founder HEXA mutations (c.1278insTATC, c.1421+1G>C and p.Gly269Ser) is 
the most cost-effective and efficient approach to carrier screening for TSD in individuals of 
confirmed AJ ancestry, with sensitivity of 93.1 to 99.1%.(28, 34) A small residual risk relates to 
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other HEXA mutations beyond these three that are being tested. (41) HEXA mutations may then be 
characterised by DNA sequencing, to identify the mutation (or pseudomutation) present.(42)  
 
HEXA enzyme testing is the gold standard for TSD screening and diagnosis, yielding 98% 
sensitivity in pan-ethnic populations and in the presence of rare or de novo mutations.(9) However, 
enzyme testing should not be first line for TSD screening in AJ individuals. Enzyme testing is 
technically complex, requires laboratory expertise and may yield indeterminate,(41) false 
negative(43, 44) and false positive results. (45) Unlike DNA testing, which can utilise either 
venepuncture or cheek brush/mouthwash sampling, enzyme testing requires venepuncture. This 
may limit test uptake(22) and also complicate timing of testing, sample collection and transport of 
samples. Medications such as the combined oral contraceptive pill may affect HEXA enzyme 
concentration.(46) 
 
Non-AJ Jewish individuals of Sephardi or Moroccan descent may have alternative mutations for 
TSD at relatively high frequencies. These individuals and AJ partners of known TSD carriers may 
request enzyme testing to optimise test sensitivity and avoid the very small possibility of a false 
negative result. Enzyme testing is recommended for non-Jewish individuals being screened for 
TSD carrier status  (due to the lower false negative rate).(47)    
 
It should also be noted that TSD testing in a reference laboratory for the purpose of making or 
confirming a diagnosis of TSD may utilise slightly different diagnostic algorithms and reference 
limits for test results than those used for genetic carrier testing and screening.  The 
recommendations in this current document are focussed on carrier testing and screening. 
 
4.2. Cystic fibrosis 
CF is an autosomal recessive disorder causing multi-organ dysfunction and reduced life 
expectancy. CF is due to mutations in CFTR (gene map locus 7q31.2, MIM# 602421). The CFTR 
gene product is a trans-membrane conductance regulator protein. CF has a wide clinical spectrum 
depending on the mutation profile and degree of protein product depletion/dysfunction in affected 
individuals. CF is characterised by progressive disruption of exocrine function, affecting the 
pancreas (pancreatic insufficiency), bronchial glands (chronic bronchopulmonary infection with 
emphysema), biliary tree (biliary cirrhosis), intestinal glands (meconium ileus) and sweat glands 
(high sweat electrolyte content). Males are infertile due to congenital bilateral absence of the vas 
deferens. Female subfertility may also occur.(48) Despite advances in treatment, median survival is 
37 years.(49) AJ CF carrier frequency is 1 in 23. (50) 
 
4.2.1. CF carrier detection 
The mutation profile of AJ CF carriers differs from other Caucasian populations. (51) 23 mutations 
were included in the pan-ethnic screening panel endorsed by ACMG in 2004, which achieves 94% 
AJ carrier detection sensitivity (Table 3).(26) Inclusion of additional AJ mutations not included in 
the ACMG panel (Table 3, marked with *) further increases AJ carrier detection sensitivity.(51)Non-
AJ individuals may accurately be counselled of their residual carrier risk when mutation testing is 
negative, based on their ethnicity. For non-AJ, non-Hispanic Caucasians ACMG panel mutation 
carrier detection sensitivity is 88% with 12% residual risk.(26) 
 
Table 3: Common CFTR mutations 
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ACMG CF Screening panel, AJ mutations absent from ACMG panel* 
AJ and shared Non-AJ 
W1282X 
p.Trp1282ter 
ǻ) 
p.Phe508del 
 
G551D 
p.Gly551Asp 
ǻ, 
p.Ile507del 
2184delA 
c.2052delA 
N1303K 
p.Asn1303Lys 
G542X 
p.Gly542ter 
621+1GߝT 
c.489_1G>T 
 
R1162X 
p.Arg1162ter 
 
A455E 
p.Ala455Glu 
 
3849+10kbCߝT 
c.3718-
2477C>T 
17171GߝA 
c.1581-1G>A 
 
R553X 
p.Arg553ter 
 
1898+1GߝA 
c.1766+1G>A 
 
R347P 
p.Arg347Pro 
 
D1152H* 
p.Asp1152His 
G85E 
p.Gly85Glu 
 
R117H 
p.Arg117His 
 
3659delC 
c.3528delC 
 
R560T 
p.Arg560Thr 
 
405 + 1G-->A* 
c.273+1G>A 
W1089X* 
p.Trp1089ter 
2789+5GߝA 
c.2657+5G>A 
 
711+1GߝT 
c.579+1G>T 
 
 
Y1092* 
p.Tyr1092ter 
S549R (T-->G)* 
p.Ser549Arg(T>G) 
3120+1GߝA 
c.2988+1G>A 
 
R334W 
p.Arg334Trp 
 
 
 
 
4.3. Bloom syndrome 
BLM results from a founder mutation in RECQL3 (gene map locus 15q26.1, MIM# 604610) which 
encodes for RecQ protein-like-3, a DNA helicase. RECQL3 is tightly linked to the proto-oncogene 
FES. BLM is a chromosome instability disorder with autosomal recessive inheritance.  One third of 
all reported cases of BLM have occurred in AJ subjects (carrier frequency 1 in 110). A single AJ 
founder mutation (c.2207_2212delATCTGAinsTAGATTC) causing a complex frameshift in BLM 
has been identified in all AJ cases.(52)  
 
Babies with BLM exhibit proportionate intrauterine and postnatal growth restriction. BLM is 
associated with reduced life expectancy; chromosomal instability predisposes to malignancy, often 
leukaemia, in childhood or early adulthood. Other features of BLM include reduced intelligence, 
reduced fertility, photosensitivity, telangiectasia and uneven skin pigmentation. 
 
4.4 Familial dysautonomia/Riley Day syndrome (FD) 
FD is a progressive sensorimotor neuropathy with sympathetic autonomic dysfunction. FD is 
caused by mutation of IKBKAP gene (locus 9q31.3, MIM# 603722). FD has autosomal recessive 
inheritance and occurs almost exclusively in individuals of AJ descent (AJ carrier frequency 1 in 
32). 99.5% of AJ individuals with FD demonstrate homozygous inheritance of a single founder 
mutation, c.2204+6T>C. c.2204+6T>C creates a donor splice site, which leads to deletion of exon 
20 from mRNA.(53, 54) A second IKBKAP gene mutation identified is p.Arg696Pro.(55) 
  
Clinically FD is evident from birth with early feeding difficulties and hypotonia. Gastro-oesophageal 
reflux disease can be associated with aspiration and resultant chronic lung disease. Autonomic 
dysfunction may include absence of tears, severe episodes of nausea and vomiting and rapid 
swings in blood pressure from severe hypertension to postural hypotension and resultant 
cardiovascular arrhythmias. Other characteristic features include decreased pain and temperature 
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perception and absent lingual fungiform papillae with impaired taste. Intelligence is normal. Life 
expectancy is reduced.(56)  
 
4.5. Niemann Pick disease type A (NPDA) 
NPDA is a lysosomal storage disease with recessive inheritance, caused by mutations in SMPD1 
(gene locus 11p15.4, MIM# 607608). In NPDA, a deficiency of sphingomyelinase enzyme results in 
lysosomal accumulation of sphingomyelin. NPDA is characterised by severe neurodegeneration 
from infancy leading to death by early childhood (usually by age 3 years).(57) NPDA affected 
infants appear normal at birth but develop early and persistent jaundice. Other features usually 
develop by 6 months. Early signs include enlarging abdomen with hepatosplenomegaly, failure to 
thrive and failure to reach developmental milestones. Later signs include psychomotor retardation 
with hypotonia and spasticity.(57) Three AJ founder point mutations have been identified ( 
c.911T>C(p.Leu304Pro), c996delC and c.1493G>T(p.Arg498Leu) ) accounting for 97% of AJ 
carriers.(58, 59) (60) 
 
4.6. Canavan disease  
CD is a recessive neurodegenerative disease associated with central nervous system (CNS) 
leukodystrophy and demyelination. Spongiform cerebral degeneration is characteristic. High levels 
of N-acetylaspartic acid are found in CNS tissue and in urine.(61) CD is caused by mutations in 
ASPA (gene map locus 17p13.2 MIM# 608034), which encodes for aspartoacylase (ASPA) 
enzyme. In AJ populations, 97% of CD is caused by two mutations: c.854A>C(p.Glu285Ala) 
(missense mutation) and c.693C>A(p.Tyr231ter) (nonsense mutation).(62, 63) AJ carrier frequency 
is 1 in 40. Affected infants appear normal at birth but subsequently become hypotonic with 
persistent poor head control and failure to meet developmental milestones. Other clinical features 
of progressive neurodegeneration include megalocephaly, spasticity characterised by lower limb 
extension and upper limb flexion, sleep disturbance, feeding difficulty, inability to sit, walk or talk 
and optic atrophy resulting in severe visual impairment. CD is universally fatal; average life 
expectancy for affected infants is 18 months.  
 
4.7. Fanconi anaemia complementation group C (FANCC) 
FANCC is a genome instability disorder with autosomal recessive inheritance. FANCC is 
associated with congenital skeletal and other abnormalities with varying penetrance (absent 
thumbs, radial hypoplasia, scoliosis, café au lait spots, horseshoe kidney, cardiac, gastrointestinal 
and neurological abnormalities) aplastic anaemia and cancer susceptibility (acute myeloid 
leukaemia and solid tumours). Infants may appear normal with normal blood cell parameters; 
however 90% develop pancytopaenia in the first decade of life.(64) 
 
The gene product of FANCC (locus 9q22.32 MIM# 613899) is the FACC protein. The FACC protein 
is thought to be involved in multiple pathways for DNA repair(65) and to play a regulatory role in 
the growth, differentiation and survival of haematopoietic progenitor cells.(66) At a cellular level, 
FANCC is associated with a hypersensitivity to DNA cross-linking agents. Conventional 
chemotherapeutic agents are extremely toxic to FANCC patients. AJ carrier frequency for the 
single AJ founder mutation c.456+4A>T is 1 in 89. (67) FANCC due to homozygous c.456+4A>T 
mutations is always associated with a severe phenotype.(67) The main causes of death are 
haemorrhage or infection. Median survival is 23 years,(64) however some patients have survived 
longer when successfully treated with haematopoietic stem cell transplantation.(68).  
 
Ashkenazi Jewish Population Screening Position Paper 
2015PS01 
February 2015                                                                                         Page 12 of 30 
4.8.Mucolipidosis type IV (MLPIV) 
MLPIV is a lysosomal storage disease with autosomal recessive inheritance characterised by 
psychomotor retardation and ophthalmic abnormalities. MLPIV is caused by mutations in MCOLN1 
(gene map locus, 19p13.2 #MIM 605248). The exact role of the mucolipin-1 protein product in the 
lysosome pathway is uncharacterised.(69) The protein localises to the cell plasma membrane and 
may have a role in endocytosis(70) and/or clearance of intra-mitochondrial free radicals.(71) Over 
80% of affected individuals are of AJ descent. Two founder mutations cause 95% of AJ MLPIV 
cases; c.406-2A>G, a splice site mutation and g.511-6943del, a 6.4-kb deletion.(72) Overall AJ 
carrier frequency is approximately 1 in 103.(72) 
 
5.0 Limits to Inclusion in recommended AJ panel 
 
The Committee considered whether there was sufficient evidence or ethical need to include various 
other conditions within these guidelines. Consideration of particular disorders, with the Committee’s 
assessment, is described below. 
 
5.1 DFNB1 Sensorineural deafness 
The gene GJB2 (locus 13q12.11, MIM# 121011) encodes the gap junction protein connexin 26. 
Mutations in GJB2 cause non-syndromic deafness in many populations. The most common GJB2 
in European populations is c.35delG (carrier frequency 1 in 51).(73) The founder mutation 
c.167delT, is found exclusively in AJ populations at a carrier frequency of 2-4%.(74)  
 
Recommendation: The Committee did not recommend that this condition be included in the 2014 
version of the HGSA recommended panel for AJ genetic screening.  
 
Basis for exclusion: 
Affected individuals have normal intelligence and life expectancy.  
 
5.2. Gaucher disease 
 
GD is a lysosomal storage disease with autosomal recessive inheritance caused by mutations in 
GBA gene (locus 1q22. MIM# 606463) that codes for beta-glucocerebrosidase enzyme. GD is 
characterised by intracellular accumulation of glucosylceramide, particularly in cells of macrophage 
lineage.(75) “Gaucher cells” may accumulate in multiple tissues with various effects. 
 
GD has 3 main subtypes. In GD type 1 “Gaucher cell” infiltrations can cause hepatosplenomegaly, 
pancytopenia, and physical manifestations of bone marrow infiltration (e.g. avascular necrosis of 
the femoral head). No neurological involvement is present. There is a wide spectrum of clinical 
severity, ranging from symptomatic infants to unaffected adults. GD types II and III are associated 
with CNS involvement. AJ populations are predominately at risk of type I GD, with a carrier 
frequency of 1 in 10. The four most common AJ GBA mutations account for 96% of GD in AJ 
populations: c.1226A>G, c.84insG, c.115+1G>A and c.1448T>C.(76) DNA testing for GD in Non-
AJ individuals has 73% diagnostic sensitivity. A combination of DNA and enzyme testing provides 
improved diagnostic sensitivity in non-AJ partners of AJ GD carriers.(77) 
 
Recommendation: The Committee did not recommend that this condition be included in the 2014 
version of the HGSA recommended panel for AJ genetic screening.  
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Basis for exclusion: 
The majority of homozygotes and compound heterozygotes with AJ GBA mutations will predictably 
have mild or even asymptomatic GD. Based on AJ gene frequencies, an estimated 60% of 
c.1226G homozygotes with GD are undiagnosed, presumably due to an extremely mild 
phenotype.(78) Phenotypic variability, however, cannot be fully explained or predicted by genotype 
analysis.(78) Arends et al. (2013) reported that Gaucher patients have an increased relative risk 
(RR) of malignancy in general (1.7 95%CI 1.3 to 2.3) and multiple myeloma (RR 25 to 51) and 
haematological malignancies (RR 3.5 to 12.7) specifically when compared to the general 
population.(79) Significant biases cannot be accounted for in this meta-analysis, including selection 
bias of index cases with increased severity of Gaucher phenotype associated with clinical 
diagnosis and related reporting bias.  Zuckerman et al. (2007) reported the vast majority of couples 
diagnosed with a GD affected fetus in pregnancy choose to continue the pregnancy.(80) 
 
5.3 Expanded AJ MPS screening 
It is likely Massively Parallel Sequencing (MPS) technologies will become the routine testing 
modality in existing AJ genetic screening programs targeting high school students. MPS will allow 
diagnostic testing and screening to be carried out with higher resolution, more quickly and more 
cost effectively.(81) MPS screening using an expanded panel of conditions will most likely become 
available in the future. It is recognized that economic considerations may make it cheaper or more 
efficient to design MPS assays utilizing expanded screening panels, than to design restricted 
panels. Discussion of expansion of AJ genetic screening beyond the recommended minimal panel 
is outside the scope of this guideline. 
 
Recommendation: The Committee did not recommend that such additional conditions be included 
in the 2014 version of the HGSA recommended panel for AJ genetic screening. However, it does 
not oppose the inclusion of additional conditions, provided there is full disclosure and informed 
consent. 
 
6. Routes of access to Ashkenazi Jewish preconception/antenatal genetic screening in 
Australia 
Routes of access to AJ preconception/antenatal genetic screening in Australia include: 
1. Participation in Australian Jewish community genetic screening programs in participating 
Jewish community high schools.(20, 21, 23, 82) 
2. Participation in outreach programs associated with Australian Jewish community genetic 
screening programs.  
3. Participation in the international Dor Yeshorim screening program.  
4. General Practitioner/Obstetrician Gynaecologist facilitated screening. 
5. Genetics services facilitated screening at an Australian public hospital. 
 
6.1. Australian Ashkenazi Jewish population genetic screening programs  
The two largest Australian Jewish population centres are located in Melbourne and Sydney. 
Australian Jewish community genetic screening programs based in Melbourne and Sydney(23, 82) 
have been designed based on international best-practice principles(28, 29, 39, 83) and target 
senior AJ high school students who attend Jewish community high schools. Programs have up to 
18 years of experience in screening for TSD. More recently, these programs have offered 
screening for a panel of conditions. The Sydney screening program currently tests for TSD, CF, 
FD, FA and CD, and is in the process of introducing BLM, NPD and MLIV; as their assay system is 
based on MPS genetic testing, GSD1A will also be offered to those who consent to its inclusion. 
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The Melbourne screening program currently tests for TSD, CF, FA, CD, BLM and NPD. Screening 
is not Medicare funded. Through a combination of philanthropic sponsorship and public health 
funding, screening is provided cost free to high school students within established screening 
programs. Participation is high (99.6%)(21) and health outcome studies within screening programs 
demonstrate disease prevention.(7)  
  
In Melbourne and Sydney, fewer than 50% of current Australian Jewish high school students 
attend Jewish community high schools. (Eckstein G. Demography of the Sydney Jewish 
community: an overview of information from the 2006 Census. Unpublished report commissioned 
by the Jewish Community Appeal (JCA); copies available on request from 
http://www.jca.org.au).(7) Overall, more than 50% of Australian AJ individuals in the reproductive 
age group have not had the opportunity to participate in existing Jewish high school based 
screening programs. In Australian Jewish communities living outside of Melbourne and Sydney, 
where no high school based screening programs are conducted, the proportion of unscreened AJ 
individuals of reproductive age is likely to be even higher.  Table 4 summarizes the Australian 
Jewish population by State of residence as reported in the 2011 ABS Census of Community and 
Housing.(2) Table 5 summarizes the New Zealand Jewish population by region.(84) 
 
Table 4. 2011 ABS Census: Australian Jewish population by State of residence 
 
Australian State/Territory Number of Jewish residents  
NSW 39730 
VIC 45149 
QLD 4442 
SA 1090 
WA 5854 
TAS 248 
ACT 673 
NT 146 
Other 3 
Total 97335 
 
Table 5: 2013 New Zealand Census (Statistics New Zealand): Jewish Religious affiliation by 
Region  
 
Region of New Zealand Number of Jewish residents 
All regions 6867 
Auckland City 3102 
Wellington City 756 
Christchurch City 435 
Lower Hutt City 171 
Dunedin City 171 
Hamilton City 156 
Tauranga City 160 
All other regions total (Individual regions 
Jewish population <100 people per region) 
1944 
6.2. Outreach programs 
Outreach screening services can be accessed by AJ individuals in Sydney and Melbourne.  
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Contact details: 
Sydney: Wolper Jewish Hospital (www.wolper.com.au)  
Melbourne: Austin Health (megan.cotter@austin.org ). 
 
There are currently no community screening programs or associated outreach services operating 
outside of Sydney and Melbourne.  Access to testing for those outside of Sydney and Melbourne 
can be arranged either via the local Genetics Services (see section 6.5), or by medical referral to a 
Pathology Service, who can arrange for collection of the appropriate blood (or in some cases, 
cheek-brush) sample. AJ communities in other major populations centres that wish to consider 
establishing local outreach screening services are welcome to approach the established Sydney 
and Melbourne programs for advice and assistance. 
 
6.3. Dor Yeshorim 
Dor Yeshorim(83) is an international Jewish genetic screening program based overseas but 
accessible to Australians. Sample collection and laboratory testing may be conducted overseas. 
The program targets an ultra-orthodox demographic and is accessed by clients prior to marriage. 
The genetic compatibility of a proposed couple is disclosed without revealing the results of the 
individuals. In this way, program participants’ results remain anonymous. 
 
Contact details: 
Dor Yeshorim Institute 
 
New York Office 
429 Wythe Ave 
Brooklyn, NY 11249 
Telephone: (+718) 384-6060/ (+718) 384-2332 
 
Jerusalem Office 
21 Strauss Street, Jerusalem,  
P.O. Box 91057 Israel,  
Telephone: (+972) 26499888 
https://www.jewishgenetics.org/dor-yeshorim 
 
6.4. General Practitioner/Obstetrician Gynaecologist initiated screening 
General Practitioner/Obstetrician Gynaecologist initiated genetic screening is the most readily 
accessible route to screening for AJ Australians outside of high school based genetic screening 
programs. Barriers to screening in the primary care context include lack of clinician and patient 
education,(85, 86) incomplete genetic history taking, low patient knowledge(46) , cost of testing(87) 
and unplanned pregnancy; 30 to 50% of all pregnancies in developed countries are unplanned. 
(88)  
 
Genetic risk (AJ heritage) should be identified on medical history taking. Appropriate patient 
education and counselling should be provided. Discussion should cover the disorders being 
screened, including their clinical features, mode of inheritance, and implications for relatives. 
Reproductive options for at risk couples should be discussed. Voluntary informed consent should 
be obtained from the patient(s) and documented. 
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Non-AJ partners of AJ carriers for one or more monogenetic autosomal recessive condition should 
also be offered screening. Ideally, where results of screening are not time critical, the AJ individual 
should be tested first (Figure 1: Two step screening). The non-AJ partner should subsequently 
be tested for any condition(s) for which the AJ partner was found to be a carrier. During pregnancy 
when results are needed with urgency, simultaneous screening of the AJ client and their non-AJ 
partner is appropriate. For conditions other than TSD and CF non-AJ individuals must be 
counselled regarding imprecise residual risk when found to be non-carriers based on analysis of 
common AJ mutations. In the case of TSD the enzyme test identifies nearly all carriers and thus 
the non-AJ partner of a TSD carrier should be offered enzyme testing rather than genetic testing. 
The mutation detection rate and carrier frequencies among different ethnic groups is known for CF 
and thus precise test sensitivity and residual risk counselling can be offered.  
 
For couples with a known family history of a particular AJ monogenetic condition, testing is not 
“screening” per se, and a referral should be arranged to a Genetics service for genetic counselling.  
 
6.4.1 Laboratory referral 
Testing should be performed through laboratory service accredited for testing of the relevant 
genetic disorders. The Royal College of Pathologists of Australasia (RCPA) and the HGSA 
maintain a database of tests (rcpamanual.edu.au) and laboratories performing genetic tests 
(http://genetictesting.rcpa.edu.au/). Note that the listing of a laboratory in this database does not 
necessarily indicate it has undergone accreditation, and before referring patients or specimens for 
testing, specific enquiries should firstly be made of the laboratory, or alternatively its scope of 
accreditation can be viewed at the accrediting authorities’ website. In Australia, accreditation is 
undertaken by the National Association of Testing Authorities, Australia (NATA, www.nata.com.au), 
in a joint program with the Royal College of Pathologists of Australasia (RCPA, www.rcpa.edu.au). 
In New Zealand, accreditation is undertaken by International Accreditation New Zealand (IANZ, 
www.ianz.govt.nz). Pathology requests should specify the patient’s AJ heritage in the clinical notes. 
Best-practice testing methodology will at times differ for AJ and non-AJ individuals (e.g. TSD: DNA 
testing for c.1278insTATC, c.1421+1G>C and p.Gly269Ser in AJ individuals, and HEXA enzyme 
testing for non-AJ individuals). In couple screening, where logistically possible, both partners’ 
samples should be tested in the same laboratory. Where a family member has previously been 
affected by, or diagnosed to be a carrier of a genetic condition being screened, full details of the 
clients’ genetic and family history should be provided to the testing laboratory, to ensure that the 
most appropriate tests are performed. 
 
Currently AJ genetic screening in Australia is not Medicare-funded and may incur a cost to patients 
for diagnostic services.    
 
AJ genetic testing (not screening) is also not Medicare funded at present, but some State genetic 
services may offer to defray the costs of testing; in other cases, testing may incur a cost to 
patients. 
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6.5. Referral for specialist genetic services 
AJ genetic screening can be facilitated via specialist genetics services referral. This method of 
screening is optimal where a family history for a serious genetic condition is present. Referral for 
genetic counselling and testing through a public hospital genetics service is cost-free to patients, 
although there may be waiting-lists at some busier clinics and services. 
 
Australia 
New South Wales 
Genetic Services, New South Wales Health 
www.genetics.edu.au/Genetics-Services 
Royal North Shore Hospital Community Health Centre 
+61 (0) 2 9462 9599 
Email: contact@genetics.edu.au 
 
Victoria 
Victoria Clinical Genetics Services 
www.vcgs.org.au  
Royal Children’s Hospital  
+61 (0) 3 8341 6201 
Email: vcgs@vcgc.org.au 
 
Australian Capital Territory 
ACT Genetics Service 
Canberra Hospital 
+61 (2) 6174 7630  
Email: genetics@act.gov.au  
 
Queensland 
Genetic Health Queensland 
www.health.qld.gov.au/ghq  
Royal Brisbane and Women’s Hospital 
+61 (0) 7 3646 1686 
Email: GHQ@health.qld.gov.au  
 
South Australia 
South Australian Clinical Genetics Service 
Paediatric and Reproductive Genetics Unit 
www.wch.sa.gov.au/services/az/divisions/labs/geneticmed/  
Women’s and Children’s Hospital Adelaide 
+61 (0) 8 8161 7375 
Email: sapathology.prgu@health.sa.gov.au  
 
Western Australia 
Genetic Services of Western Australia 
www.kemh.health.wa.gov.au/services/genetics 
King Edward Memorial Hospital Perth 
+61 (0) 8 9340 1525 
Email: gswa@health.wa.gov.au 
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Northern Territory 
Referral to interstate genetic services, or 
Northern Territory Clinical Genetics Service 
Royal Darwin Hospital 
+61 (0) 8 8944 8731 
 
Tasmania 
Tasmanian Clinical genetics Service 
www.dhhs.tas.gov.au 
Royal Hobart Hospital 
+61 (0) 3 6222 8296 
 
New Zealand 
AJ genetic screening is available through Genetic Health Service New Zealand (GHSNZ) 
http://www.genetichealthservice.org.nz/home 
 
GHSNZ Northern Hub 
Auckland Hospital 
+64 (0) 9 307 4949 Ext 25870 
Toll free: 0800 476 123 
Email: GenSec@adhb.govt.nz 
 
GHSNZ Central Hub 
Wellington Hospital 
+64 (0) 4 385 5310 
Toll free: 0508 364 436 
Email: genetic.services@ccdhb.org.nz 
 
GHSNZ South Island Hub 
Christchurch Hospital 
+64 (0) 3 378 6574 
Toll free: 0508 364 436 
Email: geneticservicenz@cdhb.health.nz 
 
6.6. Direct-to-consumer genetic testing 
Direct-to-consumer (DTC) genetic and genomic testing is available in Australia and overseas. 
Simultaneous genetic screening is offered for a broad range of conditions, targeting a pan-ethnic 
population, without mandatory medical involvement or genetic counselling. AJ high risk conditions 
may be included in DTC screening models. 
Ethical and regulatory issues relating to DTC screening remain unresolved.(89) Australians 
surveyed regarding their opinions and knowledge of DTC genetic testing revealed that genetic 
screening is perceived to be important and over one quarter of respondents would be interested to 
pursue this testing modality.(90)  
Australian Guidelines for health providers on DTC genetic testing have been developed by the 
National Health and Medical Research Council (NHMRC) 
 (https://www.nhmrc.gov.au/guidelines/publications/g7) and the National Pathology Accreditation 
Advisory Council (NPAAC)  
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(https://www.health.gov.au/internet/main/publishing.nsf/Content/health-npaac-path-bestpractice). 
 
7. Screening models 
Three screening models are described in Figures 1 to 3: 
 
 
     Figure 1: Two-step screening  
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 Figure 2: One-step couple screening  
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 Figure 3: One step couple screening (ultra-orthodox unmarried couple)  
 
 
 
 
 
 
 
The advantages and disadvantages of different screening strategies should be considered in the 
context of a couple’s circumstances to maximise cost benefit (Table 6). 
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Table 6: Advantages and disadvantages of AJ monogenetic autosomal recessive disease 
screening strategies 
 
Please refer to Figures 1, 2 and 3 for definitions of two-step and one-step screening models   
 
 
Model Two step  One step 
(established 
couple) 
One step 
(potential 
couple) 
Individuals tested Partner A 
initially. 
Partner B 
where 
Partner A is 
a carrier 
Partners A 
and B 
Partners A 
and B 
Member of couple informed of 
their own results 
One or both Both Neither 
Laboratory testing required  Less More More 
Counselling required 
(medical/genetics/reproductive) 
Less More Least 
Total cost Least Most Less 
Elapsed time before result 
available 
Slower Faster Faster 
Suitability for pre-conception 
testing 
Good Good Good 
Suitability for antenatal testing Less 
desirable  
Good N/A 
Autonomy of result reporting Yes Yes No 
Cascade testing of relatives Suboptimal  Optimal No 
 
8. Timing of screening 
Preconception screening in an informed consenting adult or mature minor(91, 92) should be 
considered the gold standard.(47, 93) Preconception screening maximises reproductive choice for 
at risk couples (Table 7) and is associated with lower patient anxiety than screening conducted 
during pregnancy.(19) Clinicians should consider and offer AJ genetic screening opportunistically 
when at-risk patients present for other reasons (e.g. general or sexual health check).(86) 
 
Presentation for screening commonly occurs in early pregnancy.(86) A significant proportion of 
pregnancies are unplanned.(88) Even where pregnancy is planned, genetic risk may not be 
considered pre-conception. Where an at-risk couple is identified during pregnancy, prompt referral 
for appropriate genetic counselling and, if indicated, maternal fetal medical review should be 
undertaken. Management may include fetal diagnostic testing.(8) 
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Table 7: Reproductive options for couples at risk of a pregnancy affected by a severe 
monogenetic autosomal recessive disease 
 
Option Description Advantages Disadvantages 
No diagnostic testing Natural conception Avoids pre-natal 
diagnostic testing and 
associated risk of 
pregnancy loss. 
 
Avoids termination of 
pregnancy. 
25% risk of an 
affected child with 
each pregnancy 
Pre-implantation 
genetic diagnosis 
(PGD) 
In vitro fertilization 
(IVF) conception. 
Embryos biopsied and 
tested for the 
condition. Healthy 
embryo is returned to 
mother’s uterus. 
Avoids pre-natal 
diagnostic testing and 
associated risk of 
pregnancy loss. 
 
Avoids termination of 
pregnancy. 
Requires IVF: 
Hormonal ovarian 
stimulation, invasive 
procedures. 
 
Significant costs; 
currently no 
government rebate for 
PGD. 
Detection of free fetal 
DNA in Maternal 
circulation 
Testing performed on 
maternal serum 
sample. 
Avoids costs and 
complications 
associated with IVF. 
 
Possible in unplanned 
pregnancy. 
 
Avoids pre-natal 
diagnostic testing and 
associated risk of 
pregnancy loss. 
Currently in 
experimental use 
only.  
 
Emotional and 
medical complications 
associated with 
termination of disease 
affected pregnancy. 
 
Pre-natal diagnosis: 
CVS (11 to 14 weeks 
gestation) 
 
Amniocentesis (>15 
weeks gestation) 
Natural conception. 
 
Testing of biopsied 
pregnancy tissue to 
diagnose disease risk 
during pregnancy. 
Avoids costs and 
complications 
associated with IVF. 
 
Possible in unplanned 
pregnancy 
1 in 200 risk of 
pregnancy loss 
associated with 
diagnostic 
procedures. 
 
Emotional and 
medical complications 
associated with 
termination of disease 
affected pregnancy. 
 
Stress associated with 
uncertainty faced 
throughout the first 
trimester of 
pregnancy. 
Donor gamete Donor ovum or sperm 
(Donor is non-carrier 
for the condition). 
May avoid risks 
associated with IVF. 
Avoids risks 
One partner is non-
biological parent to 
offspring. 
 
Ashkenazi Jewish Population Screening Position Paper 
2015PS01 
February 2015                                                                                         Page 24 of 30 
associated with 
prenatal diagnostic 
testing. 
Avoids termination of 
pregnancy. 
Adoption Child is adopted. Avoids disease risk.  
 
Avoids pregnancy-
associated risks. 
 
Avoids termination of 
pregnancy. 
Many barriers to 
adoption exist. 
 
Child is not 
biologically related to 
the adoptive parents. 
Decision not to 
proceed with union 
Some individuals may 
be screened prior to a 
potential arranged 
introduction/marriage.  
Avoids disease risk. 
Avoids stigma 
associated with 
disclosure of carrier 
status. 
Undesirable for the 
majority of couples. 
 
Decision not to have 
children 
No children Avoids disease risk.  
Avoids pregnancy-
associated risks. 
May not represent 
reproductive wishes of 
parent couple 
 
9. Internet resources  
Internet resources that may be useful for genetic counselling and patient education can be found at 
the following websites: 
http://www.jewishgeneticdiseases.org 
HGSA Guideline: Process of genetic counselling 
http://www.hgsa.org.au/resources/hgsa-policies-and-position-statements 
Many State Health Departments offer on-line educational resources for genetic 
conditions. Examples are: 
NSW: http://www.genetics.edu.au  
VIC: http://www.health.vic.gov.au/genetics/links.htm 
 
10.  Audience Organizations  
 
Medical Colleges 
Royal Australasian College of General Practitioners 
Royal Australia and New Zealand College of Obstetricians and Gynaecologists 
Royal Australasian College of Physicians 
Royal College of Pathologists of Australasia 
 
Professional Societies 
Human Genetic Society of Australasia 
Australasian Association of Clinical Biochemists 
 
Associations 
Australian Medical Association 
Genetic Alliance Australia (formerly Association of Genetic Support of Australasia) 
Rare Voices Australia 
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Departments of Health 
The Australian Government Department of Health 
The New Zealand Ministry of Health 
The Australian National Health and Medical Research Council 
The Australian National Pathology Accreditation Advisory Council 
Australian State and Territory Health Departments and Ministries 
 
Standards and Accreditation Bodies 
Australian Commission on Safety and Quality in Health Care 
Australian Council on Healthcare Standards 
National Association of Testing Authorities. Australia 
National Pathology Accreditation Advisory Council of Australia 
International Accreditation New Zealand 
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Chapter 9: Discussion and conclusions 
 
The broad aim of this thesis was to critically assess processes of Ashkenazi Jewish 
population screening for Tay Sachs disease (TSD) and to establish an evidence 
based approach to guide the future evolution of AJ preconception genetic screening 
in Australia. Working in collaboration with the two established Australian TSD 
screening programs.1, 2 I have researched and documented the Australian 
experience. 
 
Existing TSD screening programs in Australia target Ashkenazi high school students 
who attend independent Jewish high schools in Sydney and Melbourne. Outreach 
opportunities co-ordinated by existing TSD screening programs offer access to TSD 
screening outside of this limited target population.    
 
During the course of this PhD I investigated the effectiveness of screening in this 
specific target population (adolescent AJ high school-based screening program 
participants). In terms of risk identification, I compared student’s self-reporting of 
Ashkenazi Jewish heritage with documented grandparents country of birth and TSD 
mutation carrier frequencies.3 
 
I identified a sustained high TSD carrier frequency amongst Australian Jewish high 
school students and young adults of reproductive age, comparable to international 
study findings conducted since the 1970s.3    
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I assessed Australian Bureau of Statistics collated census data to achieve a best 
possible estimate of the proportion of all Australian Ashkenazi Jewish students who 
access TSD screening via existing programs and of Australian Ashkenazi Jewish 
students and adults of reproductive age who have not accessed these programs.4 
Through this research, it was found that a majority of Australian AJ individuals of 
reproductive age had not had the opportunity to access AJ community screening 
programs facilitated mainly in a limited number of private school settings in Sydney 
and Melbourne. 
 
I designed a strategy to enable auditing of all cases of TSD diagnosed in Victoria 
and NSW from 1995 to 2012 inclusive, this being the period Australian Ashkenazi 
Jewish TSD population screening programs were in operation. I determined that 
fewer than expected new Jewish TSD cases occurred during the study period.4 I 
found that of the two Ashkenazi Jewish cases of TSD that were diagnosed during the 
study period, none of their four Ashkenazi Jewish parents had undergone 
preconception or antenatal TSD screening.4 I determined that no TSD screening 
program participant had gone on to parent a child affected by TSD. 4 
 
Having proved the effectiveness of Australian Ashkenazi Jewish TSD preconception 
screening programs and having identified that a major pitfall of these programs was 
restriction of access to only a fraction of the Australian Ashkenazi Jewish population 
of reproductive age at risk of TSD, I endeavoured to research a practical solution to 
extend the benefits of TSD screening to the entire Australian Ashkenazi Jewish 
population at high risk of TSD.  
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Australian Ashkenazi Jewish populations are concentrated within metropolitan areas, 
the largest communities residing in   Melbourne, Sydney and Perth. Australian cities 
have existing health care infrastructure offering excellent access to the services of 
primary health care clinicians such as general practitioners and 
obstetricians/gynaecologists. No recent systematic review of the literature relating to 
TSD preconception screening research and practice had been published in the 
international literature. I endeavoured to systematically and comprehensively assess 
the Australian and international evidence for TSD preconception and antenatal 
screening. Resulting from my original research and systematic review of the 
Australian and international literature, I have presented the first evidence-based 
practice model for TSD preconception/antenatal screening in the Australian primary 
health care setting.5    
 
By invitation, I have authored the first open access Australasian clinical practice 
guideline for AJ preconception screening, ratified and published in 2015 by HGSA 
(Chapter 8). 
 
I have ongoing involvement with the planning and preliminary analysis of the first 
Australasian AJ preconception genetic screening pilot study using MPS based 
diagnostic technology (Appendix 1).   
 
I have presented new arguments about: 
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• Persisting high risk of TSD in Australian Ashkenazi Jewish populations (Chapter 4) 
• High accuracy of risk identification in Australian Ashkenazi Jews (Chapter 4) 
• Effectiveness and cost efficacy of existing Australian Ashkenazi Jewish TSD 
population genetic screening programs (Chapter 5) 
• The unequal access to preconception/antenatal TSD screening across the Australian 
Ashkenazi Jewish populations at high risk of TSD (Chapter 5)   
• The pivotal role of primary health care clinicians in extending 
preconception/antenatal TSD screening to all Australian Ashkenazi Jewish 
individuals of reproductive age. (Chapter 6) 
• The need for an evidence based guideline to assist primary care clinicians in the 
achievement of ubiquitous access to TSD screening of Ashkenazi Jewish individuals 
at high risk (Chapter 6, Chapter 7, Chapter 8) 
• The imperative to reassess screening testing methodology and supporting clinical 
infrastructure with the emergence of massively parallel sequencing diagnostic 
technologies (Chapters 7, Appendix 1). 
 
In the following sections I will discuss each of the specific aims of this thesis, the 
respective study outcomes and the contributions they have made to the literature. 
 
Answering the aims of this thesis: 
 
Aim 1: To assess the ability of Australian Jewish individuals screened for TSD to 
self-report Ashkenazi Jewish heritage. To assess how AJ heritage and grandparental 
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country of origin correlates with TSD risk, both overall and in the case of specific 
common AJ HEXA gene mutations. 
 
Over the 12-year period 1995 to 2007, 4105 Jewish high school students in 
Melbourne and Sydney participated in the Australasian Community Genetics 
Program and were provided with TSD preconception genetic screening (Chapter 3).  
At the time of sample collection, students were required to complete a questionnaire. 
Demographic information collected included nominated ethnicity (Ashkenazi Jewish, 
Sephardi Jewish, mixed heritage, non-Jewish heritage) and birthplace of the 
student’s parents and grandparents. I correlated and statistically analysed the 
relationship between TSD carrier frequency, including subgroup analysis for 3 
common Ashkenazi specific HEXA mutations: c.1278insTATC, p.Gly269Ser and  
c.1421+1G>C.   
 
Study Outcomes 
It was determined that screening of self-declared Ashkenazi Jewish subjects 
identified 95% of TSD carriers within a Jewish cohort of students who identified as 
either Ashkenazi, Sephardi or mixed heritage. 
 
Self-declaration of Ashkenazi Jewish heritage was more predictive of TSD carrier 
status (carrier frequency 1:25) than was analysis of grandparents’ country/countries 
of birth. Having mixed Ashkenazi and non-Ashkenazi heritage reduced TSD carrier 
frequency to 1:97. 
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In the case of the specific HEXA mutation c.1421+1G>C, Ashkenazi Jewish subjects 
with South African heritage were found to have a four-fold increased risk of carriage 
compared with other Ashkenazi Jewish subjects (Odds ratio 4.19; 95% confidence 
interval 1.83–9.62, p=0.001), This was the only case where geographic ancestral 
origin was associated with greater diagnostic sensitivity than Ashkenazi Jewish 
heritage alone. Overall TSD carrier frequencies (3 mutation) in Ashkenazi Jewish 
subjects with South African heritage did not differ significantly from other Ashkenazi 
Jewish subjects. 
Carriers of c.1278insTATC mutations were more likely to have Western European 
heritage (OR, 1.65 (95% CI, 1.04–2.60), p=0.032) or South Eastern European 
heritage (OR, 1.77 (95% CI, 1.14–2.73), p=0.010). Heritage from specific European 
countries investigated did not significantly alter the overall odds of TSD carrier 
status.     
 
Impact of study outcomes on the literature 
Historically, Australian Ashkenazi Jewish populations formed and expanded with 
relation to specific world events. The largest event was immigration of Jewish 
refugees to Australasia from Europe post World War II in the mid to late 1940’s. A 
second event was immigration from former Eastern European members of the Soviet 
Union in the 1960s. A third event occurred in the 1980’s and 1990’s with immigration 
from Apartheid South Africa and the former Soviet Union.    
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The majority of the current generation of Australian Ashkenazi Jewish individuals of 
reproductive age were born in Australia, and in many cases, their parents were also 
born in Australia.  
 
It is an important finding that Ashkenazi Jewish heritage has been accurately 
reported in the current generation at risk of TSD. It is an equally important finding 
that reporting of Ashkenazi Jewish heritage in this cohort correlates with 
identification of 95% of TSD carriers identified by screening, and that carrier 
frequencies of HEXA mutations among this cohort remain high (1:25). 
 
These findings are central to the potential to translate the successes of Ashkenazi 
Jewish TSD population genetic screening programs from the limited screening 
program setting to the primary health care setting. A general practitioner or 
obstetrician/gynaecologist may identify a patient at increased risk of having TSD 
affected offspring by simply inquiring if that patient has Ashkenazi Jewish heritage. 
Where this risk factor is identified, TSD preconception/antenatal genetic screening is 
cost-effective and can potentially be facilitated in a primary healthcare setting.  If 
existing barriers were identified, assessed and tackled, all Australian Ashkenazi 
Jewish individuals of reproductive age could potentially gain access to TSD 
preconception/antenatal genetic screening through their own doctor. The publication 
of Chapter 8 of this thesis is a supporting aid for primary care clinicians to overcome 
some of the existing access barriers to community based AJ preconception genetic 
screening.  
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 Aim 2: To perform the first complete and consecutive audit of all cases of TSD 
diagnosed in Melbourne and Sydney during the period of Jewish TSD screening 
programs operation. To identify Jewish and non-Jewish heritage of historical TSD 
cases. To assess for a reduction in observed versus expected Jewish TSD cases in 
the era of AJ preconception genetic screening program operation. Predicted TSD 
cases were determined on the basis of Australian Bureau of Statistics census 
population data and known TSD carrier frequencies in Jewish and general 
populations. 
 
I designed a strategy for a retrospective national audit of all laboratory testing results 
for TSD case diagnosis and carrier screening from 1995 through to 2011. This 
included diagnosis of TSD cases, cascade screening and screening program 
referrals. In order to achieve this, I collaborated with all of the three Australian 
laboratories in which all samples were processed (by one or more sites) during the 
study period (PaLMS, Pathology North, NSW Health Pathology, Sydney; VCGS, 
Melbourne; and SA Pathology, Adelaide). Ethics approval was separately obtained 
from the Melbourne and Sydney sites, and was acknowledged and approved by the 
third South Australian testing site. The database I created had never been accessed, 
collated or synthesized by any previous investigator. Past attempts by these three 
national laboratories to perform such a study had been unsuccessful due to the scale 
and complexity of the proposed project and the difficulties in identifying and 
accessing the required data (Leslie Burnett, personal communication). 
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12 TSD cases diagnosed in Sydney (four cases) and Melbourne (eight cases) from 
1995 through 2011 were identified.  Laboratory records pertaining to each case were 
reviewed. All existing archived clinical patient history files were reviewed by me on 
site in NSW and Victoria.  Two cases were Jewish (a ratio of Jewish to non-Jewish 
births of 1:5). The estimated expected number of TSD-affected births in Melbourne 
and Sydney in 1995–2011 was 4.1 for Jewish births and 7.4 for other births (a ratio 
of Jewish to non-Jewish births of 1:2). WHO published TSD carrier frequency of 1 in 
250 was used to model expected TSD cases in non-Jewish Australians. This 
estimate was calculated using Australian Bureau of Statistics population data and 
known Australian Jewish TSD carrier frequencies. As the Australian Bureau of 
Statistics 2006 census population data quoted did not distinguish between 
Ashkenazi and non-Ashkenazi Jewish individuals, the carrier frequency of 1:31  
(3.26%; 95% CI, 2.89%–3.68%) was used for TSD carrier risk in Australian Jewish 
individuals.  
 
This finding of fewer than expected Jewish TSD cases corresponded to the period 
during which screening programs were operating. There were no Jewish TSD-
affected children born to parents who were screened previously. TSD 
preconception/antenatal carrier screening, supported by community education and 
the appreciation of autosomal recessive inheritance are the likely key factors 
explaining the fewer than expected Jewish babies born with TSD. As screening 
program participants are currently aged 16 to 40 years, many have not yet 
completed their families. The full benefit of Australian TSD screening programs is yet 
to be realized. 
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While fewer than expected TSD Jewish babies have been born since the introduction 
of Australian AJ preconception genetic screening programs, the prevention of 
virtually all AJ cases of TSD should be achievable. As AJ preconception screening is 
highly protective and cost-effective, the following question was framed: In the 
Australian context: how can preconception genetic screening for TSD be extended to 
all individuals of reproductive age with AJ heritage? 
 
  
 163 
Aim 3: To systematically review the Australian and international literature and 
develop an Australasian best-practice model for primary care clinician-lead AJ TSD 
screening. 
 
No systematic review of the Australian and International literature relating to TSD 
preconception genetic screening had been undertaken prior to my PhD candidature. 
In order to facilitate a potential future application for a Medicare item number to be 
created to fund TSD preconception screening, experts in the area of genetic 
screening have the onus of proof that the practice is beneficial, cost effective, 
evidence based best practice and relevant within the Australian health care setting.  I 
conducted a systematic review of the literature using the NHMRC framework to 
assess the impacts of TSD screening internationally and in the Australasian context. 
This review allowed me to generate recommendations that were published in the 
Journal of Paediatric and Child Health, a PubMed indexed journal with a wide 
circulation amongst Australian physicians. The dual aim of this review was: 
1) To raise awareness of AJ preconception genetic screening strategies amongst 
Australian Medical practitioners, and 
2)  To provide supportive evidence based material to promote community based TSD 
screening.  This was achieved. 
 
Via my undertaking of this extensive work, the collaborations involved created the 
opportunity for me to chair a subcommittee of the HGSA and to author the first 
Australasian clinical practice guideline for AJ preconception genetic screening. The 
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first edition of this guideline was published in 2015 and is included in this thesis  
(Chapter 8). 
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Aim 4: To compare current with projected future rates of significant genetic findings 
using a conventional DNA mutation testing panel versus a massively parallel 
sequencing model to conduct Ashkenazi Jewish pre-conception genetic screening. 
To evaluate the clinical and workforce implications of adopting modernised DNA 
sequencing technologies for TSD carrier screening in the context of an expanded 
Ashkenazi Jewish panel. 
 
Chapter 7 summarises major challenges pre-conception screening strategies will 
pose to the Australian Health system moving forward. In this chapter I explored the 
clinical, ethical and workforce implications of adopting MPS based expanded panel 
preconception genetic screening strategies. Such strategies will in the future 
undoubtedly form part of a pan-ethnic preconception preventive medicine and health 
promotion strategy to help couples achieve healthy families. I explain how existing 
AJ preconception genetic screening programs may be an educative model for policy 
development surrounding the changing practice of “multi-condition” simultaneous 
genetic screening. I outline my preliminary research in this area, presented in 
Appendix 1.  
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Future Directions 
 
Through the work presented in this thesis, I have provided definitive answers to the 
aims and questions developed during my PhD candidature. Developments and 
progress in genetic diagnostic technology have now opened new areas for research 
and intervention. In the future, I plan to extend my work as follows: 
 
1) I am involved in ongoing research to analyse and report findings of the AJ 
preconception genetic screening MPS pilot study underway through the Sydney 
Community Genetic Screening program (Chapters 7 and Appendix 1). 
 
2) I am undertaking a collaborative audit to report all cases of TSD carrier couples 
who have utilised PGD/ART to achieve the live birth of a healthy child (free of TSD) 
and also all cases where prenatal diagnosis has been used to detect TSD by 
CVS/Amniocentesis. This work is a follow-up study of the work reported in Chapter 5 
of this thesis. 
 
3) In February 2015, I was awarded a fellowship of the Australia and New Zealand 
College of Obstetricians and Gynaecologists (FRANZCOG). I am completing the 
Royal Australia and New Zealand College of Obstetricians and Gynaecologists 
further subspecialty medical qualification, Certificate of Reproductive Endocrinology 
and Infertility (CREI). My aim is to perpetuate an ongoing commitment to research in 
the area of pre-conception health promotion as a clinician-scientist. With this aim, as 
part of my final CREI training year in 2016, I will be working with VARTA (Victorian 
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Assisted Reproductive Technology Authority) in the area of preconception health 
promotion research and strategic planning. 
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Appendix 1: 
 
 
Appendix 1 is a collection of 4 posters, presented at international peer review 
forums and reporting preliminary work relating to exploration of MPS based 
expanded panel preconception genetic screening of Australian AJ consenting 
mature minors planned to be conducted under research conditions.  
 
The Posters contained in this Appendix do not form an examinable part of my 
Thesis, but are included for relevant background and supplementary 
information. 
 
 
Poster 1 
Lew R, Burnett L, Proos, A, Massively Parallel DNA Sequencing for 
Ashkenazi      Jewish community pre-conception genetic screening programs: 
Predicted outcomes, ethical and workforce implications, British Society of 
Genetic Medicine     
(BSGM) Liverpool, UK, September 2013     
 
Poster 2 
Lew RM, Burnett L, Chesher D, Proos AL, Ding, L-EC, Nguyen L (2014) 
Reporting findings of Massively Parallel Sequencing: A model for genetic 
screening of autosomal recessive conditions in at-risk communities. Twin Res. 
Hum. Genet. 17(4):336. Presented at HGSA 38th Annual Scientific Meeting, 
Adelaide, South Australia, 3-6 August 2014 
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Poster 3 
Burnett L, Ding LC, Chesher D, Lew, R, Proos A (2013) Modelling of 
downstream counselling impact of ACMG Recommendations for Reporting of 
Incidental Findings in Clinical Exome and Genome Sequencing. 63rd Annual 
Meeting of The American Society of Human Genetics, Boston MA, October 
2013. 
 
Poster 4 
Burnett L, Chesher D, Nguyen L, Lew, R, Proos A, Ding LC, Koe L (2014) 
Implications of massively parallel sequencing in screening for autosomal 
recessive conditions: the risk of being a “genetic wallflower”. 64th Annual 
Meeting of The American Society of Human Genetics, San Diego CA, October 
2014. (http://www.ashg.org/2014meeting/abstracts/fulltext/f14xxxx.htm) 
 
 
 
 
 
 
 
 
 
Massively Parallel DNA Sequencing for Ashkenazi Jewish  
community pre-conception genetic screening programs:  
Predicted outcomes, ethical and workforce implications    
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 INTRODUCTION 
Ashkenazi Jewish (AJ) individuals are at high risk of several genetic conditions.1  
Preconception genetic screening programs were introduced in Jewish high schools in 
Sydney (1995)2 and Melbourne (1998)3 to detect asymptomatic Tay Sachs disease 
carriers. The scope of these screening programs has expanded to now assess for 
multiple relevant autosomal recessive conditions (Table 2).4  
Effectiveness in primary prevention5, safety4 and cost effectiveness6 of these 
programs have been validated. Conditions screened for and method of laboratory 
testing has changed over time (1995-2004 TSD: Enzyme testing + Restriction Length 
Fragment Polymorphism (RFLP), 2005-2012: Amplification Refractory Mutation 
System(ARMS)).7  
In Sydney, future testing may be conducted using massively parallel DNA sequencing 
technologies  (MPS) as the routine modality,  extending screening to  a broader range 
of conditions.  
  
METHODS 
A panel of conditions was designed for use in AJ preconception genetic screening for 
common autosomal recessive conditions.  
Criteria for inclusion was according to accepted principles for screening.8 
For modelling, the average number of students screened per annum was based on 
actual screening program data. 
The known AJ prevalence of conditions included in the current and expanded panel  
(Table 1) was used to calculate the predicted number of carriers of one or more 
conditions that would be detected using the expanded panel, vs. the current screening 
method.  
The probability calculation used was 1- [(1-P1)*(1-P2)*…(1-Px)], where p1 to p25 refer 
to the carrier frequency of each condition referenced 1 to 25 in Table 1. 
The proportion of individuals screened that would require referral for genetic 
counselling services for both screening models was calculated.  
RESULTS 
DISCUSSION 
1) Zlotogora J. Population programs for the detection of couples at risk for severe monogenic genetic diseases. Hum Genet. 2009; 126: 247-53. 2) Burnett L, Proos AL, Chesher D, et al. The Tay-Sachs disease prevention program in Australia: Sydney 
pilot study. Med J Aust. 1995; 163: 298-300. 3) Gason AA, Sheffield E, Bankier A, et al. Evaluation of a Tay-Sachs disease screening program. Clin Genet. 2003; 63: 386-92. 4) Ioannou L, Massie J, Lewis S, et al. Evaluation of a multi-disease carrier 
screening programme in Ashkenazi Jewish high schools. Clin Genet. 2010; 78: 21-31. 5) Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A and Fietz MJ. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in 
Australian Jews. Med J Aust. 2012; 197: 652-4. 6) Gillick v West Norfolk and Wisbech Health Authority  1986. 7) Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). 
Nucleic Acids Res. 1989; 17: 2503-16. 8) Wilson JM and Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968; 65: 281-393.9) Raffan E and Semple RK. Next generation sequencing--implications for clinical 
practice. British medical bulletin. 2011;  
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AIM 
To estimate the clinical impact of  AJ preconception genetic screening using an MPS 
expanded panel.  
TABLE 1: Current and proposed expanded AJ 
panel for preconception genetic screening 
Conventional DNA testing for 5 conditions (Table 1, marked with *)  has an AJ calculated 
a priori risk carrier risk (for at least 1 condition) of 12%. In the Sydney program's 
experience implementing this model (2005-12), the observed number of carrier 
participants (12% - see Table 2) was in agreement with this predicted number, and 
these were referred for genetic counselling. 
In the proposed MPS screening model, ((Table 1, conditions 1 to 25), the a priori risk of 
being diagnosed a carrier for at least 1 condition is 50.8%. 
 
Some 50% (1 in 2) AJ individuals screened with the proposed MPS panel would be diagnosed a carrier for ≥ 1 recessive condition, which 
predicts a more-than-four-fold (12% to 50%) increase in referrals for genetic counselling. This escalation highlights future workforce 
demands predictable with whole population uptake of genomic preventative medicine.  
MPS also poses challenges to traditional concepts of informed consent.Currently, Jewish Community Genetic screening programs target 
Senior high school students.2, 4, 5 Mature minors6, can provide informed consent for conventional DNA testing for a limited number of 
conditions.4Studies are now underway to ensure that informed consent is achievable in Community Genetics screening programs utilising 
MPS for multiple conditions simultaneously 
TABLE 2: Outcome summary Sydney Jewish 
community genetic screening programs  
Development of health policy regarding ethical, legal and workforce implications of the implementation of diagnostic genome sequencing 
technology must be addressed with some urgency. 
Probability*
Disease*
(**=*Included*in*current*screening*panel)* Gene*
No*of*
muta=ons*
Jewish*
Carrier*
Frequency
(P)** 1EP*
P1* Tay*Sachs*disease*(TSD)** HEXA* 14* 1*in*27** 0.96*
P2* Canavan*disease*(CD)** ASPA* 4* 1*in*55* 0.98*
P3* Familial*Dysautonomia*(FD)** IKBKAP* 2* 1*in*31* 0.97*
P4* Bloom*disease* BLM* 1* 1*in*134* 0.99*
P5* Fanconi*Anaemia*(FA)** FANCC* 4* 1*in*100* 0.99*
P6* NiemannEPick*(A&B)* SMPD1* 4* 1*in*115* 0.99*
P7* Mucolipidosis*type*4*
MCOLN
1* 2* 1*in*89* 0.99*
P8* Glycogen*storage*disease*1a* G6PC* 2* 1*in*64* 0.98*
P9* Cys=c*ﬁbrosis*(CF)** CFTR* 11* 1*in*29* 0.97*
P10* Gaucher*Disease* GBA* 6* 1*in*15* 0.93*
P11* Maple*Syrup*disease*Type*1B* BCKDHB* 3* 1*in*97* 0.99*
P12* Hyperinsulinism* ABCC8* 2* 1*in*68* 0.99*
P13*
Dihydrolipoamide*Dehydrogenase*
Deﬁciency**
(E3)* DLD* 1* 1*in*107* 0.99*
P14* USH3* CLRN1* 1* 1*in*120* 0.99*
P15* USH1F* PCDH15* 1* 1*in*147* 0.99*
P16* Nemaline*Myopathy(NM)* NEB* 1* 1*in*168* 0.99*
P17* Joubert*Syndrome*T2*
TMEM2
16 1 1*in*92* 0.99*
P18* Spinal*Muscle*atrophy* SMN1 1 1*in*41* 0.98*
P19* Walker*Walburg* FKTN* 1* 1*in*149* 0.99*
P20* Haemophilia*C* F11* 3* 1*in*23* 0.96*
P22* Familial*Mediterranean*fever* MEFV* 15* *1*in*5* 0.80*
P23* Deafness* GJB2* 2* 1*in*25* 0.99*
P24* Glycogen*storage*disease*T3*
GDE/
AGL* 1* 1*in*35* 0.97*
P25* Alpha*1*an=trypsin*Deﬁciency*
SERPINA
1* 4* *1*in*30* 0.98*
Year Participants Carriers Disorders  
1995 170 6 TSD 
1996 123 13 TSD, CF 
1997 181 4 TSD 
1998 178 13 TSD, CF 
1999 175 11 TSD, CF 
2000 166 13 TSD, CF 
2001 172 6 TSD 
2002 192 4 TSD 
2003 215 10 TSD 
2004 242 6 TSD 
2005 245 28 CF,TSD,CD,FD,FA 
2006 298 34 CF,TSD,CD,FD,FA 
2007 254 32 CF,TSD,CD,FD,FA 
2008 281 22 CF,TSD,CD,FD,FA 
2009 252 43 CF,TSD,CD,FD,FA 
2010 220 23 CF,TSD,CD,FD,FA 
2011 278 37 CF,TSD,CD,FD,FA 
2012 252 28 CF,TSD,CD,FD,FA 
Carriers detected(%) TSD TSD,CF CF,TSD,CD,FD,FA 
 36(3%) 50(8%) 247(12%) 
REFERENCES 
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Massively parallel sequencing (MPS) has dramatically lowered the cost 
of genomic sequencing for multiple genetic conditions. Best ethical and 
clinical practice for clinical diagnostic testing using traditional targeted 
sequencing technologies requires informed consent and availability of 
genetic counselling.  
High infant mortality from severe autosomal recessive (AR) childhood 
conditions has led to the establishment of genetics screening programs in 
communities with increased risk of AR conditions due to ancestral origins. 
For example, Australian Ashkenazi Jewish (AJ) preconception and carrier 
screening programs test for conditions relevant to the AJ community and 
have been effective in decreasing the incidence of AR-affected births (1).
The greater speed, lower costs and parallel nature of genetic testing 
using MPS technologies allows the testing panel of screening programs 
to be expanded to encompass a broader range of conditions. The effects 
of broader testing on carrier detection rates are yet to be fully evaluated. 
INTRODUCTION 
A simple mathematical model was developed based on the binomial 
distribution: p(X) =  1- [(1-P1) • (1-P2) •…(1-Pn)], where P1 to Pn are the 
carrier frequencies of various genetic conditions and p(X) is the 
probability of being a genetic carrier for any one of these conditions 
(assuming all conditions are inherited independently). 
The model was validated in silico using the testing panels and data from 
Australian AJ community genetics screening programs. Known or best 
estimate carrier frequencies for the 26 most prevalent AR conditions in 
the AJ community were obtained from published literature (2,3). The 
predicted annual detection rate of AR genetic carriers was compared to 
the actual number of carriers.  
To simulate the effect of increasing the number of tested conditions, each 
carrier frequency was iteratively added to the model one by one, from the 
most to least frequent, to calculate the cumulative AR carrier rate. The 
carrier frequency was varied over a 4-fold range to simulate the effect of 
uncertainty in carrier prevalence or errors in sequencing on the predicted 
AR carrier rate. 
METHODS 
We validated the model using data from an Australian AJ community genetics screening program. Our model closely predicts the observed 
rates of AR genetic carriers detected in the Sydney AJ community screening program over an 18-year period.  
 
Using our model, we studied the likely impact on carrier detection rates of the introduction of MPS into screening. We show that the primary 
driver of the AR genetic carrier rate is the number of tested conditions. This is in contrast to autosomal dominant conditions where the 
proportion of individuals with a pathogenic variant plateaus as the number of tested conditions is increased (4). Increasing the number of AR 
conditions screened from the current panel of 5 up to 26 would result in a 4-fold increase in the proportion of AR genetic carriers detected.  
 
Jewish Australians represent a population minority and, in clinical terms, this projected increase in total community genetics services use is 
modest. It does however highlight important workforce issues that health systems will face as the rapidly evolving field of genomic preventative 
medicine becomes more mainstream. Future increases in the number of included conditions will increase the number of genetic carriers 
detected and have implications for downstream health costs and resources. 
DISCUSSION 
Figure 1: Predicted and actual rates of AR genetic carriers 
 Number of conditions tested for: 1 (1995, 1997, 2001-2004), 2 (1996, 
1998-2000) or 5 (2004-2013) 
To develop and validate a model to predict the AR genetic carrier rate in a 
dataset or population as the testing panel expands. This model was used 
to study the effects of increasing the number of AR conditions included in 
population screening programs.  
AIM 
For further information please contact: leslie.burnett@sydney.edu.au HGSA Annual Scientific Meeting 2014 
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Figure 2: Predicted proportion of AR genetic carriers with 
increasing number of AR conditions tested   
RESULTS 
There was good agreement between the predictions of our 
model and the actual rate of AR genetic carriers detected in the 
community screening program (Figure 1). Expansion of the 
testing menu to screen for 26 conditions is predicted to increase 
the proportion of AR genetic carriers to 58% (Figure 2). 
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Probability Disease Phenotype Carrier Frequency 
Low estimate 
Carrier Frequency 
Most likely 
estimate 
Carrier Frequency 
High estimate 
P1 Hereditary Breast and Ovarian Cancer 0.1060% 3,4 0.4589% 2.8820%4,5 
P2 Li-Fraumeni Syndrome 0.0050%6 0.0100% 0.0200%6 
P3 Peutz-Jeghers Syndrome 0.0004%7 0.0012% 0.0040%7 
P4 Lynch Syndrome 0.0500%8 0.1066% 0.2273%8 
P5 Familial adenomatous polyposis 0.0023%9 0.0027% 0.0032%9 
P6 
MYH-Associated Polyposis; Adenomas, multiple 
colorectal, FAP type 2, Colorectal adenomatus 
polyposis, autosomal recessive, with pilomatricomas 1.0000%10 1.4142% 2.0000%10 
P7 Von Hippel Lindau syndrome 0.0014% 0.0028%11 0.0056% 
P8 Multiple Endocrine Neoplasia Type 1 (MEN1) 0.0017% 0.0033%12 0.0067% 
P9 Multiple Endocrine Neoplasia Type 2 (MEN2) 0.0014% 0.0029%13 0.0057% 
P10 Familial Medullary Thyroid Cancer (FMTC) * * * 
P11 PTEN Hamartoma Tumor Syndrome 0.0003% 0.0005%14 0.0010% 
P12 Retinoblastoma 0.0067%15 0.0058% 0.0050%15 
P13 
Hereditary Paraganglioma-Pheochromocytoma 
Syndrome 0.0001%16 0.0003% 0.0009%16 
P14 Tuberous Sclerosis Complex 0.0086% 0.0172%17 0.0345% 
P15 WT1-related Wilms tumor 0.0005%18 0.0006% 0.0006%18 
P16 Neurofibromatosis type 2 0.0025%19 0.0028% 0.0030%19 
P17 EDS - vascular type 0.0005%20 0.0010% 0.0020%20 
P18 
Marfan Syndrome, Loeys-Dietz Syndromes, and 
Familial Thoracic Aortic Aneurysms and Dissections 0.0102%21,22,23 0.0144% 0.0205%21,22,23 
P19 Hypertrophic cardiomyopathy, Dilated cardiomyopathy 0.1100%24 0.1241% 0.1400%24 
P20 Catecholaminergic polymorphic ventricular tachycardia 0.0050%25 0.0058% 0.0066%25 
P21 Arrhythmogenic right ventricular cardiomyopathy 0.0800%26 0.2530% 0.8000%26 
P22 
Romano-Ward Long QT Syndromes Types 1, 2, and 3, 
Brugada Syndrome 0.0143%27 0.0218% 0.0333%27 
P23 Familial Hypercholesterolemia 0.1500% 0.3000%28 0.6000% 
P24 Malignant hyperthermia susceptibility 0.0010% 0.0071%29 0.0500% 
Each probability, P1 – P24, represent the combined probabilities of the conditions listed. E.g. P1 represents the combined 
probabilities of BRCA1 and BRCA2. 
Frequency estimates with a white background represent values found in the literature, while those with grey backgrounds 
indicate calculated estimates (see Methods). 
* Probabilities for FMTC included with those of the related syndrome MEN2 
Massively parallel sequencing (MPS), also called next generation 
sequencing, has dramatically lowered the cost of nucleic acid sequencing 
for multiple genetic conditions.  
Best ethical and clinical practice for clinical diagnostic testing using 
traditional targeted sequencing technologies requires obtaining informed 
consent and ensuring availability of genetic counselling. 
Testing for specific genetic conditions using MPS may incidentally 
discover off-target genetic conditions. The American College of Medical 
Genetics and Genomics (ACMG) has recently published 
recommendations for the clinical reporting of incidental findings for a list 
of 24 specific conditions.1,2 
INTRODUCTION 
A diagnostic panel was simulated based on the ACMG recommended 
minimum list of genes to be reported, regardless of the original indication 
for the clinical sequencing (incidental findings). 
The number of patients with significant variants in one or more conditions 
that would be detected using the screening panel was calculated from 
known (or best estimate) prevalence. Where a range of variant 
prevalence data was available, we selected the lowest and highest 
values, and calculated the most-likely estimate as the geometric mean. 
Alternatively, where only a single datum was available, we selected half 
and twice this prevalence as the low and high estimates.  
 
Assuming all disorders were inherited independently, the probability 
calculation used was 1- [(1-P1)*(1-P2)*…(1-P24)], with P1 to P24 as the 
carrier frequencies of the 24 proposed ACMG conditions. Calculations 
were repeated separately for the lower and higher limits.  
 
The proportion of individuals screened who would require supplementary 
consultation and genetic counselling was calculated. 
METHODS 
Our modelling of the ACMG Recommendations for Clinical Reporting of Incidental Findings has shown that a non-trivial percentage (1.5% - 6.5%) of screened 
individuals will have a significant reportable finding. These individuals would require confirmatory testing, education, counselling and potentially treatment but 
might derive significant benefit from the incidental findings. 
 
All the conditions on the current ACMG list are relatively rare. Information about the population carrier frequencies of such rare conditions is necessarily limited, 
and calculations based on such limited information must be regarded with caution. Many of the estimates of carrier frequency are based on the prevalence of a 
particular disorder. The true carrier frequency may be much higher if the disorder has incomplete penetrance; this would lead to a falsely low estimation of the 
predicted number of incidental findings. Similarly, some pathogenic phenotypes will be due to genetic variations not yet described or currently considered of 
uncertain significance; these will lead to a falsely high estimation of the number of true incidental findings. However, over time, with increasing experience and 
larger population sample numbers, the true rate of incidental findings will become apparent. 
 
Ongoing research continues to reveal the genetic basis for more and more conditions. The ACMG list of Recommendations is likely to grow, not shrink, over time. 
The implementation of the ACMG Recommendations for Clinical Reporting of Incidental Findings will require major increases in resources for the health system. 
To adopt the ACMG Recommendations, these increased resource requirements need to be identified, costed and addressed. The costs to implement the 
recommendations need to be compared to the potential benefits, cost offsets and utility of reporting and acting on these findings. 
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TABLE 1: Carrier Frequency Estimates of Recommended Conditions 
The proposed ACMG recommended screening panel would 
require supplementary consultation and genetic counselling for 
approximately 2.7% (range 1.5%-6.5%) of screened individuals. 
RESULTS 
To predict the clinical impact of expanded genomic testing with MPS 
using the ACMG Recommendations for Clinical Reporting of Incidental 
Findings. 
AIM 
TABLE 2: Expected Incidental Findings Using ACMG Panel 
Carrier Frequency Estimate Low Most likely High 
Percentage of individuals who screen positive 
for at least one of the 24 conditions 1.52% 2.70% 6.48% 
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Genetic screening for autosomal recessive (AR) genetic carriers is available in 
many communities “at risk” due to high prevalence of pathogenic variants. 
Examples include Tay-Sachs disease testing in the Ashkenazi Jewish (AJ) 
community. The range of tests included in screening programs is broadening, 
and will accelerate with the introduction of Massively Parallel Sequencing.  
We recently modelled the frequency of autosomal dominant (AD) genetic 
conditions arising as Incidental Findings (IF) in Whole Genome Sequencing. We 
found that the proportion of tested individuals with significant IFs plateaus to a 
limit even as the number of genes tested increases beyond those in the ACMG 
IF Recommendations (1).  
In contrast, modelling of AR conditions showed that the carrier rate continues to 
increase with the number of genes tested (2). As more gene panels are included 
in screening programs, a risk emerges of being a “genetic wallflower”, someone 
rejected by every suitor because of the common AR variants they carry. 
INTRODUCTION 
We developed a computer simulation model to create a virtual population of 
individuals with randomised genomes. The simulation model could be adjusted 
to vary population size (we used 103-104), the number of genes tested (each 
genome consisted of 1-27 genes of known AJ prevalence, supplemented by 
102 - 104 simulated genes, so that at maximal values, the simulated genome 
approximated the size of the human exome), the prevalence of pathogenic AR 
variants (using actual gene prevalence for known AJ genes, and 10-2 - 10-4 for 
simulated genes) and number of iterations (range 10-100). Random couples 
were then chosen from each population to ‘mate’. The average AR genetic 
carrier rate, number of variants present per individual and proportion of at-risk 
couples (i.e. both partners being carriers for the same pathogenic AR genetic 
condition) for a population were calculated.  
The simulation model was validated using actual testing panels and data from 
Australian AJ community genetics screening programs. Known or best estimate 
carrier frequencies for the 26 most prevalent AR conditions in the AJ community 
were obtained from published literature (3,4). The simulated annual rate of AR 
genetic carriers was compared to the actual rate of carriers and our previous 
mathematical modelling results (2). 
The effect of increasing the number of genes tested on the overall carrier rate 
and on the proportion of at-risk couples was simulated on a population of 
10,000 individuals and averaged from 100 iterations. 
METHODS 
As the number of AR conditions included in testing panels is increased, the 
number of AR genetic carriers identified in a population will increase. This 
behaviour is in marked contrast to that for AD conditions, where the proportion 
of a population with a reportable IF will plateau. These findings have significant 
implications for health economic evaluation and planning.  
However, regardless of the number of AR conditions tested, the number of “at-
risk” carrier couples increases more slowly, lessening the risk of emergence of 
genetic wallflowers. We are currently quantifying this risk. 
CONCLUSIONS 
Figure 1: Predicted and actual rates of AR genetic carriers 
Number of conditions tested for: 1 (1995, 1997, 2001-2004), 2 (1996, 1998-2000) 
or 5 (2005-2013) 
To model the rate of increase in AR genetic carriers with increasing numbers of 
AR genes in test menus. We also explore the likelihood of genetic wallflowers 
emerging. 
AIM 
For further information please contact: leslie.burnett@sydney.edu.au ASHG Annual Meeting 2014 
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Figure 2: Predicted rate of AR genetic carriers with increasing 
number of AR conditions tested 
RESULTS 
Figure 3: Average number of variants in an individual with 
increasing number of AR conditions tested 
Figure 4: Average proportion of couples at-risk of an AR 
affected child with increasing number of AR conditions tested 
No. of variants 
No. of genes 
Our simulation model correctly predicts the observed rates of AR genetic 
carriers detected in the Australian AJ community over an 18-year period, and 
closely tracks our mathematical model. 
Figs 1-4 illustrate the behaviour of AR conditions in our simulated populations. 
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Appendix 2 is a poster reporting preliminary work that was later expanded on 
and published in Chapter 4 of this thesis. 
The Poster contained in this Appendix does not form an examinable part of 
my Thesis, but is included for relevant background and supplementary 
information 
 
 
Poster 5 
Lew R, Proos A, Burnett L, Delatycki M, Bankier A, Fietz M, Tay Sachs  
Disease: Evaluating the impact of genetic screening on disease incidence in 
Australia, Building consensus in Gynaecology, Infertility and Perinatology 
(BCGIP) Barcelona, May 2012 
 
 
 
 
 
 
 
 
Tay Sachs Disease:  
Evaluating the impact of genetic screening on 
 disease incidence in Australia  
Raelia Lew*,1,3 Anné Proos,1,2  Leslie Burnett,1,2 Martin Delatycki 4,5, Agnes Bankier5, Michael Fietz6 
 1 The University of Sydney, 2Pacific Laboratory Medicine Services (PaLMS), Pathology North, 3Royal Prince Alfred Hospital, 4  Victorian Clinical Genetics Service (VCGS), Murdoch 
Children’s Research Institute, Royal Children’s Hospital (RCH), 5Austin Health Clinical Genetics Service, 6 Department of Biochemical Genetics, SA Pathology (at WCH) 
 
INTRODUCTION 
• Tay Sachs disease (TSD) is a lethal, 
recessive, neurodegenerative lysosomal 
sphingolipid storage disorder1, where 
mutations of HEXA MIM *606869 (15q23-
q24)2 result in hexosaminidase A enzyme 
deficiency3. 
• TSD is more common in Jewish individuals  
• We investigated the effect of 17 years of 
preconception genetic screening programs4,5 
for TSD in Jewish communities in Sydney 
and Melbourne on disease incidence 
METHODS 
• Ethics approval was obtained.  
• A comprehensive audit of medical case and 
laboratory records (RCH, VCGS, PaLMS, 
SA Pathology) identified all infantile and 
intermediate TSD cases diagnosed in 
Sydney and Melbourne (1995-2011).  
• TSD carrier frequency was calculated for 
Jewish Australians using screening program 
data (Sydney/Melbourne, 1995-2011).  
• We used TSD carrier frequency 1 in 250 
(0.4%) for other Australians (WHO)6. 
• Population demographic data was extracted 
from the Australian census (1996-2006) and 
birth registry reports (1995-2010)7,8.  
• Jewish 0-4 year olds were used as a proxy 
measure of Jewish births (elsewhere 
unrecorded).   
• TSD case incidence was estimated for 
general and Jewish populations (Hardy-
Weinberg equation).  
RESULTS 
• Of 88,826 Australians who reported their 
religion as “Jewish” in the 2006 census, 46% 
live in Melbourne and 40% in Sydney.  
• 7756 Jewish High school students screened 
for TSD (1995-2011) in Melbourne and 
Sydney demonstrated TSD carrier frequency 
1 in 31 (3.3%) (95% CI 2.9%-3.7%).  
• TSD expected incidence (1995-2011) was 
calculated for estimated Jewish (2.6, 34%) 
and other births (5.0, 66%) in Melbourne and 
Sydney.  
• Our comprehensive audit (1995-2011) found 
12 TSD cases diagnosed in Sydney (4) and 
Melbourne (8), of which 2 (17%) were 
Jewish.  
• No Jewish TSD case was born to parents 
who has undertaken preconception genetic 
screening  previously.  
DISCUSSION 
• The Majority of Jewish Australians reside in Melbourne (46%) 
and Sydney (40%)9,10. 
• 50% of young Jewish adults in Sydney and 70% in 
Melbourne attend schools that access preconception genetic 
screening programs for TSD and other recessive conditions 
more common in Jewish people (Gaucher disease, cystic 
fibrosis, mucolipidosis type IV, Fanconi anemia, familial 
dysautonomia, Canavan disease, Bloom syndrome). 
• 78% of Jewish students screened for TSD in Melbourne and 
Sydney (1995-2008) identified as Ashkenazi11. 
• Screening programs are co-ordinated in Melbourne 
(1997-2012) by Victorian Clinical Genetics Services, Murdoch 
Children’s Research Institute, Royal Children’s Hospital, 
Melbourne and in Sydney (1995-2012) by The Australian 
Community Genetics Program through the Wolper Jewish 
Hospital using the Laboratory and Community Genetics 
Department, Pacific Laboratory Medicine Services [PaLMS, 
Pathology North], Royal North Shore Hospital.  
• Genetic material is now collected by mouth wash sampling.  
• Following pre-screening education and counselling, 
participation rates approach 100%12.   
• Jewish TSD cases in Sydney and Melbourne were audited 
over the period 1995-2011, corresponding to widespread 
young Jewish adult participation in TSD preconception 
screening programs. 
• The clinically evident 50% reduction in Jewish TSD cases 
has not yet achieved statistical significance due to the small 
size of the Australian population.  During the 17 year study 
period, N=12 TSD cases were diagnosed. Using the binomial 
test to show a 50% reduction in Jewish cases (80% power, 
p<0.05) would require N=43 TSD cases. 
• Adoption of TSD preconception genetic screening program 
models may be expected to show similar disease incidence 
reductions  when applied to other mendelian disorders with 
similar carrier frequencies in target populations such as cystic 
fibrosis in Caucasian populations. 
• Our study has limitations: retrospective design, low TSD 
prevalence, relative small sample size, limited Jewish 
population census data. 
CONCLUSIONS 
• The effectiveness of community education, 
appreciation of autosomal recessive 
inheritance and carrier screening pre-
pregnancy are likely factors to explain fewer 
than the expected number of Jewish babies 
born affected with TSD.  
• Ongoing monitoring must be continued, so 
as to ensure outcomes evaluation. 
• Carrier frequency for TSD in Australian 
Jewish high school students screened 
between 1995-2011 was 1 in 31. Without 
ongoing intervention through community 
screening, this population remains at 
significant risk for TSD. 
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 ! Melbourne! Sydney!
Year! Students screened! Carriers! Non-carriers! Carrier frequency! Students screened! Carriers! Non-carriers! Carrier frequency!
1995!  !  !  !  !
169! 5! 164!
1 in 34!
1996!  !  !  !  !
124! 8! 116!
1 in 16!
1997!  !  !  !  !
183! 4! 179!
1 in 46!
1998! 92! 3! 89! 1 in 31!
186! 5! 181!
1 in 37!
1999! 275! 8! 267! 1 in 34!
184! 6! 178!
1 in 31!
2000! 236! 11! 225! 1 in 21!
169! 6! 163!
1 in 28!
2001! 283! 10! 273! 1 in 28!
172! 5! 167!
1 in 34!
2002! 290! 11! 279! 1 in 26!
191! 4! 187!
1 in 48!
2003! 362! 10! 352! 1 in 36!
218! 10! 208!
1 in 22!
2004! 356! 14! 342! 1 in 25!
241! 7! 234!
1 in 34!
2005! 362! 7! 355! 1 in 52!
242! 9! 243!
1 in 27!
2006! 324! 13! 311! 1 in 25!
295! 9! 286!
1 in 33!
2007! 321! 6! 315! 1 in 54!
246! 8! 254!
1 in 31!
2008! 320! 11! 309! 1 in 29!
283! 7! 276!
1 in 41!
2009! 291! 10! 281! 1 in 29!
251! 12! 239!
1 in 21!
2010! 291! 12! 279! 1 in 24!
223! 8! 215!
1 in 28!
2011! 294! 3! 291! 1 in 98!
282! 11! 271!
1 in 26!
Total (1995-2011)!
4097! 129! 3968!
1 in 32!
3659! 124! 3561!
1 in 30!
 !  !  !  !  !  !  !  !  !
 ! Melbourne and Sydney Screening Combined Results 1995-2011!  !  !  !  !
 ! Students screened! Carriers! Non-carriers! Carrier frequency!  !  !  !  !
 ! 7756! 253! 7529! 1 in 31!  !  !  !  !
TABLE 1:  
TSD PRECONCEPTION JEWISH PROGRAMS 
MELBOURNE AND SYDNEY 1995-2011 
	 178	
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The article contained in Appendix 3, written by medical journalist David Brill 
appeared in the magazine Australian Doctor published on the 10th December 
2012, in response to the publication of  chapter 5 of this thesis. 
 
Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ. 
Tay Sachs disease in Australia: reduced disease incidence despite stable 
carrier frequency in Australian Jews. Med J Aust 2012; 197(11):652-654.  
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Screening sees demise of Tay-Sachs
10 December, 2012  David Brill  0 comments
Tay-Sachs disease has been all but eliminated
among Australian Jews, thanks to a high school
genetic screening program, research shows.
Just two affected infants have been born to
Jewish families since screening began in 1995,
neither of whose parents had partaken in
screening, according to a study published
Monday in the Medical Journal of Australia.
Tay-Sachs disease is an autosomal recessive
lysosomal storage disorder characterised by
slow neurological decline from early infancy. It is
typically fatal by age four.
The gene mutation is disproportionately common
among Jews, particularly those of Ashkenazi
descent, one in 25 of whom carry it.
It is found in one in 97 Jews of mixed or
non-Ashkenazi heritage, and one in 250 people
in the general population.
Study author Dr Raelia Lew said the screening
program carried out in the Jewish community had been a clear success.
Population modelling showed that without screening, there would have been four infants born to
Jewish families over the study period.
"It not only facilitates individuals' awareness of their carrier statues, but it also increases the
awareness of Tay-Sachs disease for the community and increases understanding of the mode of
inheritance," said Dr Lew, a senior obstetrics and gynaecology registrar at Sydney's Royal Prince
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Alfred Hospital, who is researching Tay-Sachs disease for a PhD.
The community-funded screening program, which targets students at Jewish high schools free of
charge, was launched in Sydney in 1995 and Melbourne in 1998.
It also screens for cystic fibrosis, Fanconi anaemia, Canavan disease and familial dysautonomia.
Uptake is extremely high, at more than 99%. About 7750 students were screened from 1995 to 2011.
The research could not establish what decisions had been made by families in which both partners
were identified as carriers.
Dr Lew said they had several options: adoption, IVF with preimplantation genetic screening, use of
eggs or sperm from a non-carrier donor, or proceeding with a natural pregnancy and having chorionic
villus sampling and amniocentesis, if necessary.
The choice was often influenced by people's level of religious observance, she said.
Professor Leslie Burnett, honorary medical director of the screening program, said the research
showed it had been "a remarkable success".
"It's a dreadful disease. The child is born healthy and you see it wither and die before your eyes," said
Professor Burnett, a consultant pathologist at NSW Health and clinical professor in pathology at the
University of Sydney.
"[This research] shows that by introducing a screening program, particularly one that's ethically
sound, based on education, knowledge and informed consent, you can avoid families having to go
through the trauma."
Ten infants with Tay-Sachs disease were born to non-Jewish parents over the period of the study,
compared to a predicted number of seven.
The study looked only at births in Sydney and Melbourne, where the majority of Australia's Jewish
population lives.
Professor Burnett said the program could be expanded to all Australians in future.
He hoped to submit an application to list the test on the MBS next year.
Previous research had shown that community-wide screening for Tay-Sachs disease was more
cost effective than targeting only families with an affected child.
Screening in Sydney is funded by the Wolper Jewish Hospital, which runs the school-based program
and once-monthly screening sessions.
CEO Harry Aizenberg said the project had cost about $500,000 since its launch in 1995 — roughly
$30,000 per year.
Medical Journal of Australia 2012; 197:652-54.
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Appendix 4 
 
Appendix 4 contains a newspaper article written by journalist Gareth 
Narunsky was published in the 19th August 2011 edition of the Australian 
Jewish News in response to work published as chapter 4 of this thesis: 
 
Lew R, Burnett L, Proos A, Tay-Sachs disease preconception screening in 
Australia: self-knowledge of being an Ashkenazi Jew predicts carrier state 
better than does ancestral origin, although there is an increased risk for 
c.1421+1G>C mutation in individuals with South African heritage. J 
Community Genet. 2011 Dec;2(4):201-9.  
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Appendix 5 
 
Appendix 5 contains a magazine article by Claire Bridgeman, entitled  
Congratulations to Dr Raelia Lew, that appeared in the Sydney University 
Northern Clinical School Newsletter in February 2013 in response to the work 
published in Chapter 5 of this thesis: 
 
Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ. 
Tay Sachs disease in Australia: reduced disease incidence despite stable 
carrier frequency in Australian Jews. Med J Aust 2012; 197(11):652-654. 
 
The article can also be accessed via the following link: 
http://sydney.edu.au/medicine/northern/news-events/2013/february2013-
newsflash.php#taysachs 
 
FEATURE ARTICLE
Congratulations to Dr Raelia Lew, a
PhD student of Professor Leslie
Burnett and an O&G Registrar at
Sydney’s Royal Prince Alfred Hospital,
who has just published a paper in the
Medical Journal of Australia 2012;
197:652-54, reviewing almost two
decades of genetic screening for Tay-
Sachs disease...read more...
Dr Raelia Lew
E-NEWSFLASH - FEBRUARY 2013
Happy New Year!
We are very excited to be starting a new year in 2013, with our new stage 1 students starting in a few weeks time, and our
stage 3 students already back and immersing themselves on the wards!
We look forward to sharing another great year with you all, don’t forget if you have any news you would like to see
published in the newsletter we would love to hear from you. Please send any stories to claire.bridgman@sydney.edu.au
(mailto:claire.bridgman@sydney.edu.au) claire.bridgman@sydney.edu.au
(mailto:claire.bridgman@sydney.edu.au)
A Sydney Medical School – Northern celebration
Save the date for the upcoming Sydney Medical School – Northern celebration, Medical Education – All Together Better
Health.
On the evening of Tuesday the 19th March we would love you to join us at this annual event where we celebrate medical
education in all its facets, and award prizes over a glass of wine and canapés.
Invitations will go out shortly but in the meantime make sure you have the date (19th March 2013) and time (5:30pm) in
your diarys. We look forward to seeing you there!
Congratulations to Dr Raelia Lew
Congratulations to Dr Raelia Lew, a PhD student of Professor Leslie Burnett and an O&G Registrar at
Sydney’s Royal Prince Alfred Hospital, who has just published a paper in the Medical Journal of
Australia 2012; 197:652-54, reviewing almost two decades of genetic screening for Tay-Sachs disease
(a classic neurodegenerative autosomal recessive disease, which affects newborn children). 
Screening of parents for Tay-Sachs disease was introduced into Australia by Professor Burnett and Ms
Anné Proos in 1992, and was first offered to the Sydney population via community genetic screening in
1995 then, following Professor Burnett’s and Ms Proos’ joining the Kolling Institute in 1997, offered to
the rest of Australia in 1998. Their laboratory is currently housed in PaLMS Pathology on the RNS
Hospital campus, but continues to publish its work under the auspices of the University of Sydney. 
You are here: Northern Clinical School / News & events / News & events
NORTHERN CLINICAL SCHOOL
Professor Burnett explained the significance of Dr Lew’s findings: ‘While our past research has demonstrated genetic
screening is medically effective and cost-effective, we had not been able to demonstrate "outcomes effectiveness", i.e. that
genetic screening actually works when applied to an entire population. Raelia's paper has now done just that. She has
shown that, since the introduction of genetic screening to the entire Australian population, there has not been a single case
of Tay-Sachs disease in the screened population, while those who did not take up screening continued to have children
affected with the disease at the baseline rate. This is a very important demonstration, as it now means we have an
evidence base for effectiveness of this new form of diagnosis and treatment.’
Further information can be found in Australian Doctor 10 December, 2012.
If you would like to contribute to this newsletter, or have any feedback, please contact Claire Bridgman.
Sydney Medical School - Northern
Phone: 02 9926 4678
Email: claire.bridgman@sydney.edu.au(mailto:claire.bridgman@sydney.edu.au)
claire.bridgman@sydney.edu.au(mailto:claire.bridgman@sydney.edu.au) 
Web: http://sydney.edu.au/medicine/northern(http://sydney.edu.au/medicine/northern)
© 2002-2015 The University of Sydney. Last updated:
ABN: 15 211 513 464. CRICOS number: 00026A. Phone:
Authorised by: Head of Northern Clinical School
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Appendix 6 
 
Appendix 6 contains an article that appeared in the Wolper Hospital 
Newsletter in response to the publication of work published in Chapter 5 of 
this thesis: 
 
Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ. 
Tay Sachs disease in Australia: reduced disease incidence despite stable 
carrier frequency in Australian Jews. Med J Aust 2012; 197(11):652-654. 
 
The Wolper Hospital together with the Sydney Jewish Community Genetics 
screening program, co-ordinates outreach screening strategies in Sydney for 
TSD and other genetic conditions relevant to Jewish communities.   
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Appendix 7 
 
Appendix 7 contains the individual signed statements of contribution from co-
supervisors of this thesis and co-authors of published works included in this 
thesis. These statements make reference specifically and accurately to the 
nature and extent of co-authors’ contributions to published chapters.   
 
Contribution Statement and Co-Authors 
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows: 
1. Professor Leslie Burnett was my primary research supervisor. He provided 
intellectual input into the review of chapters 3,4,5, 6 and 8. 
2. Professor Lucy Raymond was an associate supervisor. She provided support 
during my period of study in Cambridge, UK. 
3. Dr Robert Markham was an associate supervisor. He provided intellectual 
input into review of this thesis. 
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the 
review of chapters 3,4,5, 6 and 8. 
5. Professor Martin Delatycki was a co-investigator. He provided intellectual 
input into the review of chapters 3,5 and 6. 
6. Professor Agnes Bankier was a co-investigator. She provided intellectual input 
into the review of chapters 5 and 6. 
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the 
review of chapters 5 and 6. 
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the 
review of chapter 8. 
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
10.Dr Lan Nguyen was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
11. Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual 
input into the review of chapter 6. 
12.Dr Yemima Berman was a co-investigator. She provided intellectual input into 
the review of chapter 6. 
13.Mr Ron Fleischer was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
14.Mr Harry Aizenberg was a was a co-investigator. He provided intellectual input 
into the review of chapter 6. 
15.Dr Michael Field was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
The final editorial authority remained my own. 
Declared by: Signature: Date:
 Raelia Lew
Leslie Burnett 18/11/14
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Contribution Statement and Co-Authors 
 
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows: 
 
1. Professor Leslie Burnett was my primary research supervisor. He provided 
intellectual input into the review of chapters 3,4,5, 6 and 8. 
2. Professor Lucy Raymond was an associate supervisor. She provided support 
during my period of study in Cambridge, UK. 
3. Dr Robert Markham was an associate supervisor. He provided intellectual 
input into review of this thesis. 
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the 
review of chapters 3,4,5, 6 and 8. 
5. Professor Martin Delatycki was a co-investigator. He provided intellectual 
input into the review of chapters 3,5 and 6. 
6. Professor Agnes Bankier was a co-investigator. She provided intellectual 
input into the review of chapters 5 and 6. 
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the 
review of chapters 5 and 6. 
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the 
review of chapter 8. 
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
10. Dr Lan Nguyen was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
11. Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual 
input into the review of chapter 6. 
12. Dr Yemima Berman was a co-investigator. She provided intellectual input into 
the review of chapter 6. 
13. Mr Ron Fleischer was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
14. Mr Harry Aizenberg was a was a co-investigator. He provided intellectual 
input into the review of chapter 6. 
15. Dr Michael Field was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
 
The final editorial authority remained my own. 
Declared by: Signature: Date: 
 Raelia Lew   
Lucy Raymond 
 
29/10/14 
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Contribution Statement and Co-Authors 
 
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows: 
 
1. Professor Leslie Burnett was my primary research supervisor. He provided 
intellectual input into the review of chapters 3,4,5, 6 and 8. 
2. Professor Lucy Raymond was an associate supervisor. She provided support 
during my period of study in Cambridge, UK. 
3. Dr Robert Markham was an associate supervisor. He provided intellectual 
input into review of this thesis. 
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the 
review of chapters 3,4,5, 6 and 8. 
5. Professor Martin Delatycki was a co-investigator. He provided intellectual 
input into the review of chapters 3,5 and 6. 
6. Professor Agnes Bankier was a co-investigator. She provided intellectual 
input into the review of chapters 5 and 6. 
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the 
review of chapters 5 and 6. 
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the 
review of chapter 8. 
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
10. Dr Lan Nguyen was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
11. Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual 
input into the review of chapter 6. 
12. Dr Yemima Berman was a co-investigator. She provided intellectual input into 
the review of chapter 6. 
13. Mr Ron Fleischer was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
14. Mr Harry Aizenberg was a was a co-investigator. He provided intellectual 
input into the review of chapter 6. 
15. Dr Michael Field was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
 
The final editorial authority remained my own.  
 
Declared by: Signature: Date: 
 Raelia Lew  5/1/15 
Robert Markham  5/1/15 
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Contribution Statement and Co-Authors 
 
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows: 
 
1. Professor Leslie Burnett was my primary research supervisor. He provided 
intellectual input into the review of chapters 3,4,5, 6 and 8. 
2. Professor Lucy Raymond was an associate supervisor. She provided support 
during my period of study in Cambridge, UK. 
3. Dr Robert Markham was an associate supervisor. He provided intellectual 
input into review of this thesis. 
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the 
review of chapters 3,4,5, 6 and 8. 
5. Professor Martin Delatycki was a co-investigator. He provided intellectual 
input into the review of chapters 3,5 and 6. 
6. Professor Agnes Bankier was a co-investigator. She provided intellectual 
input into the review of chapters 5 and 6. 
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the 
review of chapters 5 and 6. 
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the 
review of chapter 8. 
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
10. Dr Lan Nguyen was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
11. Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual 
input into the review of chapter 6. 
12. Dr Yemima Berman was a co-investigator. She provided intellectual input into 
the review of chapter 6. 
13. Mr Ron Fleischer was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
14. Mr Harry Aizenberg was a was a co-investigator. He provided intellectual 
input into the review of chapter 6. 
15. Dr Michael Field was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
 
The final editorial authority remained my own. 
Declared by: Signature: Date: 
 Raelia Lew   
Agnes Bankier 
 
3/11/14 
 
 
 





Gontribution Statement and Go-Authors
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows:
1. Professor Leslie Burnett was my primary research supervisor. He provided
intellectual input into the review of chapters 3,4,5,6 and B.2. Professor Lucy Raymond was an associate supervisor. She provided support
during my period of study in Cambridge, UK.
3. Dr Robert Markham was an associate supervisor. He provided intellectual
input into review of this thesis.
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the
review of chapters 3,4,5, 6 and B.
5. Professor Martin Delatycki was a co-investigator. He provided intellectual
input into the review of chapters 3,5 and 6.
6. Professor Agnes Bankier was a co-investigator. She provided intellectual
input into the review of chapters 5 and 6.
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the
review of chapters 5 and 6.
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the
review of chapter 8.
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the
review of chapter 8.
10. Dr Lan Nguyen was a co-investigator. She provided intellectual input into the
review of chapter 8.
11.Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual
input into the review of chapter 6.
12.Dr Yemima Berman was a co-investigator. She provided intellectual input into
the review of chapter 6.
13. Mr Ron Fleischer was a co-investigator. He provided intellectual input into the
review of chapter 6.
14.Mr Harry Aizenberg was a was a co-investigator. He provided intellectual
input into the review of chapter 6.
15. Dr Michael Field was a co-investigator. He provided intellectual input into the
review of chapter 6.
The fina editorial authoritv rema ined mv own.
Declared by: Signature: Date:
Raelia Lew
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Contribution Statement and Co-Authors 
 
The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows: 
 
1. Professor Leslie Burnett was my primary research supervisor. He provided 
intellectual input into the review of chapters 3,4,5, 6 and 8. 
2. Professor Lucy Raymond was an associate supervisor. She provided support 
during my period of study in Cambridge, UK. 
3. Dr Robert Markham was an associate supervisor. He provided intellectual 
input into review of this thesis. 
4. Ms Anné Proos was a co-investigator. She provided intellectual input into the 
review of chapters 3,4,5, 6 and 8. 
5. Professor Martin Delatycki was a co-investigator. He provided intellectual 
input into the review of chapters 3,5 and 6. 
6. Professor Agnes Bankier was a co-investigator. She provided intellectual 
input into the review of chapters 5 and 6. 
7. Dr Michael Fietz was a co-investigator. He provided intellectual input into the 
review of chapters 5 and 6. 
8. Dr Doug Chesher was a co-investigator. He provided intellectual input into the 
review of chapter 8. 
9. Dr Lucy Ding was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
10. Dr Lan Nguyen was a co-investigator. She provided intellectual input into the 
review of chapter 8. 
11. Dr Kristine Barlow-Stewart was a co-investigator. She provided intellectual 
input into the review of chapter 6. 
12. Dr Yemima Berman was a co-investigator. She provided intellectual input into 
the review of chapter 6. 
13. Mr Ron Fleischer was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
14. Mr Harry Aizenberg was a was a co-investigator. He provided intellectual 
input into the review of chapter 6. 
15. Dr Michael Field was a co-investigator. He provided intellectual input into the 
review of chapter 6. 
 
The final editorial authority remained my own. 
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The roles played by the co-authors in chapters 3, 4, 5, 6 and 8 were as follows:
1. Professor Leslie Burnett was my primary research supervisor. He provided
intellectual input into the review of chapters 3,4,5, 6 and B.
2. Professor Lucy Raymond was an associate supervisor. She provided support
during my period of study in Cambridge, UK.
3. Dr Robert Markham was an associate supervisor. He provided intellectual
input into review of this thesis.
4. Ms Ann6 Proos was a co-investigator. She provided intellectual input into the
review of chapters 3,4,5, 6 and 8.
5. Professor Martin Delatycki was a co-investigator. He provided intellectual
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review of chapters 5 and 6.
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review of chapter 6.
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The roles played by the co-authors in chapters 3,4,5,6 and I were as follows:
1. Professor Leslie Burnett was my primary research superuisor. He provided
intellectual input into the review of chapters 3,4,5,6 and 8.2. Professor Lucy Raymond was an associate supervisor. She provided support
during my period of study in Cambridge, UK.
3. Dr Robert Markham was an associate supervisor. He provided intellectual
input into review of this thesis.
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5. Professor Martin Delatyckiwas a co-investigator. He provided intellectual
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review of chapter 8.
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